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Infection and cardiovascular disease represent the two most important sources of 
mortality in ANCA associated vasculitis (AAV).  Expansions of CD4+CD28null T-cells that 
are only present in cytomegalovirus (CMV) positive individuals have previously been 
associated with increased infection and mortality in AAV, and cardiovascular disease in 
other inflammatory diseases. 
The work described in this thesis examines the hypothesis that subclinical CMV 
reactivation in AAV drives the expansion of CD4+CD28null T-cells thereby leading to 
the observed adverse outcomes.  To investigate this, a proof of concept clinical trial of 
6 months valaciclovir treatment or no additional therapy was designed and 
implemented in CMV seropositive AAV patients in remission. 
Valaciclovir treatment successfully blocked CMV reactivation and in turn this led to a 
reduction in the proportion of CD4+CD28null T-cells in the treated patients together 
with favourable changes in other associated CMV induced changes on the immune 
system.  CD4+CD28null T-cells in AAV were identified as Th1, proinflammatory 
cytotoxic T-cells, able to target endothelial cells and were independently associated 
with increased arterial stiffness, an established marker of cardiovascular risk. 
These findings implicate subclinical CMV reactivation as a potentially reversible cause 
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Chapter 1 Introduction 
1.1 ANCA associated vasculitis 
1.1.1 Definitions and nomenclature 
The ANCA associated vasculitides (AAV) are a group of systemic, autoimmune 
inflammatory conditions.  They are primary small vessel vasculitides, and are 
characterised by the presence of circulating anti-neutrophil cytoplasm antibodies 
(ANCA) and a lack of immune complex deposition [1-3].  The AAV are typified by 
necrotising inflammation affecting small to medium blood vessels leading to end organ 
damage, commonly affecting the kidneys, lungs and upper airways [4] and include 
granulomatosis with polyangiitis (GPA; previously known as Wegener’s 
granulomatosis), microscopic polyangiitis (MPA), eosinophilic granulomatosis with 
polyangiitis (EGPA; previously known as Churg-Strauss) and renal limited vasculitis 
(RLV).   
 
The AAV were officially defined according to the first International Chapel Hill 
Consensus Conference on the Nomenclature of Systemic Vasculitides (CHCC1994)[5] 
that was recently updated in 2012[6].  The CHCC 2012 definitions for the AAV are given 
in Table 1.1.  
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Table 1.1 2012 Chapel Hill Consensus Conference: definitions of anti-neutrophil 
cytoplasm antibody associated vasculitis [6] 
ANCA-associated vasculitis 
(AAV) 
Necrotising vasculitis, with few or no immune deposits, 
predominantly affecting small vessels (i.e. capillaries, 
venules, arterioles, and small arteries), associated with 
MPO ANCA or PR3 ANCA.  Not all patients have ANCA.  





Necrotising granulomatous inflammation usually 
involving the upper and lower respiratory tract, and 
necrotising vasculitis affecting predominantly small to 
medium vessels (e.g., capillaries, venules, arterioles, 




Necrotising vasculitis, with few or no immune depositis, 
predominantly affecting small vessels (i.e., capillaries, 
venules or arterioles). Necrotising arteritis involving 
small and medium arteries may be present. Necrotising 
glomerulonephritis is very common. Pulmonary 
capillaritis often occurs. Granulomatous inflammation is 
absent. 
Eosinophilic granulomatosis 
with polyangiitis (EGPA; 
Churg Strauss) 
Eosinophil-rich and necrotising granulomatous 
inflammation often involving the respiratory tract, and 
necrotising vasculitis predominantly affecting small to 
medium vessels, and associated with asthma and 
eosinophilia.  ANCA is more frequent when 
glomerulonephritis is present. 
ANCA: Anti-neutrophil cytoplasm antibody; MPO: Myeloperoxidase; PR3: Proteinase 3 
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1.1.2 Epidemiology of AAV 
The annual incidence of AAV is approximately 20 per million with a point prevalence of 
130/million for GPA and 47.9/million for MPA in the United Kingdom[1, 7, 8].  The peak 
age of onset is 65-74 with an incidence of 65 per million per year for that age group 
although the disease can occur at any age [8, 9].  AAV is more common in men 
however women tend to develop the disease at a younger age [10].  GPA is more 
common in the northern hemisphere and in particular within Caucasian populations of 
Northern Europe and the United States, whilst MPA is more common in Southern 
Europe, India and the Far East[7, 10-12].  EGPA is the least common of the AAV [12].    
 
1.1.3 Clinical Features of AAV 
Clinical features in AAV depend on the extent of organ involvement as well as the 
disease subtype.  Many clinical features, particularly the non-specific inflammatory 
symptoms of malaise, fatigue, anorexia, weight loss, fever and joint and muscle aches 
often described as a ‘flu-like’ syndrome are common to all AAV [1, 4].  An array of 
other features exist (Figure 1.1) depending on the organs involved and the severity of 
the disease, with GPA more commonly affecting the ear, nose and throat and upper 
airways leading to symptoms such as epistaxis, nasal crusting, sinusitis, hearing loss 
and recurrent otitis media and MPA having a predilection for renal involvement 
frequently leading to rapidly progressing glomerulonephritis requiring renal 
replacement therapy [1, 4, 13-15].  Pulmonary manifestations range from focal 
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infiltrates and granulomas to life threatening pulmonary haemorrhage and 





Figure 1.1 Clinical features in AAV 
Constitutional flu-like symptoms are common to all AAV whilst other features depend 
on the extent of organ involvement and severity.  * Indicate lesions that can be seen 
on chest radiography and computed tomography.  Reproduced from [1] with 
permission from BMJ Publishing Group Ltd.   
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1.1.4 AAV pathophysiology 
The last few decades have seen an abundance of studies investigating the 
pathophysiology of AAV.  Although EGPA is included in the umbrella term of AAV, its 
pathophysiology is significantly different from that of GPA and MPA and will not be 
discussed here. 
 
ANCA have been associated with AAV since their first description in 1985 [17].  ANCA 
are categorised as cytoplasmic (c-ANCA) or perinuclear (p-ANCA) depending on their 
staining pattern by indirect immunofluorescence.  The main antigenic targets of ANCA 
are proteinase 3 (PR3) and myeloperoxidase (MPO), located in the azurophilic granules 
of neutrophils and the peroxidase positive lysosomes of monocytes [18]. PR3 specific 
ANCA usually exhibit a cytoplasmic pattern and are preferentially seen in GPA whilst 
MPO specificity tends to be associated with a perinuclear pattern and MPA or RLV [19].  
Other antigen specificities such as human lysosomal membrane protein 2 have also 
been recently described [20, 21]. 
 
Initial evidence for the pathogenicity of ANCA came from in vitro studies where both 
PR3 and MPO ANCA were shown to be able to activate neutrophil activation leading to 
oxidative burst and degranulation.  This effect was dose dependent and was 
significantly enhanced following neutrophil priming with TNF- [22].  In vivo evidence 
for MPO-ANCA pathogenicity was provided by mouse experiments performed by Xiao 
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and colleagues where the transfer of murine MPO-ANCA to wild-type or recombinant 
activating gene 2-deficient (Rag2-/-) mice led to glomerulonephritis suggesting that 
even in the absence of T-cells and B-cells MPO-ANCA alone are sufficient to cause 
disease [23].  Studies utilising the MPO ANCA mouse model have shown that disease 
induction can be ameliorated via several ways including neutrophil depletion, 
inhibition of plasma cell function and blocking of proinflammatory cytokines such as 
TNF-.  Recently, complement has also been implicated in AAV pathogenicity with 
experiments showing that blocking the complement component C5 can ameliorate the 
disease process [23-30].  On the other hand, there is no convincing animal model to 
date that is able to replicate the granulomatous inflammation seen in PR3-ANCA 
mediated disease, suggesting that cellular effector mechanisms play a significant role 
in the development of GPA.   
 
In summary, our current model for tissue injury in AAV involves the binding of ANCA 
on surface expressed MPO and PR3 auto-antigens on circulating cytokine-primed 
neutrophils, resulting in neutrophil adhesion and transmigration on activated 
endothelial cells with ensuing neutrophil degranulation and endothelial tissue injury 




CMV Modulation of the Immune System in AAV 8 
 
1.1.4.1  Involvement of T-cell immunity in AAV pathophysiology 
As alluded to earlier, T-cells have also been shown to be implicated in AAV 
pathophysiology.  ANCA are class switched IgG antibodies, implying a requirement for 
T-cell help as well as a breach in self-tolerance giving rise to auto-reactive T-cells [33].  
Furthermore, a reduction in the proportion and functionality of regulatory T-cells has 
previously been found in AAV patients [34] whilst multiple studies have shown 
evidence of persistent activation of T-cells in patients with MPA and GPA as well as 
infiltrating T-cells in granulomatous lesions [35-38].  Finally, T-cell depleting agents 
such as anti-thymocyte globulin and the anti-CD52 antibody alemtuzumab can induce 
remission in refractory cases of AAV suggesting a significant role for T-cell mediated 
immunity in disease pathophysiology [39, 40]. 
 
Indeed, multiple lines of evidence have recently suggested involvement of T-cells in 
AAV pathophysiology.  T-helper cells (see also section 1.2) are aberrantly polarised in 
AAV with a predominance of a Th1 pattern seen in localised GPA and MPA and a 
mixture of Th1 and Th2 CD4-cell involvement in active generalised GPA [41-44].  IL-17 
secreting CD4 T-cells (Th17) have recently been shown to be a major pathogenic cell 
subset involved in the trigger of autoimmunity and the establishment of inflammation 
[45-47].  IL-17 promotes the release of proinflammatory cytokines essential for 
triggering the surface expression of MPO and PR3 on activated neutrophils and auto-
antigen specific Th17 cells are relatively increased in ANCA positive patients in 
comparison to ANCA negative patients and controls [46-51]. 
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Persistent T-cell activation has been observed in AAV and has been found to correlate 
with disease activity and severity [52].  Furthermore an expansion of a subset of CD4 T-
cells, known as effector memory CD4 T-cells (EM), has been described in AAV patients 
together with a reciprocal decrease in naïve CD4 T-cells [37].  Effector memory T-cells 
are found in increased numbers in AAV patients in remission compared to controls.  
Interestingly their proportion in peripheral blood has been shown to decline during 
active renal disease in patients with AAV in parallel with an increase in the presence of 
CD4 EM T-cells in the urinary sediment, suggesting migration towards target organs 
during episodes of disease activity [53].  
 
Finally, CD4 T-cells lacking the co-stimulatory molecule CD28 that comprise a cytotoxic 
TEM subset (CD4+CD28null T-cells; discussed in detail in Section 1.2) are also expanded 
in AAV patients [54].  These CD4+CD28null T-cells have been found in abundance in the 
granulomatous lesions of patients with GPA [35, 36].  They possess cytotoxic abilities 
reminiscent of natural killer cells and have been shown to express the activating C-type 
lectin-like homodimeric receptor NKG2D [55].  The ligand for NKG2D, major 
histocompatibility complex class-I chain-related molecule A (MICA), is in turn 
upregulated in glomerular epithelial cells in active renal AAV disease and is expressed 
in granulomatous lesions of GPA patients [56, 57].         
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1.1.5 Treatment of AAV 
The principles of treatment in AAV are to induce and maintain remission utilising the 
minimum necessary immunosuppression that is appropriate to disease severity.  
Induction of remission is achieved by the use of highly potent immunosuppressive 
agents that generally target T-cells or B-cells.  The European Vasculitis Study Group 
(EUVAS) provided a framework of disease severity in order to guide the development 
of clinical trials in the treatment of AAV and harmonise approaches to treatment 
(Table 1.2) [58].   
 
 
Table 1.2  European Vasculitis Study Group Disease Severity Categories [58] 
Localised Upper and / or lower respiratory tract disease without any other 
systemic involvement or constitutional symptoms. 
Early systemic Any system, without organ-threatening or life threatening disease. 
Generalised Renal or other organ-threatening disease, serum creatinine < 500 
mol/L. 
Severe Renal or other vital organ failure, serum creatinine > 500 mol/L. 
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The majority of AAV clinical trials carried out to date have been based on the EUVAS 
classification of severity.  A brief account of some important studies that have shaped 
current treatment strategies in AAV follows.   
 
1.1.5.1  Induction of remission in AAV 
In early systemic disease, comparison of induction therapy with oral corticosteroids 
and either cyclophosphamide or methotrexate (Non-Renal Wegener’s Alternatively 
Treated with Methotrexate; NORAM) demonstrated methotrexate to be as effective as 
cyclophosphamide in inducing remission [59] although long-term follow up revealed 
that patients treated with methotrexate relapsed more quickly and were more likely to 
receive further immunosuppression [60].   
 
In generalised disease, use of pulsed cyclophosphamide therapy as opposed to daily 
oral cyclophosphamide in addition to oral corticosteroids was shown to be equivalent 
in terms of achieving remission (The Cyclophosphamide Daily Oral versus Pulsed 
(CYCLOPS) Trial) [61].  Patients in the pulsed cyclophosphamide arm received a lower 
cumulative dose of cyclophosphamide and had fewer episodes of leucopoenia; 
however long-term follow up revealed a higher risk of relapse in the pulsed group, 
although rates of renal failure and mortality were equivalent [62].   
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Two recent trials considered the monoclonal anti-CD20 antibody rituximab as an 
alternative to cyclophosphamide for induction of disease remission in patients with 
generalised or severe AAV.  RITUXVAS (An International, Randomised, Open-label, Trial 
Comparing a Rituximab Based Regimen with a Standard Cyclophosphamide / 
Azathioprine Regimen in the Treatment of Active, “Generalised” AAV) and RAVE 
(Rituximab in ANCA-Associated Vasculitis) had important differences in their 
methodology, however both trials concluded that rituximab was at least as effective as 
cyclophosphamide in achieving remission whilst the rate of adverse events including 
infection were comparable between rituximab and cyclophosphamide treated patients 
[63, 64].   
 
Given that in vitro studies have revealed a role for tumour necrosis factor-alpha (TNF-
) in activating neutrophils in AAV pathophysiology [24], anti-TNF monoclonal 
antibodies such as infliximab, adalimumab and etanercept have also been utilised for 
induction of remission in AAV [65-68].  The addition of infliximab to standard therapy 
with corticosteroids and cyclophosphamide was shown not to lead to additional 
benefit [67] whilst adalimumab and etanercept demonstrated some improvement in 
disease activity scores and some limited evidence of reduced corticosteroid exposure 
[66, 68].  Due to the open-label, non-randomised nature of these studies as well as 
their mixed results, TNF blockade is reserved for cases of refractory disease where 
patients have not responded to conventional therapy.   
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In the management of severe life-threatening disease, the Methylprednisolone Versus 
Plasma Exchange as Additional Therapy for Severe ANCA-Associated 
Glomerulonephritis (MEPEX) trial, randomised patients with serum creatinine > 500 
mol/L to receive either three 1 g infusions of methylprednisolone on consecutive 
days or seven 60 mL/kg treatments of plasma exchange within 14 days.  All patients 
also received high dose oral corticosteroids and daily oral cyclophosphamide for 
induction of remission followed by azathioprine for maintenance of remission [69].  
Patients randomised to the plasma exchange arm exhibited better renal recovery and 
this difference was maintained at 12 months although subsequent long-term follow up 
has shown no difference between the two arms in terms of survival or renal function 
at a median follow-up of 3.95 years [70].   
 
The Plasma Exchange and Glucocorticoid Dosing in the Treatment of AAV: an 
International Randomised Controlled Trial (PEXIVAS; ClinicalTrials.gov Identifier: 
NCT00987389) is an ongoing multi-centre trial that aims to further clarify the efficacy 
of plasma exchange in improving renal recovery in patients with glomerulonephritis 
secondary to AAV as well as determine whether a reduced corticosteroid dose is 
associated with similar efficacy to the conventional dose but an improved adverse 
even rate.  
 
A recent retrospective study showed that pulsed cyclophosphamide in addition to high 
dose corticosteroids and plasma exchange was associated with a favourable outcome 
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when compared to the MEPEX arm that received daily oral cyclophosphamide 
suggesting that pulsed cyclophosphamide is a viable alternative also in severe disease 
to reduce cumulative dose of cyclophosphamide and ensuing toxicity [71].  
 
1.1.5.2  Maintenance of remission in AAV 
AAV is associated with a high rate of relapse that is seen in 50% of patients within the 
first 5 years following diagnosis and commencement of therapy [72-75].  Long-term 
maintenance immunosuppression is therefore usually necessary to adequately 
suppress disease activity.  Choice of maintenance immunosuppression must be 
balanced with the toxicity of available agents.  Cyclophosphamide was initially used to 
induce as well as maintain remission for prolonged periods of time resulting in high 
rates of infection and malignancy, particularly urothelial cancer [76, 77].  The 
Cyclophosphamide Versus Azathioprine for Early Remission Phase of Vasculitis 
(CYCAZAREM) trial showed that switching to oral azathioprine for maintenance of 
remission after 3-6 months of oral cyclophosphamide treatment was associated with 
equal rates of relapse and adverse events compared to continuing oral 
cyclophosphamide until month 12 [78]. 
 
The effectiveness of mycophenolate mofetil as a remission maintenance agent was 
compared to azathioprine in the Mycophenolate Mofetil Versus Azathioprine for 
Maintenance Therapy in AAV (IMPROVE) trial that demonstrated mycophenolate 
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mofetil to be less effective than azathioprine with a significantly higher rate of relapse 
[79].  The preferred agent for maintaining remission is therefore azathioprine although 
mycophenolate mofetil remains an option for patients that are intolerant to 
azathioprine.  Finally, rituximab has been described as an effective agent to maintain 
remission in several large case series [80-84] and a clinical trial (Rituximab Vasculitis 
Maintenance Study; RITAZAREM; ClinicalTrials.gov Identifier: NCT01697267) is 
currently underway to evaluate the effectiveness of rituximab in maintaining remission 
compared to azathioprine.  
 
1.1.5.3  Treatment of refractory AAV disease 
Refractory disease that is unresponsive to conventional therapy remains a very difficult 
area in the treatment of AAV.  To date there has only been one randomised controlled 
trial that randomly assigned patients to receive either intravenous immunoglobulin 
(IVIG) or placebo infusions for 5 days and showed short term reduction in disease 
activity in the IVIG treated group [85].  Various agents such as rabbit anti-human 
thymocyte globulin (ATG) [40], the lymphocyte depleting antibody alemtuzumab (anti-
CD52) [86], the immunosuppressant 15-deoxyspergualin [87-89], infliximab [90] and 
rituximab [91] have been utilised in the treatment of refractory or frequently relapsing 
AAV disease with mixed results although a detailed discussion of these studies is 
beyond the scope of this thesis.       
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1.1.5.4  Current treatment recommendations for AAV 
Recently published guidelines by the British Society of Rheumatology / British Health 
Professionals in Rheumatology have suggested that all patients with AAV should be 
considered to have severe, potentially life-threatening or organ-threatening disease 
[92].  The proposed treatment algorithm (Figure 1.2) therefore suggests consideration 
of ‘stepping down’ induction therapy to methotrexate or mycophenolate mofetil in 
addition to corticosteroids instead of cyclophosphamide or rituximab and 
corticosteroids in cases of no organ threatening involvement and increasing the 
intensity of induction therapy by adding plasma exchange to high dose corticosteroids 
and cyclophosphamide or rituximab in the presence of vital organ or life-threatening 















Figure 1.2  AAV treatment algorithm   
Following disease assessment, induction of remission is achieved by the use of 
glucocorticoids (GC) and cyclophosphamide (CYC) or rituximab (RTX).  Methotrexate 
(MTX) or mycophenolate mofetil (MMF) can be considered in place of CYC or RTX in 
cases of no organ threatening involvement whilst plasma exchange (PLEX) should be 
added in cases of vital organ / life threatening features.  Maintenance is with 
azathioprine (AZA), MTX or RTX and gradual tapering of GC.  Reproduced from [92] 
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1.1.6 Morbidity and mortality in AAV 
1.1.6.1  Prognosis 
Prior to the use of treatment regimens that employ cyclophosphamide and high dose 
corticosteroids, AAV was almost universally fatal with 2-year survival rates of less than 
20% [74].  Current 5-year survival for AAV is approximately 80% [93] and although the 
disease remains life-threatening and potentially fatal if left untreated, modern 
therapeutic strategies as described in the previous section have transformed AAV into 
a chronic inflammatory condition with a relapsing-remitting course. 
 
1.1.6.2  Infection and cardiovascular disease in AAV 
Nevertheless, following induction of remission, AAV patients have a mortality ratio of 
2.6 compared to an age and gender matched general population [93].  Furthermore, 
although survival has greatly improved, one of the most significant challenges facing 
clinicians treating AAV patients at present is reducing treatment associated morbidity 
and mortality, particularly related to infection.  Indeed, a recent study that examined 
long-term prognosis in 535 patients with AAV that participated in four EUVAS clinical 
trials between 1995 and 2002 found that active disease was the cause of death in 19% 
of cases whereas infection accounted for 48% of deaths amongst patients who died 
within the first year after enrolment.  Following the first year, patients died mainly due 
to cardiovascular disease (26%), malignancy (22%) and again infection (20%).  As such, 
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infection and cardiovascular disease (CVD) represent the two most importance sources 
of morbidity and mortality in AAV.   
 
A matched pair cohort study has further highlighted the importance of CVD as a 
significant cause of morbidity and mortality in AAV [94].  In this study patients with 
AAV had a significantly higher incidence of cardiovascular events, with a hazard ratio of 
2.23, compared to matched patients with non-inflammatory chronic kidney disease 
(CKD), a group of patients already at an increased risk of CVD compared to the general 
population [95-97].   
 
Other studies have shown that patients with AAV display enhanced atherosclerosis 
[98] with increased surrogate markers of CVD such as endothelial dysfunction [99-101], 
arterial stiffness [102], carotid artery intima-media thickness [103] and a high 
frequency of arterial plaques [104], whilst further observational studies have observed 
increased morbidity from ischaemic heart disease in patients with AAV [98, 105].  The 
inflammatory nature of atherosclerosis, the underlying lesion in CVD, is becoming 
increasingly appreciated and excess mortality associated with other systemic 
inflammatory disorders such as rheumatoid arthritis and systemic lupus erythematosus 
has been attributed to accelerated atherogenesis leading to CVD [106-111].         
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Some of the clinical trials and studies discussed in the previous section have aimed to 
address the challenge of treatment related morbidity, particularly in relation to 
infection, for example by utilising pulsed cyclophosphamide rather than continuous 
daily cyclophosphamide [61, 71] in an effort to reduce overall dosage and toxicity, 
whilst other ongoing trials such as PEXIVAS aim to address whether it is possible to use 
lower doses of corticosteroids.   
 
Nevertheless there exists a significant unmet need to reduce the burden of infection 
and cardiovascular disease, two of the leading causes of death in patients with AAV.   
 
1.1.6.3  Dysregulated T-cell immunity contributes to AAV morbidity 
Aberrant T-cell immunity is relevant in the pathophysiology of disease related 
morbidity in AAV.  Indeed, Morgan et al. showed that in patients with AAV the size of 
the effector memory CD4+CD28null T-cell subset (discussed in detail in the next 
section) was correlated with an increased risk of infection, reduced renal function and 
increased mortality [112].  Importantly, expansion of CD4+CD28null T-cells in that 
study was not confined to AAV patients as both patients and controls exhibited similar 
proportions of CD4+CD28null T-cells.  CD4+CD28null T-cells however, were specific for 
Cytomegalovirus (CMV) seropositivity as only CMV seropositive AAV patients and CMV 
seropositive healthy controls exhibited significant expansions of CD4+CD28null T-cells.  
As such, dysregulation of T-cell immunity in AAV significantly impacts prognosis.      
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1.2 CD4+CD28null T-cells 
1.2.1 Organisation of the immune system 
The human immune system consists of an innate system that constitutes the first line 
of defence against foreign invading pathogens [113] and an acquired adaptive part 
that develops in response to infection, is able to recognise small differences in foreign 
molecules, recognise and eliminate foreign pathogens as well as develop 
immunological memory in order to provide an effective response upon re-challenge 
[114].  The lymphocyte population of the immune system is predominantly comprised 
of natural killer cells (NK) of the innate system and T-cells and B-cells that form part of 
the adaptive system.  In addition, other less common cell types such as NK T cells and 
 T cells have been described [115-117]. 
 
T-cells derive their prefix T from the fact that they mature in the thymus as opposed to 
B-cells that mature in the bone marrow [118].  T-cells are involved in cellular immunity 
where foreign antigens are recognised and suppressed by a cellular immune response, 
as well as in the generation and maintenance of self-tolerance.  Three main types of T-
cells have been characterised to date, cytotoxic T-cells (TC), helper T-cells (TH) and 
regulatory T-cells (TREG).  Cytotoxic and helper T-cells can be distinguished by the 
presence of CD8 and CD4 membrane glycoproteins on their surface, with CD4 T-cells 
generally functioning as helper T-cells [119].  The ratio of CD4+ to CD8+ T-cells is 
normally approximately 2:1 although this can be altered in various disease states [120, 
121] as discussed further in Section 1.3.4.   
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1.2.2 CD4 T-cells and their subsets 
Following activation CD4 T-helper cells, the key regulators of the immune system, are 
able to differentiate into various TH cell lineages with distinct biological functions 
(Figure 1.3).   
 
1.2.2.1  T-cell activation 
The traditional model of T-cell activation requires two signals for optimal activation of 
CD4 T-cells.  The first signal is provided by the interaction of the antigen with the major 
histocompatibility complex (MHC) and the T-cell receptor (TCR) whilst the second 
signal involves co-stimulatory cell surface molecule interaction on the antigen 
presenting cell (APC) with stimulatory receptors on the surface of the CD4 T-cell [122] 
(Figure 1.3).  The best characterised co-stimulatory pathway is the CD80/CD86 – 
CD28/CTLA-4 pathway where CD80 and CD86 represent ligands on the APC and CD28 
and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) represent stimulatory and 
inhibitory receptors on the surface of CD4 T-cells that orchestrate the responses of 
naïve, memory and effector cells [122-125].  In the absence of appropriate co-
stimulatory signals T-cells are thought to enter a state of anergy where proliferation 
and effector functions can be inhibited [126].  However, recently other alternative 
pathways of T-cell stimulation and inhibition including new members of the B7-CD28 
superfamily such as ICOS (inducible T-cell co-stimulator) and PD-1 (programmed death 
1) have been described [127, 128] and it is now accepted that other receptor ligand 
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interactions can support T cell proliferation and development of effector functions 
[129-131].      
 
 
Figure 1.3 CD4 T-helper subsets   
Following interaction with antigen presenting cells and depending on the nature of 
antigen stimulation signal received naïve CD4 T-cells differentiate into distinct T-cell 
subsets.  This process is enabled by recognised cytokines that provide the relevant 
‘polarising milieu’ and different CD4 T-cell subsets in turn are associated with secretion 
of key cytokines and distinct functions.   
Treg = T regulatory; ThF = T follicular 
Adapted from [132] under a Creative Commons Attribution Licence. 
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1.2.2.2  CD4 T-cell memory differentiation 
As alluded to CD4 T-cells can differentiate into distinct subtypes (Figure 1.3).  For some 
of these subtypes unique patterns of chemokine receptor expression have been 
described as a way of identification.  For example Th1 cells have recently been 
described to express the chemokine receptor CXCR3 (C-X-C motif chemokine receptor 
type 3) but lack expression of CCR6 (C-C motif chemokine receptor type 6) and CCR4 
(C-C motif chemokine receptor type 4) whereas Th2 cells express CCR4 but lack CXCR3 
and CCR6 expression whilst Th17 cells express both CCR4 and CCR6 but not CXCR3 
[133].   
 
Th1 cells produce the type 1 cytokines interferon gamma (IFN-), tumour necrosis 
factor alpha (TNF-) and interleukin 2 (IL-2) and are crucial in activating macrophages 
and enabling cell mediated immunity against intracellular pathogens [134].  Recently 
the role of Th1 cells in the development and exacerbation of inflammation in 
autoimmune disease as already discussed as well as in vascular pathology is 
increasingly being recognised [135, 136].      
 
CD4 T-cells can also phenotypically be described with regards to their differentiation 
status from naïve to effector and memory lymphocytes.  Naïve T-cells express the 
CD45RA isoform of CD45 as opposed to memory T-cells that express the CD45RO 
isoform and are generally negative for CD45RA expression [137].  In addition, naïve T-
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cells express the cell adhesion molecule L-selectin (CD62L) and the chemokine receptor 
CCR7 (C-C chemokine receptor type 7) and are able to circulate between peripheral 
blood and lymphoid tissue [138].  Following activation, naïve T-cells differentiate into 
effector cells.  Following clearance of the antigen, a large contraction phase ensues 
with some survivors differentiating to become memory cells that can confer long term 
protection and give rise to an enhanced response upon secondary antigenic challenge 
[139, 140].   
 
Memory T-cells are CD45RA negative and can be further sub-divided into central (CM) 
and effector memory (EM) subsets.  Central memory T-cells maintain expression of 
CD62L and CCR7 and are able to migrate into lymph nodes to mount secondary 
proliferative responses but lack effector functions [141].  Effector memory T-cells on 
the other hand exhibit heterogeneous expression of CD62L and have lost expression of 
CCR7.  They express characteristic sets of chemokine receptors and adhesion 
molecules, home into inflamed tissues and display immediate effector function [141, 
142].  Effector memory T-cells were originally described within the CD8 compartment 
but recently the existence of CD4 EM T-cells is increasingly being recognised [143, 
144].  As EM T-cells differentiate further they lose expression of CD27 and CD28 and 
gain expression of CD57 with a concomitant increase in cytolytic activity reflected by 
the ability to produce cytotoxic molecules like perforin, granzyme A and granzyme B 
[145].  Revertant EM T-cells are highly differentiated cells that have re-expressed 
CD45RA (EMRA) and show features of senescence and terminal differentiation [142].            
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1.2.3 CD28 expression and downregulation 
CD28 is constitutively expressed on the surface of CD4 and CD8 T-cells [122].  It is 
essential for optimal activation of T-cells and deletion of the CD28 gene in mice results 
in severe immunocompromise with reduced T-helper activity and impaired production 
of immunoglobulins [146], although the generation of T-cell cytotoxicity in these 
experiments was not affected suggesting the presence of alternate co-stimulatory 
pathways that can induce cytokine production [129, 146].  CD28 expression can be 
down-regulated leading to CD4 and CD8 T-cells that lack expression of CD28 
(CD4+CD28null; CD8+CD28null) that are now commonly seen with increasing age in 
healthy individuals as well as in the presence of chronic infection [147-151].  
CD4+CD28null T-cells lack CD28 mRNA indicating that CD28 downregulation occurs via 
transcriptional silencing that is reversible with IL-12 administration [147, 152].    
 
1.2.4 Characteristics of CD4+CD28null T-cells 
CD4+CD28null T-cells were first described in patients with rheumatoid arthritis (RA) 
[153, 154] but have since then been described in association with a multitude of 
inflammatory disorders [54, 155-167], viral infections [150, 168-170], cardiovascular 
disease [171-181] and in the context of an ageing immune system where they have 
been found to represent as much as 50% of the total CD4 compartment [149, 151, 
182].   
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They exhibit important differences compared to their CD4+CD28+ counterparts in that 
they are oligoclonal with limited TCR diversity [153, 154, 183], the loss of CD28 and 
oligoclonality both suggestive of repeated exposure to a persistent antigen [184].  
Furthermore, they show evidence of an increased replicative history as they have been 
found to contain significantly shortened telomeres [185, 186].  Despite that, 
CD4+CD28null T-cells are relatively resistant to apoptosis and are long lived [129, 182, 
185, 187].  They exhibit cytotoxic properties with the ability to produce Th1 type 
cytokines IFN- and TNF- as well as cytolytic enzymes such as granzyme B and 
perforin [167, 188-191].  They express the chemokine receptor CXCR3 and in that 
respect, resemble the chemokine receptor expression pattern of Th1 cells suggesting 
that they can be classified as cytotoxic Th1 type cells [184, 192].   
 
In addition, CD4+CD28null T-cells have been shown to express molecules that are 
usually found on the surface of cells of the innate immune system as well as an array 
of surface adhesion molecules.  CD4+CD28null T-cells express receptor molecules 
typically found on NK cells such as CD57 and CD11b [184], the latter being important in 
regulating leukocyte endothelial adhesion and inflammation [193], although they do 
not express the NK specific molecule CD16.  Furthermore, they do not express the 
invariant TCR -chain and therefore cannot be characterised as NK T cells [194].  
NKG2D receptors have been shown to be expressed by CD4+CD28null T-cells in RA, 
giant cell arteritis, polymyalgia rheumatica and AAV [55, 195-197] while other killer cell 
immunoregulatory inhibitory receptors (KIR) such as KIR2DS2 have been found on 
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CD4+CD28null T-cells from acute coronary syndrome (ACS), chronic kidney disease and 
RA patients [196, 198-200].  In RA the presence of KIR2DS2 is considered a risk factor 
for the development of vasculitis but not synovitis [184].           
 
As mentioned earlier, CD4+CD28null T-cells express CXCR3, the ligand of which, IP-10 
(interferon gamma-induced protein 10), has been implicated together with CXCR3 in 
the pathophysiology of inflammatory arthritis and atherosclerosis [201].  However, 
differential expression of CXCR3 has been observed in certain patient groups with 
psoriasis patients exhibiting a decreased proportion of CXCR3 expressing 
CD4+CD28null T-cells in the periphery [202].  Similarly, although CD4+CD28null T-cells 
from RA patients have been found to express CCR5 (C-C chemokine receptor type 5) 
thereby being able to traffic to the inflamed synovium [203], CCR5 expression has been 
shown to be very low in CD4+CD28null T-cells of ankylosing spondylitis patients [167] 
suggesting differential expression of chemokine receptors by CD4+CD28null T-cells in 
different inflammatory conditions.  Patients with RA and multiple sclerosis (MS) have 
also been shown to express the VLA-4 (Very Late Antigen-4) and LFA-1 (Lymphocyte 
Function Associated Antigen 1) receptors whose ligands VCAM-1 (Vascular Cell 
Adhesion Molecule-1) and ICAM-1 (Intercellular Adhesion Molecule 1) are found on 
endothelial cells as well as in soluble form and on APC (ICAM-1) [184]. 
     
Another important chemokine receptor expressed by CD4+CD28null T-cells is the 
receptor for fractalkine, CX3CR1 (CX3C chemokine receptor 1).  Fractalkine, or CX3CL1, 
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exists in a soluble as well as a membrane bound form and functions as both a 
chemoattractant (soluble form) and an adhesion molecule (membrane bound form) 
promoting shear resistant adhesion of CX3CR1 expressing leukocytes [204].  The role of 
fractalkine is increasingly being recognised in inflammatory pathology including 
atherosclerosis and renal disease [205-207] and membrane bound fractalkine can be 
induced on endothelial cells via activation by Th1 type inflammatory cytokines such as 
IFN- and TNF-.  CX3CR1 is expressed on CD4+CD28null T-cells from RA and MS 
patients.  In RA, activated synoviocytes express fractalkine [209-211], whereas in MS 
the chemokine gradient of soluble fractalkine induces migration of CD4+CD28null T-
cells in inflamed brain lesions [163].   
 
1.2.5 CD4+CD28null T-cells are associated with inflammation 
Given the characteristics of CD4+CD28null T-cells discussed above these cells are 
thought to represent a proinflammatory cytotoxic subset.  Furthermore, it has been 
shown that an inflammatory milieu contributes to the expansion of CD4+CD28null T-
cells explaining the association between this cell subset and chronic inflammatory 
conditions as well as with advancing age owing to the increase in proinflammatory 
cytokines that is known to occur with age [212-214].  In RA, Bryl et al. have shown that 
TNF- induces downregulation of surface expressed CD28 through transcriptional 
repression by inhibiting the binding of nuclear protein complexes that recognise 
regulatory sequences [212].  On the other hand, treatment with the anti-TNF- 
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monoclonal antibody infliximab in RA as well as in unstable angina patients leads to 
partial reappearance of the CD28 molecule on the CD4+ cell surface [175, 215-217].     
 
1.2.5.1  CD4+CD28null T-cell expansion in inflammatory disease states 
Following the original description of CD4+CD28null T-cells in RA [153, 154], expansions 
of these cells have been reported in a multitude of inflammatory conditions.  Recently 
they have been implicated in the pathogenesis of primary sclerosing cholangitis (PSC) 
where CX3CR1 expressing CD4+CD28null T-cells were found in higher frequencies in 
liver tissue from PSC patients compared to primary biliary cirrhosis or non-alcoholic 
steatohepatitis [218].  In the same study, TNF- was found in abundance in PSC liver 
tissue and TNF- downregulated the expression of CD28 in vitro, an effect that was 
prevented by administration of 1,25(OH)2D3 vitamin D.  CD4+CD28null T-cells have 
been shown to induce muscle cell death in vitro via secretion of granzyme B and 
perforin in experiments utilising cells from patients with polymyositis [219].   
 
CD28 downregulation on CD4 T-cells is associated with poor prognosis in patients with 
pulmonary fibrosis [220], extra-articular disease such as rheumatoid nodules and 
vasculitis in RA [221] and in vitro experiments have shown that CD4+CD28null T-cells 
may be implicated in the pathophysiology of MS, an effect that is augmented by IL-15 
[162, 163].  The frequencies of CD4+CD28null T-cells in RA and healthy individuals 
follow a bimodal distribution, defining carriers and non-carriers [221].  Given the 
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extensive association with inflammatory and autoimmune disease it has been 
postulated that CD4+CD28null T-cells are autoreactive in nature.  However, studies 
have failed to show auto-reactivity of these cells to RA or MS autoantigens and thus 
CD4+CD28null T-cells are more likely to cause pathology via indirect ways [159].      
       
1.2.5.2  CD4+CD28null T-cells in AAV 
Expansions of CD4+CD28null T-cells have been repeatedly observed in the peripheral 
blood of AAV patients and have been found in abundance in bronchoalveolar lavage 
fluid and within granulomas of patients with GPA [35, 36, 54, 222, 223].  The degree of 
expansion of CD4+CD28null T-cells has been shown to be proportional to the 
cumulative number of involved organs and hence disease severity across time but not 
with severity of acute disease or treatment [54].  These findings were confirmed in a 
recent study that showed no difference in the proportion of CD4+CD28null T-cells 
between AAV patients with active disease versus AAV patients in remission [224].  On 
the other hand, as already alluded to earlier, CD4+CD28null T-cell expansions in AAV 
patients have been associated with reduced kidney function, increased risk of infection 
and increased mortality [112].    
 
1.2.5.3  CD4+CD28null T-cells in renal disease 
Expansions of CD4+CD28null T-cells have also been described in patients with other 
immune mediated renal disease, chronic kidney disease (CKD) and end-stage renal 
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disease (ESRD).  In systemic lupus erythematosus (SLE), CD4+CD28null T-cells have 
been found to be independently associated with disease damage [155] echoing the 
findings in AAV.   
 
Yadav et al. found that amongst ESRD dialysis patients CD4+CD28null T-cells were 
cytotoxic as judged by their ability to produce granzyme B and perforin and were 
significantly expanded compared to healthy volunteers.  Furthermore, a greater 
proportion of CD4+CD28null T-cells from dialysis patients expressed granzyme B and 
perforin compared to healthy individuals [177].  Further studies have found 
CD4+CD28null T-cells to be associated with an increased risk of an atherosclerotic 
event shortly after renal transplantation [174], as well as increased early 
atherosclerotic damage defined as impaired flow-mediated vasodilatation and 
increased intima-media thickness in the carotid artery [173, 176, 178-181].  
Interestingly, in one study the size of the CD4+CD28null T-cell expansion was 
negatively correlated with serum vitamin D levels in agreement with the findings of 
Liaskou et al. in PSC patients [176, 218].   
 
Finally, in renal transplant recipients CD4+CD28null T-cells were associated with 
delayed graft function and reduced renal function, were found to express CX3CR1, 
NKG2D and cytolytic molecules and were capable of inducing glomerular endothelial 
cell apoptosis in vitro in an NKG2D dependent fashion [225]. 
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1.2.5.4  CD4+CD28null T-cells in cardiovascular disease 
The relevance of CD4+CD28null T-cells in cardiovascular disease was first noted in 1999 
when Liuzzo et al. compared cytokine production by T lymphocytes in patients with 
unstable angina versus stable angina.  They found a persistent increase in the 
proportion of CD4 and CD8 T-cells that produced IFN- in response to phorbol 
myristate acetate (PMA) and ionomycin and that this increased production of IFN- 
was attributed to an expansion of CD4+CD28null T-cells in patients with unstable 
angina [226].  The same investigators then showed that CD4+CD28null T-cells are 
preferentially found in unstable rather than stable atherosclerotic plaques suggesting a 
direct involvement of this cytotoxic subset in plaque disruption.  They also found that 
CD4+CD28null were highly oligoclonal and that clonotypes of different patients shared 
T-cell receptor sequences implicating chronic stimulation by a common antigen [227].  
In addition, CD4+CD28null T-cells were shown to possess the ability to lyse human 
umbilical vein endothelial cells (HUVECs) in in vitro cytotoxicity assays where cytolysis 
was dependent on granule exocytosis and augmented by pre-treatment of HUVECs 
with C-reactive protein (CRP) [228].  Since then several researchers have reported on 
associations between CD4+CD28null T-cell expansions and increased cardiovascular 
disease in the context of inflammatory disorders, diabetes and established ischaemic 
heart disease as already discussed [171, 173-175, 179, 180, 184, 205, 229] whilst 
CX3CR1 expressing CD4+CD28null T-cells linked to atherosclerotic damage have been 
described in RA and CKD patients [179, 230].   
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1.2.6 Origin of CD4+CD28null T-cells 
There is no current consensus in the literature as to the exact origin of CD4+CD28null 
T-cells [171, 184].  The oligoclonal nature of CD4+CD28null T-cells points to a 
persistent antigen as the driver behind their expansion and accumulating evidence 
now suggests that the bimodal distribution of CD4+CD28null T-cells can be explained 
by previous infection with CMV.  In a cohort of RA patients CD4+CD28null T-cells were 
only expanded in CMV seropositive patients [168, 231].  These findings were confirmed 
in MS patients [159] and renal transplant recipients [225].  Similarly in AAV significant 
expansions of CD4+CD28null T-cells are only found in CMV seropositive patients [112, 
224].  Furthermore, Morgan et al. showed that once CMV seropositivity was taken into 
account there was no difference in CD4+CD28null T-cell percentage between AAV 
patients and age-matched healthy volunteers [112]. 
 
Further support for CMV as the driver behind CD4+CD28null T-cells came from a study 
of renal transplant recipients where following primary CMV infection CD4+CD28null T-
cells capable of producing granzyme B and perforin emerged after cessation of the 
viral load indicating that CMV triggers their formation [232].  However it remains 
unclear as to what mechanisms are responsible for the maintenance and / or 
expansion of CD4+CD28null T-cells following primary CMV infection and during 
latency.      
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An intriguing alternative hypothesis for CD4+CD28null T-cell reactivity has also been 
proposed.  Zal et al. showed that CD4+CD28null T-cells from patients with acute 
coronary syndrome (ACS), but not from stable angina or healthy volunteers, 
recognised heat shock protein 60 (HSP60) as an antigen [200].  This association was 
confirmed in another study that found increased expression of IFN-, granzyme B and 
perforin when CD4+CD28null T-cells from CKD patients were incubated with HSP60 or 
HSP70 whilst again there was no reactivity in CD4+CD28null T-cells from healthy 
volunteers to these antigens [178]. 
 
Heat shock proteins can be expressed by all cells under certain conditions of stress 
such as oxidative stress or inflammation including exposure to proinflammatory 
mediators such as IFN- and TNF- potentially explaining this association.  
Furthermore, although there is some evidence for HSP60 being involved in 
atherogenesis in that high levels of autoantibodies specific for HSP60 have been 
associated with cardiovascular disease [234], the presence of high levels of HSP70 in 
serum is associated with protection against cardiovascular disease rather increased 
risk [233, 235].  Interestingly, an HSP60 epitope has recently been found to display 
homology with two human CMV-encoded proteins, UL122 and US28 [236].  In that 
study, patients with coronary artery disease were found to have circulating antibodies 
specific for this HSP60 epitope as well as the two homologous CMV proteins whereas 
healthy volunteers did not.  In addition, US28 is a chemokine receptor homologue 
encoded by CMV that has been established as a key mediator of CMV mediated 
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vascular pathology through its binding to several human chemokines including 
fractalkine [237].  As such, infection with CMV may lead to the induction of a cascade 
of immune responses leading to endothelial damage partly through molecular mimicry 
involving HSP60 [233] potentially explaining the observed reactivity of CD4+CD28null 
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1.3 Cytomegalovirus 
1.3.1 CMV epidemiology 
Human cytomegalovirus (CMV) is a common double stranded DNA beta herpes virus 
that has co-evolved with its human host over millennia.  Approximately 60-90% of the 
population worldwide is infected with CMV [238-241].  CMV is almost ubiquitous in 
developing countries in South America, Africa and Asia whereas in Western Europe 
and the United States the prevalence of infection increases with age with 
approximately 90% of individuals older than 90 years being infected compared to 40-
60% amongst middle aged people and is also significantly influenced by 
socioeconomical status [242-246].  Viral spread occurs through bodily fluids or vertical 
transmission and CMV remains a leading cause of congenital infections associated with 
a significant risk of developmental birth defects [243].  Furthermore, CMV is an 
important cause of opportunistic infection in immunocompromised individuals such as 
bone marrow and solid organ recipients and AIDS patients [247].           
 
1.3.2 CMV infection and the host response 
Following primary infection CMV establishes lifelong persistence through a latency 
phase from where the virus can be reactivated [246].  During acute infection the main 
target cells for CMV are epithelial and endothelial cells.  CMV can cause lytic infection 
in any cell type, in this way leading to organ specific symptoms and disease.  Latency 
however is mainly established in bone marrow and peripheral immature cells of 
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myeloid lineage [243, 248-252].  Acute CMV infection can be due to primary infection 
or reactivation, is characterised by constitutional symptoms and is usually subclinical 
although organ specific signs and symptoms can occur such as hepatitis, colitis, 
pancytopenia, retinitis or pneumonitis particularly in immunocompromised individuals 
[253].   
 
The host response to CMV involves both innate and adaptive immune mechanisms 
[254].  NK cells have an important role in the immediate control of acute CMV 
infection [255].  Humoural and cellular mechanisms are subsequently triggered in 
order to control primary CMV infection [256].  Viral replication is mostly controlled in 
an immunocompetent host although CMV reactivation has been documented in 
certain circumstances particularly associated with increasing age [257-259].   
 
The cell mediated response to CMV, primarily by CD8, but also CD4 T-cells, is crucial for 
successful immune surveillance and control of viral replication, as evidenced by a high 
rate of reactivation leading to severe clinical sequelae in patients with profound 
cellular immunodeficiency [260].  Patients receiving allogeneic bone marrow stem cell 
transplant grafts for the treatment of haematological malignancy are at a particularly 
increased risk of life threatening CMV reactivation.  This is especially the case when a 
CMV seropositive patient receives a graft that has been T-cell depleted or a graft from 
a CMV seronegative donor resulting in both cases in lack of specific anti-CMV immunity 
[261].  Adoptive immunotherapy has been performed by transferring donor derived 
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CMV-specific CD8+ clones [262, 263] or purified CMV-specific CD8+ T-cells by HLA-
peptide tetramer staining followed by selection with magnetic beads [261, 264].  
Transfer of virus specific CD8+ T-cells in these studies has been shown to lead to 
reconstitution of viral immunity, reduction in viral reactivation rates and in a recent 
clinical trial, clearance of infection refractory to anti-viral therapy [261].  Furthermore, 
the presence of CD4+ CMV-specific T-cells has been shown to be important for the 
persistence of transferred CD8+ T-cells [263].    
 
1.3.3 CMV leads to systemic dysregulation of the immune system 
CMV is increasingly been recognized as the most immunodominant infection 
encountered by the human immune system with up to 10% of the CD4 and 40% of the 
CD8 compartments being comprised of CMV specific T-cells [265].  In states of 
immunosuppression this is further increased [112] and may indeed reflect increased 
episodes of CMV reactivation.     
 
CMV infection in healthy individuals substantially modulates the peripheral lymphoid 
cell pool leading to the accumulation of effector memory (EM) (CD45RA- CCR7- CD28-) 
and late-stage differentiated (CD45RA+ CCR7- CD28-) CD8 and CD4 T-cells at the 
expense of a reduction in naïve T-cells (CD45RA+ CCR7+ CD28+) [266], a phenomenon 
that has been termed ‘memory inflation’ [267, 268].  The presence of large numbers of 
EM CMV-specific T-cells suggests recent encounter with viral antigen.  The highly 
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differentiated EM T-cells that accumulate following CMV infection are potent 
producers of proinflammatory cytokines such as TNF-.  Interestingly, it has 
recently been shown that TNF- can reverse the transcriptional silencing that keeps 
CMV in latency thereby forcing the virus out of latency into the lytic phase leading to 
reactivation [270].  CMV driven expansion of proinflammatory T-cells may therefore in 
this way lead to a positive feedback loop of further CMV reactivation although this is 
currently unclear.        
 
1.3.4 CMV is associated with inflammation and vascular pathology 
CMV has been repeatedly associated with an augmented inflammatory response [271-
273].  In a study of ESRD patients, CMV seropositivity was associated with 
inflammation, lower haemoglobin levels and a demand for a higher erythropoietin 
dosage that was also correlated to the size of the CD4+CD28null T-cell expansion [274].   
 
Several studies have suggested a link between CMV exposure and vascular pathology 
including cardiac allograft vasculopathy [275], increased mortality due to CVD in the 
context of renal transplantation [276, 277], atherosclerosis [278] and CVD in the 
general population [279].  In addition, CMV has been implicated in the development of 
hypertension [280, 281].  
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A study examining atherosclerotic plaques from 105 coronary artery bypass grafting 
(CABG) surgical patients found that the presence of CMV replication in plaques was 
linked to a 4-fold increase in the history of previous acute coronary syndrome after 
adjustment for other risk factors [282].  CMV may also contribute to a higher risk of 
atherosclerotic events following renal transplantation where pre-transplantation CMV 
exposure has been shown to be an independent risk factor for cardiovascular episodes 
in the post-transplantation period.  Furthermore the presence of actual CMV 
replication following transplantation further increases this risk [283].   
 
High CMV IgG antibody titres have been independently associated with systolic as well 
as diastolic blood pressure elevation and flow mediated vasodilation in young Finnish 
men [284] suggesting that latent CMV infection may lead to adverse vascular changes 
from a young age and may be linked to the development of arterial stiffness, an 
established surrogate marker of CVD risk.  Indeed a recent study from Birmingham has 
shown an association between CMV seropositivity and increased arterial stiffness in 
patients with chronic kidney disease [285].   
 
Furthermore, it has been shown that the host inflammatory response to chronic CMV 
infection is linked to immune-pathological pathways leading to vascular and 
endothelial injury.  Specifically the CD4 T-cell response to CMV can drive the 
expression of fractalkine on endothelial cells that are then susceptible to attack by 
monocytes and NK cells bearing the fractalkine receptor CX3CR1 [286].  Furthermore 
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CD4+CD28null CMV specific T-cells have been found to express high levels of CX3CR1 
and CXCR3 and in vitro and are able to migrate in a fractalkine and IP-10 dependent 
fashion towards activated endothelial cells inducing endothelial cell apoptosis [287], 
implicating CMV as the driving force behind the observed association between 
CD4+CD28null T-cells and cardiovascular disease.  Further confirmatory evidence has 
come from a recent study in octogenarians that found CMV seropositivity as well as 
expansions of CD4+CD28null T-cells to be associated with overall cardiovascular 
mortality as well as death from myocardial infarction and stroke [279].    
 
1.3.5 CMV is associated with immunosenescence 
Recent epidemiological evidence has linked CMV infection to an increased risk of 
morbidity and mortality in the elderly [267, 288-294].  CMV is thought to contribute to 
immunosenescence [288] and constitutes part of the ‘immune risk profile’ (IRP) 
comprised of an inverted CD4 to CD8 ratio of < 1, expansion of CD8 T-cells with a late-
stage differentiation phenotype, a low frequency of naïve T-cells, poor proliferative T-
cell responses, an increase in proinflammatory cytokines and CMV seropositivity [291].  
CMV seropositivity is associated with a CD4:CD8 ratio of < 1, poor cognition and 
functional disability in older adults [295].    
 
Abnormalities of the CD4 T-cell compartment are also increasingly noted with an 
increase in CD4 CMV-specific cells with age, leading to an expansion of CD4+CD28null 
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T-cells and a reduction in CD4 naïve T-cells [265, 296].  Furthermore, CMV infection 
may impair the body’s ability to fight heterologous infections such as Epstein Barr virus 
(EBV) [297], herpes simplex [298] and herpes zoster [299] and leads to decreased 
antibody responses following influenza vaccination [300]. 
 
Several studies have now linked chronic CMV infection to reduced responsiveness to 
the influenza vaccine.  In these studies a higher degree of inflammation (increased 
concentration of IL-6 and TNF-) amongst CMV seropositive patients as well as higher 
levels of anti-CMV IgG correlated with poor vaccine responses.  Importantly high 
frequencies of terminally differentiated CD4+CD28null T-cells were persistently 
associated with reduced vaccine-induced antibody responses [300-302]. 
 
1.3.5.1  CMV and immunological functional exhaustion 
In addition to memory inflation, functional exhaustion of CMV-specific cells may 
contribute to CMV driven immunosenescence by modulation of cytokine production 
over time leading to loss of function.  Following repeated antigen stimulation with 
viruses, such as HIV, cytokine production is progressively reduced in a hierarchical 
manner.  IL-2 production and cellular proliferative capacity is lost first, followed by 
TNF-α and finally IFN-γ production [303].  In a study of elderly CMV seropositive 
patients, up to 50% of CMV-specific CD4 T-cells were unable to produce IL-2 and only 
capable of IFN-γ production [304].  Furthermore, loss of IL-2 production by CMV-
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specific CD4 T-cells is associated with an increased risk of CMV end-organ disease in 
CMV seropositive individuals infected with HIV [305].  
 
Associated with cytokine modulation is an increase in the expression of inhibitory 
receptors cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 
(PD-1), T-cell immunoglobulin domain and mucin domain 3 (TIM-3) and lymphocyte 
activation gene 3 (LAG-3), as well as up-regulation of the transcription factor PR 
domain zinc finger protein 1 (BLIMP-1), thereby leading to attenuation of virus specific 
T-cell function [303].  In HIV seropositive patients [306] and in transplant patients with 
CMV viraemia [307], inhibitory receptors are expressed on CD4 CMV-specific cells, 
particularly CD4+CD28null T-cells, although to a lesser extent than found on CD4 HIV-
specific T-cells [306].  These findings were confirmed during primary CMV infection in 
pregnant women where CMV specific T-cells were found to have a reduced capacity 
for proliferation, decreased production of IL-2 and increased expression of PD-1 [308].    
 
On the other hand, recent studies have suggested that in younger people, CMV may 
confer immune protection against other pathogens.  For instance, CMV has been 
shown to augment immune responses to heterologous pathogens in young mice 
whereas it impairs immunity to other viruses in older mice [309-313].  CMV 
seropositive young adults exhibit enhanced antibody responses to influenza 
vaccination compared to CMV seronegative individuals [314] and in a study of 
Gambian infants, CMV infection was shown to enhance some immune responses in 
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infancy despite inducing an expansion of CD8 and CD4 late differentiated cells [315].  
Finally, Pera et al. have recently suggested that in young individuals (18-35 years old), 
CMV induces the expansion of a polyfunctional subset of CD4 T-cells co-expressing 
CD57 and CD154.   
 
The potential advantage conferred by past CMV infection in dealing with heterologous 
antigens during early life makes logical sense from an evolutionary perspective.  
Nevertheless, although the CMV induced expansion of proinflammatory T-cells may be 
protective to begin with, with advancing age and in the setting of inflammatory 
pathology, it is possible that inflammation drives a vicious circle of persistent CMV 
reactivation followed by further expansion of proinflammatory T-cells leading to the 
observed association between CMV and inflammatory pathology including 
cardiovascular disease.   
 
In terms of the role of CMV in immunosenescence, recent studies have continued to 
support the notion that CMV has a negative impact on cellular immunity to 
heterologous infection such as respiratory viral infections and influenza in older 
individuals [316, 317].  Furthermore in the study by Pera and colleagues the proportion 
of CD4+CD28null T-cells in CMV seropositive patients was inversely associated with the 
percentage of polyfunctional CD4+CD57+ T-cells even in young age [309] highlighting 
the complexities of the footprint of CMV infection on the immune system and 
suggesting a possible association between proinflammatory CMV specific T-cells and 
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immunosenescence even early on in life.  Finally, genetic factors are likely to also play 
a significant role in the observed variability of the impact of CMV on T-cell phenotypes 
[318].                
 
1.3.6 CMV replication in latency and pharmacological suppression 
The observed expansion of CMV specific EM cells including CD4+CD28null T-cells in 
inflammatory conditions and with advancing age suggests repeated exposure to CMV 
antigen.  There are no studies that have specifically assessed the extent of subclinical 
CMV reactivation in AAV.  However, a cross-sectional study of 18 patients with 
inflammatory connective tissue diseases such as SLE and RA on similar 
immunosuppressive therapy used in AAV, detected CMV reactivation in up to 41% of 
patients [319].  Furthermore, another study has detected CMV DNA in the urine of 90% 
of elderly individuals over a 6-month period supporting frequent sub-clinical CMV 
reactivation with advancing age [257].        
 
Valaciclovir, the prodrug of aciclovir, inhibits viral DNA polymerase and is incorporated 
in viral DNA leading to chain termination.  It has activity against several human viruses 
including CMV. Clinical trials in AIDS, bone marrow transplantation and solid organ 
transplantation have demonstrated that valaciclovir treatment leads to reduced viral 
load in blood and urine in AIDS patients [320, 321] and reduced episodes of clinical 
CMV disease in transplantation [322].  Prophylactic valaciclovir treatment for 3 months 
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in kidney transplant patients has been demonstrated to suppress viral replication 
leading to much lower rates of detectable CMV DNA in the blood compared to control 
patients [323].  In addition, treatment of CMV viraemia reduces PD-1 expression and 
increases IL-2 production in renal transplant recipients [307].  
 
To date there have not been any human interventional studies to determine whether 
treatment with an anti-viral agent can reduce subclinical CMV reactivation and 
whether this can ameliorate the negative effects of CMV on the immune system.  
Beswick et al. however have recently shown that valaciclovir therapy can potentially 
reverse the development of immunosenescence in elderly mice seropositive for 
murine CMV [324].  In this study, valaciclovir treatment for up to 12 months reduced 
the magnitude and differentiation of CMV-specific CD8 T-cells, increased the 
proportion of naïve CD8 T-cells and led to a reduction in influenza A virus loads 
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1.4 Summary and hypothesis 
Expansions of proinflammatory CD4+CD28null T-cells have been repeatedly reported in 
inflammatory conditions including AAV as well as in patients with ischaemic heart 
disease and older individuals.  Significant expansions of CD4+CD28null T-cells are only 
seen in CMV seropositive individuals, and in AAV, CD4+CD28null T-cells are associated 
with increased infection and higher mortality.   
 
In addition, CMV seropositivity and its association with an expansion of EM T-cells, 
including CD4+CD28null T-cells, is linked to immunosenescence and vascular 
pathology.  This is highly relevant in AAV where the two leading causes of morbidity 
and mortality are infection and cardiovascular disease.  However, the phenotype of 
CD4+CD28null T-cells in AAV has not been adequately described and it is currently 
unknown as to whether expansions of CD4+CD28null T-cells contribute to CVD risk in 
AAV.    
 
The mechanisms that drive the expansion of CD4+CD28null T-cells in CMV seropositive 
individuals are currently unclear.  It is also not known as to whether such CMV induced 
modulation of the immune system in inflammatory diseases can be reversed.  
Furthermore, there is some controversy in the literature in that alternative antigens 
have been postulated to be responsible for the expansion of CD4+CD28null T-cells.   
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In addition, the cytokine production and inhibitory receptor profile of CMV specific 
CD4+CD28null T-cells in patients with expansions of this subset have not yet been 
addressed.  Finally, the relationship between these features and control of CMV 
replication in vivo is also unknown.  
 
 
The hypothesis of the research presented here is that subclinical CMV reactivation in 
AAV drives the expansion of proinflammatory CD4+CD28null T-cells giving rise to 
adverse modulation of the immune system that progressively leads to vascular damage 
and immunosenescence thereby explaining the observed increase in infection and 
mortality seen in association with increased expansions of CD4+CD28null T-cells in AAV 
and that blocking subclinical CMV reactivation with valaciclovir will reduce expansion 
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1.4.1 Thesis aims and objectives 
The aims of this thesis were to characterise the ways in which CMV negatively impacts 
on the immune system in inflammatory conditions and determine whether this 
adverse modulation can be reversed using AAV as a model of inflammatory disease. 
 
The specific objectives of the research conducted were to: 
 Determine the phenotype of CD4+CD28null T-cells in AAV and compare this to 
age matched healthy volunteers 
 Investigate whether CMV specific CD4+CD28null T-cells in AAV are functionally 
exhausted by characterising their cytokine and inhibitory receptor expression 
and explore whether this has a bearing on the control of subclinical CMV 
reactivation  
 Determine the impact of CD4+CD28null T-cells on CVD risk in AAV by assessing 
their relationship to arterial stiffness, an established marker of CVD risk 
 Determine whether subclinical CMV reactivation drives the expansion of 
CD4+CD28null T-cells by conducting a proof of concept randomised controlled 
clinical trial in AAV patients, and finally 
 Explore whether pharmacological therapy can halt or reverse the adverse 
modulation of CMV on the immune system by blocking subclinical CMV 
reactivation in AAV patients. 
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Chapter 2 Methods 
2.1  Study Design Overview 
The aims and objectives of this research study were discussed in Chapter 1.  Central to 
the work undertaken during this PhD was the design and implementation of a proof of 
concept randomised controlled clinical trial.  The aim of the clinical trial was to test 
whether treatment with an oral anti-viral agent, valaciclovir, over 6 months can control 
subclinical CMV reactivation in AAV and in turn whether this can ameliorate CMV 
induced changes on the immune system.  The main objective of the clinical trial was to 
test the hypothesis that subclinical CMV reactivation leads to expansion of 
CD4+CD28null T-cells and that by blocking subclinical CMV reactivation the expansion 
of this cell subset can be halted or reduced.  The clinical trial arm of the study aimed to 
randomise 50 CMV seropositive AAV patients in disease remission, in an open label 
design to valaciclovir treatment for 6 months, versus no additional therapy.  In order to 
fully address the rest of the research study objectives, a cross-sectional study arm was 
also set up where additional AAV patients meeting the clinical trial eligibility criteria 
but that did not want to participate in the clinical trial, could be recruited for a one-off 
visit and undergo the same assessments and investigations that were performed on 
the clinical trial patients at their baseline visit.  Furthermore, the cross-sectional arm of 
the study aimed to recruit a total of 30 CMV seropositive healthy volunteers for an 
identical one-off visit in order to compare CMV induced changes on the immune 
system between AAV patients and healthy volunteers (Figure 2.1). 
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2.2  Clinical Trial Arm Design and Implementation 
The study protocol (Version 1.1) was approved by the Research Ethics Committee 
(REC) of Yorkshire & The Humber – Leeds West (REC reference 12/YH/0377) on the 21st 
of August 2012.  Approval was also gained by the University Hospital Birmingham 
(UHB) Research Governance Office (RnD) (Project reference RRK 4456) and the 
Medicines and Healthcare Products Regulatory Agency (MHRA) on the 20th of 
November 2012 (Eudract Number: 2012-001970-28).  
 
 
Figure 2.1 Study design diagram  
Clinical Trial Arm is shown on the left and the Cross-Sectional Arm of the study on the 
right side. 
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A total of six substantial amendments to the study protocol were submitted and 
approved by the REC, UHB Governance Office and the MHRA where appropriate.  The 
clinical trial was registered with ClinicalTrials.gov (Identifier NCT01633476).  The 
following section describes the clinical trial protocol and is based on the final version of 
the study protocol (Version 3.0; Appendix 2).  Section 2.3 is an excerpt of the trial 
protocol paper as published by Trials Journal [325] with minor formatting and 
explanatory modifications.  The author of this thesis was the first author in this paper 
and was extensively involved in the study design, applications for REC, MHRA and NHS 
Research and Development approvals and amendment approvals, study coordination, 
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2.3 Valaciclovir to prevent Cytomegalovirus (CMV) mediated adverse 
modulation of the immune system in ANCA associated VASculitis 
(CANVAS): Study protocol for a randomised controlled clinical trial   
 
2.3.1 Design 
This was a single-centre, open label, proof of concept, randomised controlled trial of 
oral valaciclovir treatment (2g four times a day; reduced appropriately depending on 
renal function) for 6 months versus no additional treatment, in CMV seropositive AAV 
patients in remission, followed by a 6 month follow up period.  No placebo was used.   
 
The primary outcome was the proportion of patients with CMV reactivation, as 
assessed by measurable viral load on quantitative blood and urine CMV polymerase 
chain reaction (PCR).  The secondary outcomes were safety, as defined by adverse 
events sufficient to stop treatment with valaciclovir, change in the proportion of CD4+ 
CMV specific T-cell population (defined for the purposes of the clinical trial as 
CD4+CD28null cells) and change in soluble markers of inflammation from baseline to 6 
months (Table 2.1).  Further tertiary and exploratory outcomes are listed in Table 2.1 
and included persistence of the effect of valaciclovir on the proportion of 
CD4+CD28null cells at 6 months post completion of treatment, change in the immune 
phenotype of CD4+ T-cells, change in CMV IgG titre and change in blood pressure and 
arterial stiffness parameters from baseline to 6 months. 
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Table 2.1 Clinical Trial Endpoints 
  Description Specific measurement variable 
Primary 
outcome 
    
  Proportion of patients with 
CMV reactivation 
Quantification of viral DNA copies in blood and urine by 
quantitative polymerase chain reaction (qPCR) 
Secondary 
outcomes 
    
  Safety Number of adverse events and incidence of events by system 
organ class 
Adverse events sufficient to stop treatment with study drug 
  Change in the proportion of 
CD4+CD28null cells from 
baseline to 6 months 
Proportion of CD3+CD4+CD28null T cells in peripheral blood 
  Change in the 
concentration of soluble 
markers of inflammation 
from baseline to 6 months 
Concentration of IL-2, tumour necrosis factor alpha (TNF-α), 
IFN-γ, IL-6, IL-10, IL-17 and highly sensitive C-reactive protein 
(CRP) in peripheral blood 
Tertiary 
outcome 
    
  Persistence of valaciclovir 
effect on the proportion of 
CD4+CD28null cells from 6 
months to 12 months 
Proportion of CD3+CD4+CD28- T cells in peripheral blood 
Exploratory 
outcomes 
    
 Change in the absolute 
count of CD4+CD28null T-
cells from baseline to 6 
months 
Absolute count of CD3+CD4+CD28null T-cells 
  Change in other associated 
T-cell subsets from baseline 
to 6 months 
Proportion of CD4+CD28null cells secreting IFN-γ in response 
to CMV lysate stimulation 
Proportion of CD3+CD4(-)CD28null T cells in peripheral blood 
 Change in CMV IgG 
antibody titre 
CMV IgG titre 
  Change in soluble markers 
of endothelial damage from 
baseline to 6 months 
Concentration of fractalkine, IP-10, regulated on activation, 
normal T cell expressed and secreted (RANTES), P-selectin, E-
selectin, monocyte chemoattractant protein-1 (MCP-1), 
soluble vascular cell adhesion molecule 1 (sVCAM-1) and 
soluble intracellular cell adhesion molecule 1 (sICAM-1) in 
peripheral blood  
  Change in arterial stiffness 
baseline to 6 months 
Carotid to femoral pulse wave velocity 
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The trial sponsor was the University of Birmingham and the study was delivered 
through the National Institute for Health Research (NIHR) / Wellcome Trust (WT) 
Clinical Research Facility (CRF) at the University Hospital Birmingham (UHB) NHS 
Foundation Trust that also hosts the UHB Vasculitis Clinic.  The trial was funded by the 
Wellcome Trust and Vasculitis UK.  The trial was coordinated by the Trial Management 
Group (Table 2.2) according to the current guidelines for Good Clinical Practice (GCP) 
and ensuring protection of patients’ rights as detailed in the Declaration of Helsinki.  
All laboratory assays were carried out in laboratories that fulfil the principles of Good 
Laboratory Practice and assays informing the primary and secondary outcomes were 
fully validated prior to study commencement (see Section 2.7).  The protocol was 
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Table 2.2 Trial Management Group (TMG) 
 Role Institution 
Professor Lorraine Harper Principal Investigator Institute of Clinical 
Sciences, University of 
Birmingham 
Dr Dimitrios Chanouzas Co-Investigator 
Analytical Project Manager 
Institute of Inflammation 
and Ageing, University of 
Birmingham 
Dr Matthew Morgan Co-Investigator Institute of Clinical 
Sciences, University of 
Birmingham 
Professor Paul Moss Co-Investigator Institute of Immunology 
and Immunotherapy, 
University of Birmingham 
Dr Peter Nightingale Statistical Advisor Wolfson Computer 
Laboratories, University 
Hospital Birmingham 
Sister Linda Coughlan Research Nurse NIHR Clinical Research 
Facility, University Hospital 
Birmingham 
Sister Annabel Grinbergs Research Nurse NIHR Clinical Research 





2.3.2  Participants 
CMV seropositive patients with AAV in stable remission for 6 months or longer and on 
a maximum of two immunosuppressant agents were recruited from the Vasculitis 
Clinic at UHB NHS Foundation Trust.  Recruitment took place over 15 months.  Patients 
were approached at routine clinic visits.  Patients could also be contacted via post by 
sending them a copy of the Patient Information Sheet (PIS; Appendix 3).  Patients were 
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allowed a minimum of 24 hours to reflect on the content of the PIS before informed 
written consent was obtained by completion and signing of the study specific informed 
consent form (ICF; Appendix 3).   
 
A full list of study inclusion and exclusion criteria is given in Table 2.3.  In addition, 
patients on TNF inhibitors or subcutaneous immunoglobulin (Ig) therapy were not 
eligible for inclusion into the trial as TNF inhibitors can lead to re-expression of CD28 
on CD4+CD28null T-cells [215] and subcutaneous Ig treatment can interfere with the 
production and relative concentration of anti-CMV IgG antibodies [329].  Subjects were 
withdrawn from the trial if they chose not to continue or the investigators felt that 
continued participation in the trial was inappropriate.  Subjects who withdrew from 
the intervention were asked if they would be prepared to continue to attend follow up 
clinics.  The study’s primary and main secondary outcomes were based on objective 
laboratory assays, therefore minimising the risk of performance bias in this open-label 
design.  Furthermore, treatment and medical management other than valaciclovir was 
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  Documented diagnosis of granulomatosis with polyangiitis (Wegener’s), 
microscopic polyangiitis or renal limited vasculitis according to Chapel Hill 
Consensus Conference Criteria 
  In stable remission (no documented clinical disease activity) for at least 6 
months prior to study entry 
  On maintenance immunosuppression with prednisolone, mycophenolate 
mofetil or azathioprine alone or in combination (maximum two agents) 
  Documented past evidence (any time point) of CMV infection (CMV-specific 
immunoglobulin G detected in peripheral blood) 
  Documentation that female patients of child-bearing potential are not 
pregnant and are using an appropriate form of contraception 




  Stage 5 CKD (estimated glomerular filtration rate (eGFR) <15 mL minute-1 
1.73 m-2); tests performed within 6 months of pre-baseline visit can be used 
for this assessment 
  Other significant chronic infection (HIV, hepatitis B, hepatitis C or 
tuberculosis) 
  B-cell depleting therapy within 12 months or T-cell depleting therapy within 
6 months 
 Treatment with TNF inhibitors or treatment with intravenous or 
subcutaneous immunoglobulin within 6 months 
  Treatment with anti-CMV therapies in the last month 
  Underlying medical conditions, which in the opinion of the investigator 
place the patient at unacceptably high risk for participating in the study 
  Inability to participate fully or appropriately in the study 
 
2.3.3 Schedule of Assessments 
Patients attended for a total of 14 visits over a period of just over 12 months (Figure 
2.2).  Evaluation of CMV reactivation by deoxyribonucleic acid (DNA) PCR of blood and 
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urine was done monthly.  Evaluation of the tolerability of the drug and adverse events 
occurred monthly.  Immune assessments as detailed below and in Table 2.1 were 
performed at entry, 6 months and 12 months (Figure 2.2).   
 
Figure 2.2 SPIRIT figure showing study’s schedule of enrolment, intervention and 
assessment.   
M0: baseline visit; M1 to M12: month 1 to month 12; qPCR: quantitative polymerase 
chain reaction.  * Safety blood tests were only performed on treatment group. 
Following informed written consent patients underwent an initial pre-baseline visit.  
During this visit a 5mL blood sample was drawn that was used to determine the 
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percentage of CD4+CD28null cells.  This value was utilised in the stratification of 
patients as explained below. 
 
At the baseline, 6 month and 12 month visits, a total of 50mL of blood sample was 
drawn in addition to a 50mL sample of urine.  The samples were used to determine 
CMV viral copies by DNA PCR in blood and urine (primary outcome), the proportion of 
CD4+CD28null cells in peripheral blood by flow cytometry (secondary outcome), the 
concentration of soluble markers of inflammation (Table 2.1) in peripheral blood 
(secondary outcome) and immune assessments and T-cell phenotyping as detailed in 
the exploratory outcomes (Table 2.1).  Excess sample was stored appropriately.  Blood 
pressure and arterial stiffness measurements were also carried out at the baseline, 6 
month and 12 month visits as detailed below. 
 
During the remainder of the monthly visits, a 10mL blood sample was drawn in 
addition to a 50mL sample of urine used to determine CMV viral copies by DNA PCR in 
blood and urine (primary outcome).  Excess sample was again stored appropriately. 
 
In addition, safety blood tests as defined below were performed monthly for the 
duration of treatment for those patients randomised to receive the drug. 
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Appointments were scheduled on a monthly basis with an allowance of 10 days either 
side of the estimated due date of the monthly appointment in order to allow for 
patient convenience and flexibility.  The overall treatment period (or control period) of 
6 months was also subject to the same 10 day rule in order to avoid excessive 
movement of the length of treatment. 
 
2.3.4 Study Assessments 
Enumeration of CMV DNA copies for the determination of the primary outcome (CMV 
reactivation) was carried out by PCR of plasma and urine.  This assessment was 
performed by the UHB Virology Laboratory using an existing validated assay utilised for 
clinical samples. 
 
Whole blood was stained with fluorochrome conjugated monoclonal antibodies to 
CD3, CD4 and CD28 and analysed via flow cytometry (LSR II Flow Cytometer, DIVA 
Software; BD) in order to determine the proportion of CD4+CD28null cells in peripheral 
blood.  Plasma was assessed via luminex technology for the determination of soluble 
markers of inflammation (Table 2.1).  These assays were validated for precision and 
reproducibility prior to commencement of the trial (Section 2.7).   
 
Blood pressure and arterial stiffness determination were conducted using the Vicorder 
system (Skidmore, Bristol, UK) [330, 331].  Carotid to femoral pulse wave velocity 
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(cfPWV) was used to estimate arterial stiffness (see Appendix 4 for detailed Work 
Instruction used).  The Vicorder system provides a non-invasive non-operator 
dependent method of obtaining cfPWV using a volume displacement method.  Patients 
were rested in a supine 30 degrees head tilt position for 5 minutes prior to inflating a 
100 mm wide blood pressure cuff on the non-dominant arm to determine peripheral 
blood pressure.    A 30 mm wide partial cuff was placed on the neck at the level of the 
carotid artery and a 100 mm wide blood pressure cuff placed around the proximal 
thigh.  The distance between the mid-clavicular point and the mid-point of the thigh 
cuff was measured and entered in the Vicorder instrument as the aortic path length.  
The neck and thigh cuffs were inflated to 60mm Hg and the Vicorder instrument 
utilised the resultant oscillometric signal to extract the pulse waveforms and pulse 
transit time to calculate cfPWV.  The mean value of three consistent recordings was 
used for subsequent analysis.  Inconsistent values were re-analysed by a senior 
independent examiner not involved in taking the measurements to determine the 
validity of each measurement.      
 
2.3.5 Randomisation 
Randomisation was performed using the University of Birmingham Primary Care 
Clinical Research and Trials Unit’s (PC-CRTU, fully accredited by the NIHR as a trials 
unit) independent telephone based randomisation system. Block randomisation by 
CD4+CD28null cell percentage stratification was used (cut off 40%).  The randomisation 
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used mixed blocks of random size (two, four or six), not known to the research team, 
therefore, minimising any risk of selection bias.   
 
2.3.6 Treatment 
Patients randomised to the treatment arm received valaciclovir orally at 2g four times 
a day.  The dose was reduced appropriately depending on renal function (Table 2.4).  
The study was open label and valaciclovir was used ‘off the shelf’ with no modifications 
to the packaging or labelling of the product.  Patients were asked to return unused 
tablets at each monthly visit in order to monitor compliance with medication.  Patients 
randomised to the control arm received no additional treatment.  Safety blood tests 
were conducted monthly for the duration of treatment for the patients randomised to 
valaciclovir and comprised of full blood count (FBC), urea and electrolytes (U+E) and 
liver function tests (LFT).  In the event of toxicity (scored using the NCI Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0) of grade 2 or less, the 
adverse event was discussed with one of the Investigators to determine whether drug 
administration should be temporarily withdrawn or the dose reduced.  In the event of 
toxicity of grade 3 or more, the adverse event was discussed with the Principal 
Investigator (PI).  In such a case the expectation was to withdraw drug administration 
for one week unless the adverse event was judged by the PI to be unrelated to the 
study drug.  Re-introduction of the drug was based on clinical review.  The collection 
and reporting of data on adverse events and serious adverse events was in accordance 
with EU Directive 2001/20/EC and UK Legislation.   
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Table 2.4 Dose modification of valaciclovir according to creatinine clearance 
Creatinine clearance (CrCl mL/min)a  Valaciclovir dose 
>75 2 g four times a day 
51–75 1.5 g four times a day 
26–50 1.5 g three times a day 
10–25 1.5 g two times a day 




2.3.7 Sample Size Calculation and Planned Statistical Analyses 
In an immunocompetent elderly population CMV reactivation occurred in 90% at 6 
months [257].  It was expected that CMV reactivation would be at least that in the AAV 
population as they are significantly immunosuppressed.  Information for dosing 
regimens using antiviral prophylaxis in renal transplant recipients has demonstrated 
over 90% suppression of CMV reactivation [323].  The trial sample size assumed 90% 
reactivation in the control limb and a conservative estimate of 50% reactivation in the 
treated group.  The estimated sample size was 50 patients, 25 patients in each arm, 
based on 80% power at a significance level of p<0.05 (two tailed test).  The UHB 
tertiary referral vasculitis clinic has more than 200 patients under long-term follow up.  
Approximately 90% of patients are in remission at any one time and 70% are 
seropositive for CMV.  CMV status is checked routinely on the first patient attendance 
in clinic.    It was anticipated that 125 patients attending the clinic would be eligible for 
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the study.  Recruitment of 40% would achieve the target of 50 patients.  This was a 
conservative rate given previous experience with patient recruitment at the UHB 
vasculitis clinic.     
 
All analyses were performed using the intention to treat principle.  Baseline covariates 
were compared between the two arms to observe balance and the success of 
randomisation.  The primary analysis tested the hypothesis that there was no 
difference in the proportion of patients with CMV reactivation between those 
receiving antiviral prophylaxis compared with those receiving usual treatment.    For 
secondary outcomes comparisons were made between groups using absolute 
measures of immune function and change between data at entry and end of treatment 
within groups.  Missing data were dealt with by simple imputation if missing randomly.   
 
A safety analysis was performed on all treated patients.  The number of events and 
incidence of adverse events by system organ class were summarised and relationship 
to treatment noted. 
 
2.3.8 Trial Management and Monitoring 
The trial was coordinated by the Trial Management Group (Table 2.2) and facilitated by 
the infrastructure provided by the NIHR / WT CRF.  A Trial Steering Committee (TSC) 
that included the TMG as well as two Independent Consultant Nephrologists not 
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involved in the study or regular review of patients recruited in the trial provided the 
overall supervision of the trial.  The TSC oversaw trial progress, protocol compliance, 
patient safety and review of updated information.  Part of the role of the TSC was to 
review safety data after the first 10 patients completed treatment in order to ensure 
that the rate and severity of adverse events was not disproportionate to what would 
be expected with valaciclovir treatment.  As this was a small proof of concept study 
with a short follow-up, no data monitoring committee was formed, as agreed with the 
sponsor.  Any protocol amendments were submitted to the sponsor and relevant 
regulatory bodies for approval prior to implementation and trial participants were 
informed of any protocol modifications.      
 
The University of Birmingham conducted regular monitoring visits in its capacity as the 
trial sponsor to ensure compliance with the protocol and adherence to GCP and 
regulations.   
 
The integrity of data entry was ensured using a trial-specific Data Input Quality Control 
standard operating procedure (Appendix 5).  Samples were anonymised and all 
analyses were undertaken on anonymised datasets with study identifiers replacing 
personal data.  All personal details were kept on NHS secure password-protected 
servers within UHB NHS Trust.  Anonymised data was transferred to password-
protected servers in the University of Birmingham for analysis.   
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2.3.9  Funding Declaration 
The majority of this study was funded by the Wellcome Trust following a competitive 
peer review process as part of a Research Training Fellowship Grant (097962/Z/11/Z).  
The cost of the study drug was funded by Vasculitis UK.  The study was carried out at 
the National Institute for Health Research (NIHR) / Wellcome Trust Birmingham Clinical 
Research Facility.  The views expressed are those of the author and not necessarily 
those of the NHS, the NIHR or the Department of Health. 
 
2.3.10 Sponsor 
The CANVAS study was sponsored by the University of Birmingham (Dr Sean Jennings, 
Research Governance and Ethics Manager, Research Support Group, University of 
Birmingham, Edgbaston, Birmingham, B15 2TT, UK).  The University of Birmingham 
holds public liability (negligent harm) and clinical trial (negligent harm) insurance 
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2.4 Clinical Trial Sample Flow and Analysis 
The collection and processing of clinical trial samples is shown in detail in Figure 2.3 
(see also Laboratory Manual in Appendix 6).  Briefly, monthly samples were used to 
measure the CMV viral copy load in plasma and urine (primary outcome; section 2.6.1) 
via quantitative polymerase chain reaction (qPCR), as well as estimate the CMV IgG 
titre in plasma (exploratory outcome; section 2.6.8).  Whole blood from the baseline, 6 
month and 12 month visits was used to determine the proportion of CD3+CD4+CD28- 
T-cells (secondary outcome; section 2.6.2), enumerate CD45+CD3+CD4+ T-cells and 
characterize expression of chemokine receptors and memory markers in a subset of 
patients via polychromatic flow cytometry.  Plasma sample from the baseline and 6 
month visits was used to measure soluble cytokines and inflammatory markers using 
Luminex technology (secondary outcome; section 2.6.3).  Peripheral blood 
mononuclear cells (PBMC) were isolated monthly and cryopreserved in liquid nitrogen 
(section 2.6.4).  This enabled the tracking of the CD4+CD28null T-cell percentage over 
the 12 month study period in a subset of clinical trial control patients that reactivated 
CMV during the study (section 2.6.7).  Furthermore, at the baseline, 6 month and 12 
month visits, following isolation, fresh PBMC were stimulated overnight with CMV 
lysate or staphylococcal enterotoxin B (SEB) in order to interrogate the phenotype of 
CMV specific T-cells via flow cytometry with respect to cytokine production and 
inhibitory receptor expression (exploratory outcome; section 2.6.5).   
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Figure 2.3 Clinical Trial Sample Flow and Planned Analyses 
EDTA: Ethylenediamine tetra-acetic acid; LH: Lithium Heparin; UHB: 




2.5  Cross-Sectional Arm Design 
As alluded to earlier, the cross-sectional arm of the study was designed to be 
comprised of a maximum of 65 CMV seropositive AAV patients in remission and 30 
CMV seropositive healthy volunteers.  The AAV patient group within the cross-
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sectional arm was comprised of the clinical trial participants as well as an additional 
cohort of 15 patients that attended for a single visit.  Importantly, the additional AAV 
patients recruited into the cross-sectional arm fulfilled the same eligibility criteria as 
the clinical trial patients (Table 2.3).  In recruiting the healthy volunteers all efforts 
were made to match the overall age and gender of the AAV patient and healthy 
volunteer groups.   
 
Healthy volunteers were identified from non-interventional studies at the NIHR / WT 
Clinical Research Facility (CRF), friends and family of AAV patients or the research team 
and the 1000 Elders Cohort (courtesy of Professor J. Lord, Institute of Inflammation 
and Ageing, University of Birmingham).  Past or current systemic inflammatory or auto-
immune disease as well as treatment with immunosuppression therapy was an 
exclusion criterion for HV.  Anti-hypertensive medication and asthma steroid inhalers 
were permissible.   
 
2.5.1 Schedule of assessments 
Healthy volunteers were screened in an initial visit where blood was drawn in a lithium 
heparin tube and plasma assayed for the presence of IgG antibodies to CMV (section 
2.6.7).  Subsequently, CMV seropositive healthy volunteers and CMV seropositive AAV 
patients that were recruited directly into the cross-sectional arm of the study attended 
for a single visit.  During this visit the assessments performed were the same as those 
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performed on the clinical trial patients during their baseline visit (sections 2.3.3, 2.3.4 
and 2.4) with the exception that CMV viral load was not measured as preliminary 
clinical trial data had revealed a relatively low level of CMV reactivation.  Blood 
pressure and arterial stiffness parameters were also assessed as described in section 
2.3.4.  The data points from the baseline visit of the clinical trial patients were 
employed for all analyses undertaken within the cross-sectional arm of the study and 
together with the data points from the additional AAV patients recruited directly into 
the cross-sectional arm constituted the AAV patient cohort within this arm of the 
study.   
 
2.6  Laboratory Assays  
This section describes the experimental details of the assays employed in the study.  
All assays that were used to inform the primary and secondary outcomes of the clinical 
trial arm of the study were formally validated as detailed in section 2.7.  All cell culture 
experiments and flow cytometry staining were performed in 5mL FACS tubes.  
Centrifuges used were GS-6R (Beckman) and Prism Microcentrifuge (Labnet). 
 
2.6.1 Viral load quantitation 
Measurement of CMV viral copies in plasma and urine constituted the primary 
outcome of the clinical trial arm of the study.  For this assay blood was drawn in an 
EDTA tube and urine was collected in a universal container and sent to the UHB 
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Virology Laboratory for processing in exactly the same way as clinical samples.  There 
the blood was centrifuged immediately at room temperature for 5 minutes at 3000 
rpm (Thermo Megafuge) to isolate the plasma fraction.  No additional processing was 
performed on the urine samples.  Samples were then stored at 4oC upright for a 
maximum of 72 hours before proceeding to determining the number of viral copies per 
millilitre using a well validated for clinical use qPCR assay (RealTime CMV, Abbot) that 
the UHB Virology Laboratory employs for all clinical samples. 
 
The Abbott RealTime CMV assay targets 2 short sequences within the UL34 and UL80.5 
genes of the CMV genome.  These regions are specific for CMV and are highly 
conserved based on analysis of published CMV sequences [332-334].  The assay is 
standardised against the 1st World Health Organisation (WHO) International Standard 
for Human Cytomegalovirus for Nucleic Acid Amplification Techniques (NIBSC 09/162) 
[335].  Results are reported in this thesis in viral copies / mL.  The lower limit for 
reporting positive results at the UHB virology laboratory is 200 viral copies / mL and 
therefore this was the lower limit of quantitation used for all primary analyses in this 
thesis.  However the RealTime CMV assay can quantitate down to a lower limit of 20 
viral copies / mL and therefore this threshold was utilised in secondary analyses.  
 
The Abbott RealTime CMV assay at the UHB virology laboratory is fully automated 
using the Abbott m2000sp and Abbott m2000rt instruments.  The assay combines PCR 
technology with homogeneous real time fluorescent detection for the quantitation of 
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CMV DNA.  An unrelated DNA sequence is also introduced into each specimen during 
sample preparation.  This sequence is amplified at the same time as any potential 
existing CMV sequence and functions as an internal control in order to verify that the 
assay has been completed successfully for each sample.  A positive and a negative 
control are also included with each assay run.   
 
Briefly, the virions are lysed in a step that includes proteinase K to digest proteins 
associated with the sample.  The nucleic acids are then extracted, concentrated and 
purified from the sample by the m2000sp automated instrument with the use of 
magnetic microparticles.  The bound nucleic acids are automatically eluted and 
transferred to a 96 well plate ready for amplification at which point the internal 
control is also introduced into the sample.  The CMV amplification reagent 
components (CMV Amplification Reagent that contains specific sets of amplification 
primers for CMV and the internal control, DNA polymerase, and Activation Reagent) 
are dispensed into the 96 well optical reaction plate along with aliquots of the nucleic 
acid samples already prepared and following manual application of the optical seal the 
plate is transferred to the Abbott m2000rt instrument.   
 
There the target DNA is amplified in the presence of deoxynucleotide triphosphates 
(dNTPs) and magnesium.  During each round of PCR amplification, if a suitable target is 
present the fluorescent probes anneal to the amplified target DNA.  Any CMV and 
internal control amplified sequences are distinguished from each other as their 
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respective probes are labelled with different fluorescent molecules.  The amplification 
cycle at which fluorescent signal is detected by the Abbott m2000rt is inversely 
proportional to the log of the CMV DNA concentration present in the original sample.  
Figure 2.4 shows an example of a positive and a negative for CMV viral copies assay 



























Figure 2.4 Quantitation of CMV DNA in plasma and urine 
Quantitation of CMV viral copies in plasma and urine samples for determination of the 
primary outcome was carried out by the UHB Virology Laboratory using the Abbott 
RealTime CMV assay.  The top panel shows the result of a positive run where CMV 
target has been detected at PCR amplification cycle 25.03 equating to a CMV viral copy 
number of 3,840 copies / mL whereas the bottom panel shows the results from an 
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2.6.2 Whole blood surface staining of lymphocytes 
Whole blood surface staining was used to estimate proportions of CD3+CD4+CD28- T-
cells, enumerate CD4 T-cells directly and assess the T helper and memory phenotype 
of CD4+CD28- T-cells in a proportion of patients.  Blood was drawn in lithium heparin 
(LH) tubes, left upright on the bench at room temperature, and used within a 
maximum of 5 hours of the draw.  Briefly, 100 L of whole blood, or 50 L of Cytofix 
CD4 positive control (see Section 2.7.2), was aliquoted and stained with a freshly 
prepared monoclonal antibody mix conjugated to appropriate fluorochromes (Table 
2.5) for 30 minutes at 4oC prior to incubating for 15 minutes at room temperature with 
2 mL of ready to use Red Blood Cell Lysis Buffer (eBioscience).  The sample was then 
centrifuged at 584g for 5 minutes to pellet the cells, the supernatant was decanted 
and 2 mL MACS buffer (phosphate buffered saline (PBS), 2mM EDTA, 0.5% bovine 
serum albumin (BSA)) was added to wash the cells.  After centrifugation at 584g the 
cells were re-suspended in 200 L MACS buffer.   
 
A fluorescence minus one (FMO) control was assayed with each experimental run as an 
aid for CD28 gating, where the FMO was stained with CD3, CD4 and an isotype control 
conjugated to the same fluorochrome as the CD28 monoclonal antibody (Table 2.5).  
As this assay was used to inform one of the secondary outcomes of the clinical trial it 
was formally validated before use as described in section 2.7.  For all flow cytometry 
experiments described, single stain compensation tubes were used to automatically 
set compensation values prior to running the experimental tubes (Table 2.6) and 
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events were acquired on a BD LSR II Flow Cytometer (default laser and filter 
configuration) and analysed using FACS DIVA Software Version 8.0 (BD).  
Compensation was manually checked off-line for accuracy and corrected where 
necessary.  The photomultiplier tube (PMT) voltages were set at the optimisation stage 
for each panel and kept constant throughout the experiments with only minor 
modifications where necessary.   
 
In a proportion of AAV patients and healthy volunteers 100 L of whole blood was also 
stained with a different antibody mix (Table 2.7) in order to phenotype CD4+CD28- T-
cells for T helper sub-type according to the expression of chemokines CXCR3, CCR6 and 
CCR4.   
 
In order to directly determine the absolute count of CD4 T-cells, 50 L of whole blood 
was aliquoted and stained with a freshly prepared monoclonal antibody mix 
conjugated to appropriate fluorochromes (Table 2.8) for 30 minutes at 4oC prior to 
incubating for 15 minutes at room temperature with 450 L of 1 x Red Blood Cell Lysis 
Buffer (Biolegend) (10 x Red Blood Cell Lysis Buffer was diluted 1:10 with distilled 
water).  Without washing, 50 L of counting beads (CytoCountTM, Dako) was added to 
the sample prior to acquiring events on the flow cytometer.   
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In order to calculate the cell number of a gated population, the number of events 
counted for the cells of interest was divided by the number of counting beads counted 
and multiplied by the concentration of the lot of CytoCountTM beads used in the 
experiment.    
 
 
Table 2.5 Antibodies used in the whole blood surface staining assay to determine 
CD4+CD28- proportions (secondary outcome) 
Marker Fluorochrome Isotype Clone Concentration  
L / test 
Company 




OKT3 12 g/mL 
2 L 
Biolegend 




OKT4 100 g/mL 
2 L 
Biolegend 
CD28 eFluor 450 Mouse 
IgG1,  
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Marker Channel Fluorochrome Isotype Clone Concentration 
L / test 
Company 
CD4 FITC FITC Mouse, IgG1, 
 
RPA-T4 200 g/mL 
3 L 
eBioscience 
CD4 PE PE Mouse, IgG1, 
 





















SK7 12 g/mL 
3 L 
eBioscience 
CD4 PE-Cy7 PE-Cy7 Mouse, IgG1, 
 





eFluor450 Mouse, IgG1, 
 
SK3 25 g/mL 
3 L 
eBioscience 









OKT4 100 g/mL 
3 L 
Biolegend 




OKT3 12 g/mL 
3 L 
Biolegend 
CD3 APC APC Mouse, IgG1, 
 





Alexa Fluor 700 Mouse, IgG1, 
 
RPA-T4 50 g/mL 
3 L 
eBioscience 
CD4 APC-Cy7 APC-Cy7 Mouse, IgG2b, 
 
OKT4 200 g/mL 
3 L 
Biolegend 
CMV Modulation of the Immune System in AAV 82 
 
Table 2.7 Antibodies used in a selection of whole blood surface staining 
experiments to determine T helper and memory sub-type 
Marker Fluorochrome Isotype Clone Concentration 
L / test 
Company 




OKT3 12 g/mL 
3 L 
Biolegend 




OKT4 100 g/mL 
3 L 
Biolegend 
CD28 eFluor 450 Mouse IgG1, 
 
CD28.2 25 g/mL 
4 L 
eBioscience 
CXCR3 PE-Dazzle 594 Mouse IgG1, 
 
G025H7 150 g/mL 
3 L 
Biolegend 
CCR4 PE-Cy7 Mouse IgG1, 
 
L291H4 200 g/mL 
5 L 
Biolegend 
CCR6 PerCP-Cy5.5 Mouse 
IgG2b,  






Table 2.8 Antibodies used in the whole blood surface staining assay to directly 
measure CD4 T-cells 
Marker Fluorochrome Isotype Clone Concentration 
L / test 
Company 




OKT3 12 g/mL 
3 L 
Biolegend 




OKT4 100 g/mL 
3 L 
Biolegend 
CD45 FITC Mouse IgG1, 
 
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2.6.3 Measuring soluble markers of inflammation and endothelial damage 
Soluble markers of inflammation and endothelial damage were measured in plasma.  
Blood was drawn in an EDTA tube and centrifuged within 30 minutes at 4oC, 3000 rpm 
for 10 minutes.  Plasma was aliquoted in 4 tubes and cryopreserved at -80oC.  For the 
luminex assay, analytes were plexed on a 96-well plate as per the manufacturer’s 
instructions.  Each plate contained patient samples and healthy volunteer samples.  In 
the case of clinical trial patient samples, both baseline and 6 month samples from a 
given patient were run on the same plate in order to avoid inter-assay variability.  All 
samples were run in duplicate.  Analytes were purchased from eBioscience and plexed 
as shown in Table 2.9.  Validation details for the analytes used to inform one of the 
secondary outcomes of the clinical trial arm are described in section 2.7.   
 
The wash buffer and antigen standards were prepared as per the manufacturer’s 
instructions.  Next, a 4 fold serial dilution of the antigen standards was prepared.  To 
do this, 200 L of the reconstituted standard was placed in the first tube and 150 L of 
Universal Assay Buffer in the rest of the tubes.  50 L of standard was transferred to 
tube 2, mixed, and 50 L sequentially transferred to the rest of the tubes in order to 
obtain a 7-point standard curve for the assay panel.  The detection antibody mixture 
was then prepared by combining the detection antibody concentrates of each simplex 
kit according to the manufacturer’s instructions.  The 96-well flat bottomed plate was 
then prepared with the use of a hand held magnetic washer.  The antibody magnetic 
beads for each panel (Table 2.9) were combined, vortexed and an appropriate volume 
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was added to each well.  The beads were allowed 2 minutes to accumulate at the 
bottom of the plate, then the liquid was removed by rapidly inverting the hand held 
magnetic plate washer and plate assembly over a waste container, followed by blotting 
the inverted assembly to remove any residual solution.  The antibody magnetic beads 
were then washed with 150 L of wash buffer in each well. 
 
Samples were thawed at 37oC and centrifuged at 5000 rpm for 5 minutes in order to 
remove any debris and fibrin.  The supernatant was aspirated and placed in a new tube 
and the sample vortexed before use.  For panels 2, 3 and 4, an appropriate dilution of 
the samples was made up (Table 2.9).  Standards and samples were added onto the 
plate by adding 25 L of Universal Assay Buffer into each well followed by 25 L of the 
standard or sample as appropriate.  The plate was sealed and light protected and 
shaken at 500 rpm for 2 hours at room temperature.  Following this incubation step, 
the plate was washed twice before adding 25 L of the working detection antibody 
mixture into each well.  The plate was sealed, light protected and incubated at 500 
rpm for 30 minutes at room temperature before being washed twice.  Streptavidin – 
PE was added (50 l) into each well followed by a 30 minute incubation step at 500 
rpm, room temperature and 2 further washes.  120 L reading buffer was added in 
each well prior to incubating at 500 rpm for 5 minutes at room temperature and 
reading the samples on a Biorad Luminex 200 Instrument.  Data was analysed using 
ProcartaPlex Analyst 1.0 Software (eBioscience).  Duplicate values were averaged 
during analysis.  Where samples were measured as below the level of detection a value 
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of 0.01 pg/mL was assigned.  For CRP samples measured as above the level of 
detection a value of 9 x 107 pg/mL was assigned. 
 
 
Table 2.9 List of simplex analytes plexed for the determination of soluble markers 
of inflammation and endothelial damage in plasma 
Analyte Panel 
Number 
Dilution Sensitivity Standard Curve Range 
Fractalkine 1 None 0.5 pg/mL 2.08 – 8500 pg/mL 
IFN- 1 None 0.2 pg/mL 12.21 – 50000 pg/mL 
TNF- 1 None 0.4 pg/mL 8.54 – 35000 pg/mL 
IL-2 1 None 0.8 pg/mL 4.88 – 20000 pg/mL 
IL-6 1 None 0.4 pg/mL 9.77 – 40000 pg/mL 
IL-10 1 None 0.1 pg/mL 2.44 – 10000 pg/mL 
IL-12p70 1 None 0.04 pg/mL 6.84 – 28000 pg/mL 
IL-17A 1 None 0.1 pg/mL 2.44 – 10000 pg/mL 
IP-10 1 None 0.3 pg/mL 1.95 – 8000 pg/mL 
MCP-1 1 None 0.6 pg/mL 1.22 – 5000 pg/mL 
E-Selectin 1 None 555.3 pg/mL 292.97 – 1200000 pg/mL 
P-Selectin 1 None 95.4 pg/mL 1464.84 – 6000000 pg/mL 
RANTES 2 1:50 0.2 pg/mL 0.61 – 2500 pg/mL 
VCAM 3 1:200 6.7 pg/mL 11.47 – 47000 pg/mL 
ICAM 3 1:200 76.3 pg/mL 151.85 – 622000 pg/mL 
CRP 4 1:500 0.291 pg/mL 4 – 18000 pg/mL 
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2.6.4 Peripheral blood mononuclear cell isolation 
Blood was drawn in LH tubes and left upright on the bench at room temperature for a 
maximum of 5 hours before being processed to isolate the peripheral blood 
mononuclear cell (PBMC) fraction. 
 
Prior to isolating the PBMC fraction, one LH tube from each sample was centrifuged at 
584g for 10 minutes in order to isolate plasma.  The supernatant was carefully 
aspirated, aliquoted in 4 tubes in 250 L aliquots and cryopreserved.  Plasma derived 
from LH blood tubes was used to determine the CMV IgG titre of samples (section 
2.6.8).  Next, the tube was inverted to re-suspend the whole blood sample and blood 
was diluted 1:1 with RPMI (Sigma) medium pre-warmed to 37oC.  The diluted blood 
sample was carefully layered over 15 mL Ficoll Paque Plus (GE Healthcare; Endotoxin 
tested <0.12 EU/mL) in a 50 mL tube.  The layered blood was centrifuged at 584 g for 
30 minutes at room temperature with the brake off.  The lymphocyte layer was then 
carefully harvested using a Pasteur pipette into a fresh 50 mL tube and warm RPMI 
medium added to make up the volume to 40 mL before centrifuging at 912 g for 7 
minutes.  The supernatant was carefully discarded and the cell pellet gently re-
suspended.  Next, 20 mL RPMI was added, the sample was mixed, and a 20 l aliquot 
was placed in a haemocytometer counting slide.  The sample was centrifuged again at 
584 g for 7 minutes.  In order to count the cells the average of 2 4x4 squares on the 
haemocytometer slide was multiplied by 10,000 and the volume of the sample.  The 
supernatant was then carefully discarded and the cell pellet gently re-suspended to a 
CMV Modulation of the Immune System in AAV 87 
 
concentration of 1 x 106 cells / mL with supplemented warm RPMI medium (RPMI, 10% 
foetal calf serum (FCS; sterile filtered and heat inactivated at 56oC for 30 minutes; 
Sigma), 1% penicillin / streptomycin (P/S; Gibco)).  Cells were then used for culture 
experiments as appropriate (section 2.6.5).   
 
To cryopreserve, the cells were centrifuged at 584 g for 7 minutes and re-suspended in 
Freezing Solution A (60% FCS, 40% RPMI) at 20 x 106 cells / mL.  An equal volume of 
Freezing Solution B (20% dimethyl sulphoxide (DMSO, Sigma), 80% FCS) was then 
added in a dropwise fashion with gentle agitation of the tube to achieve a final 
concentration of 10 x 106 cells / mL.  Cells were transferred to cryovials and placed in a 
Mr Frosty (Thermo Scientific) freezing container half filled with 2-propanol (Sigma) for 
a minimum of 4 hours at -80oC.  They were transferred to liquid nitrogen within a 
maximum of 7 days.              
    
2.6.5 Peripheral blood mononuclear cell stimulation 
PBMC were stimulated overnight for 16 hours (+/- 2 hours) at 37oC, 5% CO2, with CMV 
lysate (see section 2.6.6).  This time period was chosen for practical purposes and 
based on previous experience of this duration of stimulation with CMV lysate in 
Professor Moss’s lab.  For each sample, an unstimulated tube (negative control), an 
SEB (staphylococcal enterotoxin B; Sigma) stimulated tube (positive control; 200 
g/mL) and 2 CMV lysate stimulated tubes (1:100) (Panel A and Panel B, Table 10) 
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were set up.  Cultures contained 5 x 105 – 1 x 106 freshly isolated PBMC, monensin 
(1:1000) to trap cytokines intracellularly, 5 L CD154 monoclonal antibody (100 
g/mL) conjugated to PE (eBioscience) in order to identify CMV specific cells, and 
stimulant as appropriate, in a total volume of 500 L made up with supplemented 
RPMI.  In later experiments the CMV Lysate Panel A tube did not contain CD154 
antibody conjugated to PE in order to accommodate staining with an NKG2D 
monoclonal antibody conjugated to PE as shown in Table 2.10.   
 
The following day cells were washed twice in 2 mL of PBS before staining with the 
eFluor506 fixable viability dye (eBioscience).  The viability dye was used as a 1:10 
dilution with PBS at 2 l per sample and cells were incubated for 30 minutes at 4oC, 
protected from light, before washing once with PBS and once with MACS buffer.  All 
centrifugation steps were performed at 584 g for 5 minutes at room temperature.  
Next, the appropriate surface antibody mix was added to the cells (Table 2.10) and 
cells were gently re-suspended and incubated for 30 minutes at 4oC, protected from 
light.  Following a wash step in 2 mL of MACS buffer, the cells were vortexed to 
completely re-suspend the pellet and fixed and permeabilised using the FoxP3 one-
step fixation and permeabilisation kit (eBioscience).  Briefly, cells were incubated in 1 
mL of working solution for 30 minutes at 4oC before adding 2 mL of permeabilisation 
wash buffer and centrifuging for 5 minutes at 584 g.  The supernatant was carefully 
decanted, the cells gently re-suspended and the cells stained with the appropriate 
intracellular antibody mix (Table 2.10) for 30 minutes at 4oC, protected from light.  
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Following a final wash in MACS buffer, cells were re-suspended in 200 l MACS buffer 
and events were acquired on the flow cytometer.  The unstimulated sample was used 
as a guide to gate for cytokine expression.      
Table 2.10 Antibodies used to stain PBMC following overnight stimulation with 
CMV lysate or SEB 
Marker Fluorochrome Isotype Clone Concentration  




Viability eFluor 506   2 L ALL eBioscience 
       
Surface       




OKT3 12 g/mL 
3 L 
ALL Biolegend 




OKT4 100 g/mL 
3 L 
ALL Biolegend 
CD28 eFluor 450 Mouse IgG1, 
 
CD28.2 25 g/mL 
4 L 
ALL eBioscience 
NKG2D PE Mouse IgG1, 
 
1D11 200 g/mL 
5 L 
A Biolegend 







TIM-3 PE-Cy7 Mouse IgG1, 
 
F38-2E2 200 g/mL 
5 L 
B Biolegend 







       
Intracellular       





TNF- Alexa Fluor 700 Mouse IgG1, 
 
MAb11 50 g/mL 
3 L 
ALL eBioscience 



















T-bet FITC Mouse IgG1, 
 





BLIMP-1 APC Mouse IgG1, 
 
646702 10 L B R&D 
CTLA-4 PE-Cy5 Mouse 
IgG2a,  
BNI3 20 L B BD 
*
 U: unstimulated; SEB: SEB stimulated; A: CMV Lysate Panel A; B: CMV Lysate Panel B 
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2.6.6  CMV lysate production 
To prepare CMV lysate, foetal human foreskin fibroblasts (HFFF) were cultured in 20 
mL supplemented Dulbecco’s modified eagle medium (DMEM; Sigma) (10% FCS, 1% 
P/S) in 150 cm2 tissue culture flasks (37°C, 5% CO2) and allowed to become 70-80% 
confluent over a period of 5 days.   
 
The cells were then split into three 150 cm2 flasks and incubated for a further 5 days as 
above by aspirating the culture medium, gently washing with 8 mL PBS twice, treating 
with trypsin to detach the HFFF (2 mL TryPLE Express (Sigma) added and cells 
incubated at 37°C, 5% CO2 for 5 minutes)), adding culture medium and splitting.  The 
process was repeated until 15 flasks with cultured HFFF were generated. 
 
Ten of the 15 flasks were then infected with CMV AD169 strain (stock solution - titre 3 
x 107 PFu / mL) at a multiplicity of infection (MOI) of 0.05 (50 L of CMV AD169 stock 
solution was mixed with 50 mL culture medium and 10 mL was added to each flask 
having aspirated the existing culture medium first) whilst 5 flasks were kept to produce 
mock lysate.  Flasks were incubated at 37°C, 5% CO2 for 4 hours with gentle rocking 
every 4 hours after which time the supernatant was aspirated and flasks were 
replenished with 20 mL of fresh culture medium.  
 
CMV Modulation of the Immune System in AAV 91 
 
Once the HFFF displayed cytopathic changes under the microscope (5-10 days) the 
supernatant was harvested 3 times (each time 3 days apart) by carefully removing the 
supernatant and replenishing with fresh culture medium.  The harvested supernatant 
was centrifuged at 2000 rpm for 10 minutes and the ensuing supernatant combined 
into sterile Sorvall pots and frozen at -80°C whilst the pellets were combined and also 
frozen at -80°C.   
 
On the final harvest the HFFF cells were scraped off and centrifuged together with the 
supernatant at 2000 rpm for 10 minutes.  The supernatant was then added to the 
thawed Sorvall pots and the cell pellets combined with the thawed pellets from the 
previous harvests.  The combined infected cell pellet preparation was centrifuged at 
2000 rpm for 10 minutes, re-suspended to a final volume of 1 mL with RPMI and 
freeze-thawed 5 times in liquid nitrogen.  Meanwhile the Sorvall pots were centrifuged 
at 12000 rpm for 2 hours at room temperature.  The supernatant from the Sorvall pots 
was appropriately discarded and the pellets resuspended at a final volume of 6 mL 
RPMI and combined with the freeze-thawed infected cell pellet.  The final infected 
virus pellet was sonicated 5 times for 20 seconds at a time, aliquoted and stored at -
80°C.   
 
For the mock lysate, following collection of the supernatant and cell scrapings, the 
suspension was centrifuged at 2000 rpm for 10 minutes, the supernatant appropriately 
discarded and the uninfected cell pellet made up to a total volume of 3 mL, freeze-
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thawed, sonicated, aliquoted and stored as above.  The same batch of CMV and mock 
lysate were used throughout all experiments in the study in order to avoid variability 
between different lysate batches. 
 
The volume of CMV lysate required for overnight stimulation was titrated in initial 
experiments (Figure 2.5) and 5 l of CMV lysate (1:100) used in all subsequent 
experiments.  The specificity of the CMV lysate was also tested in initial experiments 
that showed IFN- production by CD4 cells only in CMV seropositive individuals in 
response to CMV lysate and no IFN- production when cells from a CMV seropositive 
individual were stimulated with mock lysate (Figure 2.6). 
 
 





































Figure 2.5 CMV lysate titration 
Initial titrating experiments showed that 5 L of CMV lysate in culture used at 1:100 
produced a good response 




Figure 2.6 Flow cytometry data showing specificity of CMV lysate stimulation 
A, unstimulated PBMC from a CMV seropositive donor.  B, mock lysate stimulated 
PBMC from a CMV seropositive donor.  C, CMV lysate stimulated PBMC from a 
seropositive donor.  D, CMV lysate stimulated PBMC from a seronegative donor.  
 
 
2.6.7 CD4+CD28null percentage tracking experiments 
The CD4+CD28- T-cell percentage over a 12 month period was tracked for a subset of 
patients that took part as controls in the clinical trial and had significant CMV 
reactivation documented in order to determine whether CMV reactivation led to a 
change in the CD4+CD28null T-cell percentage.  For these experiments PBMC were 
thawed at 37oC before adding warm supplemented RPMI medium to the cryovial 
containing the PBMC in dropwise fashion.  The PBMC were gently mixed and slowly 
added to a 50 mL tube containing 20 mL of warm supplemented RPMI.  The cells were 
then centrifuged for 7 minutes at 584 g room temperature, the supernatant carefully 
decanted and the pellet gently re-suspended with 20 mL warm supplemented RPMI 
medium before counting on a haemocytometer slide (section 2.6.4).  Following 
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another centrifugation step, cells were re-suspended at 1 x 106 cells / mL with warm 
supplemented RPMI medium.   
 
Cells from all time points from one patient were thawed and batch analysed in a single 
experiment in order to avoid inter-assay variability.  For each time point, 5 x 105 – 1 x 
106 cells, depending on cell numbers, were first washed in PBS and stained with 
viability dye as described in section 2.6.5 before staining with the surface marker panel 
detailed in Table 2.11, washing in MACS buffer, and acquiring on the flow cytometer.   
 
Table 2.11 Antibodies used to stain cells in CD4+CD28null T-cell tracking 
experiments 
Marker Fluorochrome Isotype Clone Concentration 
L / test 
Company 
Viability eFluor 506   2 L eBioscience 




OKT3 12 g/mL 
3 L 
Biolegend 




OKT4 100 g/mL 
3 L 
Biolegend 
CD28 eFluor 450 Mouse 
IgG1,  
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2.6.8 Estimation of CMV IgG titre 
Plasma sample collected in LH tubes (section 2.6.4) was used to determine CMV IgG 
titres across the clinical trial period.  A CMV IgG ELISA assay developed at the 
University of Birmingham by Professor Paul Moss’s group was used.  All time points 
from a given patient were run on the same plate in order to avoid inter-assay 
variability.  A sample from a known CMV seropositive donor (positive control) and a 
known CMV seronegative donor (negative control) for which multiple aliquots were 
frozen was run with every single plate in order to document assay precision and 
reproducibility.  All samples were run in duplicate in CMV lysate coated wells, as well 
as mock lysate coated wells, and the average absorbance value seen in the mock lysate 
coated wells (background non-specific binding) was subtracted from the average 
absorbance value in the CMV lysate coated plate.  Clinical trial samples assayed for 
CMV IgG titre were processed with the help of Dr Michael Sagmeister as part of a mini-
project during Dr Sagmeister’s renal medicine academic block that was jointly 
supervised by the author of this thesis and Professor Lorraine Harper. 
  
Briefly, a MaxiSorp flat-bottom 96 well plate (Nunc) was coated with inactivated CMV 
lysate and mock lysate.  The same batch of lysate was used for all experiments in order 
to minimise inter-assay variability.  Coating buffer was made up by dissolving one 
carbonate-bicarbonate capsule (Sigma) in 25 mL of distilled water.  Lysate was used in 
a 1:4000 dilution and wells were coated with 50 L of CMV lysate or mock lysate as 
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shown in Figure 2.7 and incubated overnight at 4oC, protected from light, for 16 hours 




Figure 2.7 Determination of CMV IgG titre  
To determine CMV IgG titre a 96 well flat bottomed plate was coated with CMV and 
mock lysate as shown and incubated overnight.  
 
 
The following morning the plate was washed 3 times with 200 L per well of wash 
buffer (PBS, 0.05% Tween 20; Sigma).  The samples and standards were prepared by 
thawing at 37oC and centrifuging at 5000 rpm for 5 minutes in a microcentrifuge to 
pellet debris and fibrin in order to avoid background non-specific binding.  The 
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supernatant was aliquoted in a fresh tube and vortexed before use.  Standards were 
made up from a 1:1:1 mix of 3 donors that remained constant throughout all 
experiments.  A 3-fold dilution of the standard was produced by adding 18 L of the 
standard to 72 L of dilution buffer (wash buffer, 1% bovine serum albumin (BSA); 
Sigma), mixing, transferring 30 L to the next well that contained 60 L dilution buffer 
and repeating this process to achieve a 7 point standard curve preparation in both the 
CMV lysate and mock lysate coated wells.  The last well was left blank.   
 
Sample, positive and negative controls were used at a 1:3000 dilution in dilution 
buffer.  Once standards, samples and controls were added to the wells they were 
incubated for 1 hour at room temperature before washing 3 times and adding 100 L 
per well of goat anti-human IgG conjugated to horse radish peroxidase (HRP) 
(Southern Biotech) at a 1:8000 dilution.  Following incubation for 1 hour at room 
temperature, the plate was washed 3 times before adding 100 L per well of the 
detection agent (Tetramethyl Benzidine (TMB) One Component HRP Microwell 
Substrate; Tebu-Bio) and incubating for 15 minutes at room temperature in the dark.  
The reaction was stopped by adding 100 L per well of a 1M solution of hydrochloric 
acid and the plate read at 450 nm absorbance.   
 
To calculate the CMV IgG titre the average absorbance values of the mock lysate 
duplicates were subtracted from the average absorbance values of the CMV lysate 
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duplicates for each sample and for the standard curve.  The values were then log 
transformed and a non-linear regression sigmoidal dose response curve was fitted 
(Figure 2.8) in order to interpolate the sample values based on the standard curve.   























Figure 2.8 CMV IgG ELISA standard curve   
Example standard curve for the CMV IgG titre ELISA assay following log transformation 
of the absorbance values for the 7-point standard curve samples. 
 
The interpolated values were then exponentially transformed to yield the CMV IgG 
titre.  A value of greater than 10 units indicated a positive result in terms of CMV 
serological status based on previous validation studies by Professor Paul Moss’s group.     
          
2.7 Formal Assay Validation Analyses 
The assays used to inform the primary and secondary outcomes of the clinical trial arm 
of the study were formally validated as per MHRA requirements prior to the 
commencement of the study.  The qPCR assay used to determine the primary outcome 
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has been formally validated for clinical use by UHB Virology Laboratories and was 
therefore not further validated for the purposes of this clinical trial.  The whole blood 
surface staining assay used to determine the proportion of CD3+CD4+CD28- cells and 
the Luminex assay used to determine plasma concentration of soluble markers of 
inflammation were formally validated.  Excerpts of the validation analyses are 
presented here whilst the full validation plans and analyses can be found in Appendix 
7.   
 
2.7.1 Surface Staining of CD3 CD4 CD28 in Whole Blood – Validation Analysis 
Part 1 
2.7.1.1  Objective 
The aim of this validation study was to establish that the performance characteristics 
of the assay that would be used to surface stain lymphocytes in whole blood for CD3, 
CD4 and CD28, met the analytical requirements of the CANVAS trial. 
 
 
2.7.1.2  Validation Parameters  
In order to examine whether the period of time blood is left at room temperature prior 
to processing affects the proportion of CD3+CD4+CD28- cells within the CD4 
compartment, blood was drawn from healthy volunteers and left at room temperature 
for 1 hour, 3 hours and 5 hours before being stained (flow cytometry panel as detailed 
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in Table 2.5) and analysed as previously described.  This experiment was repeated 
three times (Figure 2.9).  The one-sample Wilcoxon signed rank test was used to 
determine whether the median CD3+CD4+CD28- proportion at 3 hours and 5 hours 
was statistically different to that at 1 hour.  In order to test intra-assay variability all 






Figure 2.9 CD3 CD4 CD28 staining validation 
Effect of time elapsed from venepuncture to staining on the CD3+CD4+CD28- 
proportion within the CD4 compartment (y-axes).  Three separate experiments 
(different donors) are shown where staining was performed in duplicate after resting 
whole blood at room temperature for 1, 3 and 5 hours.  Coefficients of variation were 
< 20% for all duplicate runs.  There was no statistically significant difference between 
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2.7.1.3  Acceptance Criteria 
There was no statistically significant difference between the mean CD3+CD4+CD28- % 
at 3 hours and 5 hours versus 1 hour at all experiments (also see full Validation 
Analysis Report in Appendix 7).  Therefore it was decided that following collection, 
blood samples could be left at room temperature for up to a maximum of 5 hours 
before processing. 
 
The coefficient of variation was acceptable throughout the validation analysis study.  
However it was decided that a positive control with a pre-defined acceptance range of 
CD3+CD4+CD28+ cells was necessary in order to properly validate the various 
components of the assay in terms of intra-assay and inter-assay variability and also 
allow running of an aliquot of the positive control with each experimental run for 
quality control purposes. 
 
 
2.7.2 Surface Staining of CD3 CD4 CD28 in Whole Blood – Validation Analysis 
Part 2 
2.7.2.1  Precision and Reproducibility 
The precision and reproducibility of the whole blood staining assay was further 
validated using a commercially available positive control (Cytofix CD4 Normal Range 
Positive Control; Cytomark, Caltag MedSystems).  Cytofix CD4 controls are a stabilised 
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preparation of whole human blood for use as a positive control when evaluating CD4 
enumeration techniques.  They provide verification of monoclonal antibody reagents 
and red blood cell lysis as well as validation of instrument performance and operator 
technique.  Each lot of Cytofix CD4 positive control is provided with a quality control 
statement inclusive of the expected range of CD3+CD4+ lymphocytes within each lot. 
 
Positive controls from the first lot purchased were initially assayed in triplicate on five 
separate experiments as previously described (Section 2.6.2; flow cytometry panel as 
detailed in Table 2.5) in order to define intra-assay (Figure 2.10) and inter-assay 
variability as well as acceptance criteria for the assay based on the positive control 
CD3+CD4+CD28+ range (Table 2.12).  The acceptance range for each marker was 
calculated as the mean value across the five triplicate runs +/- 2 standard deviations.  
As the coefficient of variation in terms of intra-assay variability was very low (Figure 
2.10), it was decided that experimental samples and controls could be run singly for 
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Figure 2.10 CD3 CD4 CD28 staining validation  
Cytofix CD4 Positive Control was stained in triplicate (a, b, c) in 5 separate experiments 
(1-5).  Top panel shows the percentage of CD3+ cells, middle panel the percentage of 
CD3+CD4+ cells and bottom panel the percentage of CD3+CD4+CD28+ cells.  The intra-
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An aliquot of the Cytofix CD4 positive control was planned to be run alongside each 
experimental run to ensure that the relevant cell populations within the positive 
control fell within the validated accepted ranges therefore providing on-going quality 
assurance of the precision of this assay.   
 
Initial experiments showed that the CD28 expression in CD4 cells of the Cytofix CD4 
positive control altered significantly with time.  This made the setting of an acceptance 
range for CD28 expression in the positive control not possible as this value constantly 
changed during the 1-month shelf life of the product after opening the vial (Appendix 
7).  Furthermore it was noted that most of the change occurred by 1-2 weeks after the 
preparation of a new lot of the Cytofix CD4 positive control.  It was therefore decided 
that an acceptance range would be set for CD3 and CD4 expression in the Cytofix CD4 
positive control but not for CD28.  For every new lot of Cytofix CD4 control used, the 
expected CD3+CD4+ range for the purposes of its use in the secondary outcome assay 
acceptance criteria was re-validated by running a sample from the new lot in triplicate.  
In order to maintain quality assurance of CD28 staining in the experimental samples, 
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 Table 2.12 Inter-assay variability and initial acceptance ranges for positive control 
used in the whole blood surface staining assay 
 
 
2.7.3 Measurement of soluble markers of inflammation – Validation Analysis 
2.7.3.1  Objective 
The aim of this validation study was to establish that the performance characteristics 
of the assay that was used to determine the plasma concentration of IL-2, TNF-, IFN-
, IL-6, IL-10, IL-17 and highly sensitive C-reactive protein (hsCRP) at baseline and at 6 
months (secondary outcome), met the analytical requirements of the CANVAS trial. 
 
2.7.3.2  Precision and Reproducibility 
The Luminex assay permitted the plasma concentration of IL-2, TNF-, IFN-, IL-6, IL-
10, IL-17 and hsCRP to be measured in a multiplex immunoassay.  The Luminex 
 Inter-assay CV 
(%) 
Mean (%) Acceptance Range 
CD3+ within 
lymphocyte gate 
0.9 71.2 70.0 – 72.4 
CD3+CD4+ within 
lymphocyte gate 
1.2 45.5 44.4 – 46.6 
CD28+ within 
CD3+CD4+ gate 
0.2 98.2 97.7 – 98.7 
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multiplex immunoassay has excellent precision and reproducibility as evidenced by low 
coefficient of variation (CV) values with regards to intra-assay and inter-assay 
variability (Table 2.13).  This was a commercial assay that has been rigorously validated 
by the company.  Hence no further validation was planned. 
 
 
Table 2.13 Coefficient of variation (CV) values for intra-assay and inter-assay 







Analyte Intra-Assay Variability CV 
(%) 
Inter-Assay Variability CV 
(%) 
IFN- 3.6 5.5 
TNF- 7.2 6.1 
IL-2 6.2 5.1 
IL-6 6.2 4.5 
IL-10 3.1 2.3 
IL-17 6.5 6.0 
hsCRP 6.6 9.6 
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2.8 Data Collection and Quality Control 
Sample collection and processing was evidenced on appropriate worksheets (see Blood 
Sample Receipt and Processing Record in Laboratory Manual; Appendix 6).  Similarly, 
experimental detail for assays employed within the clinical trial was documented in 
real time (see Whole Blood / Positive Control Surface Staining Work Instruction in 
Laboratory Manual; Appendix 6).  These records are filed in the CANVAS Study 
Laboratory Folder and archived at the University of Birmingham.  Detailed work 
instructions for laboratory assays can also be found in the CANVAS Laboratory Manual 
(Appendix 6).   
 
Source data relating to clinical trial participants was documented in the Case Report 
Form (Appendix 8).  In order to maintain data integrity a standard operating procedure 
was designed around maintaining quality control of data input (Appendix 5).  To that 
effect, prior to any analysis being undertaken, the accuracy of data transcription was 
checked for data relating to primary and secondary outcomes of the clinical trial.  
Serious adverse events (SAE) were documented (Appendix 2; SAE form in Protocol) and 
reported to the sponsor yearly in the Development Safety Update Report (DSUR) 
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2.9 Data Presentation and Statistical Analysis 
For the purposes of statistical analysis, SPSS Statistics Version 21 (IBM) and Prism 
Version 5 and 6 (GraphPad) were used.  Data was assessed for normality using the 
D’Agostino & Pearson omnibus normality test and aided by visual inspection of 
graphical representation (histogram and Q-Q plots) of the data and skewness values in 
borderline cases.  Non-parametric data was transformed when necessary using square 
root or logarithmic transformations and re-tested for normality as above.  Parametric 
data is reported as mean with standard deviation (SD) and non-parametric data as 
median and interquartile range (IQR).  Non parametric data is graphically depicted in 
the form of Tukey boxplots or scatter dot plots with median and interquartile range 
shown.  Parametric data is depicted with mean and standard error of the mean shown.   
 
All statistical analyses were two-tailed.  Unpaired parametric and non-parametric data 
were analysed using the student’s t test (with Welch’s correction for unequal variances 
if appropriate) or the Mann Whitney U test respectively.  Paired data was analysed 
using the paired t test or the Wilcoxon-matched pairs signed rank test for parametric 
and non-parametric data respectively.  Categorical data was analysed using the chi 
square test or Fisher’s exact test where appropriate.  Correlations were assessed with 
Spearman’s rank test for non-parametric data and Pearson’s correlation for parametric 
variables.  A p value < 0.05 was considered statistically significant for all analyses.   
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2.9.1 Clinical Trial data presentation and statistical analysis 
All clinical trial analyses were carried out following the intention to treat principle as 
pre-specified in the published clinical trial protocol [325] unless explicitly stated within 
the text.  A secondary per protocol analysis that excluded patients randomised to the 
treatment arm that stopped the drug within 1 month from starting the trial was 
additionally performed on the clinical trial primary outcome data.  The primary analysis 
on the primary outcome was carried out utilising the UHB virology laboratory cut-off of 
>200 CMV viral DNA copies / mL to define CMV reactivation.  Additional secondary 
analyses were carried using a >20 CMV viral DNA copies / mL threshold.  Kaplan-Meier 
curves were drawn to analyse the primary outcome and the curves were compared 
using the Gehan-Breslow-Wilcoxon test.  As the primary and secondary analyses for 
the primary outcome only considered time to 1st episode of CMV reactivation, a 
sensitivity analysis was also carried out for the primary outcome to consider multiple 
episodes of CMV reactivation in the same patient.     
 
The secondary, tertiary and exploratory outcomes of the clinical trial were comprised 
of paired data (e.g. CD4+CD28null % at month 0 and month 6).  For such paired data 
the paired t test was utilised.  As the ratios of paired values were expected to be more 
consistent than the differences between paired values, paired ratio t tests were 
employed for such outcome data.  In order to achieve this, data was log transformed 
and a two-tailed t test (or Wilcoxon matched-pairs signed rank test for non-parametric 
data) was carried out on the transformed values.  The antilog of the results was then 
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taken to derive the geometric mean of the ratios with 95% confidence intervals.  This 
was performed separately for the treatment and control groups.   
 
Where outcome variables were assayed on more than two time-points, repeated 
measures ANOVA was carried out.  To account for multiple comparisons between the 
different time points examined in the tertiary outcome, post hoc analysis was carried 
out using Dunnett’s multiple comparisons test.  For the change in CMV IgG titre 
exploratory analysis, a post hoc analysis for linear trend was carried out to determine 
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Chapter 3 The Phenotype of CD4+CD28null T-cells in AAV  
3.1 Introduction 
Increased expansions of CD4+CD28null T-cells have been described in numerous 
inflammatory disorders including ANCA associated vasculitis (AAV) as well as in 
cardiovascular disease and in association with advancing age [112, 153, 159, 175, 188, 
212, 221].  CD4+CD28null T-cells are believed to be a pro-inflammatory subset [184].  
Although significant expansions of CD4+CD28null T-cells are only present in CMV 
seropositive individuals [112, 168, 224], the origin of this subset continues to be 
debated in the literature [171, 184, 200].  Furthermore, there is a lack of consensus as 
to whether functional exhaustion exists within this subset and whether this may 
predispose to increased and more frequent cycles of subclinical CMV reactivation 
thereby resulting in increased expansion of CD4+CD28null T-cells.  Finally, although 
CD4+CD28null T-cells have been linked to increased mortality, reduced renal function 
and increased risk of infection in AAV, their phenotype in AAV CMV seropositive 
patients has not been adequately defined. 
 
The work undertaken in this chapter aimed to: 
 Determine the cytokine production of CD4+CD28null T-cells following 
stimulation with CMV lysate in AAV and compare this to their CD4+CD28+ 
counterparts and age matched healthy volunteers 
 Identify the factors associated with CD4+CD28null T-cell expansion in AAV  
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 Determine the inhibitory receptor expression profile of CMV specific 
CD4+CD28null T-cells in AAV and explore how this relates to their ability to 
produce multiple cytokines  
 Characterise CD4+CD28null T-cells in AAV in terms of their T helper subtype 
and compare this to age matched healthy volunteers 
 
3.2 Cohort Characteristics 
In order to phenotype CD4+CD28null T-cells in AAV, 53 patients with stable disease 
and evidence of past infection with CMV (as evidenced by the presence of anti-CMV 
IgG antibodies in serum) were recruited from the University Hospital Birmingham 
(UHB) vasculitis clinic for a single visit in this cross-sectional part of the study.  Thirty-
eight of those patients were also consented to participate in the clinical trial part of 
the thesis (Chapter 5).  In order to preserve homogeneity, the remaining 15 patients 
recruited purely into the cross-sectional element of the study fulfilled the same 
eligibility criteria as the clinical trial participants (Chapter 2, Table 2.3).   
 
Thirty CMV seropositive healthy volunteers (HV) were recruited in order to compare 
and contrast the phenotype of CD4+CD28null T-cells in AAV and in the absence of 
immunosuppression or an inflammatory condition.   
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Table 3.1 describes the characteristics of the AAV patients and HV recruited into the 
cross sectional part of the study.  There were no statistically significant differences 
between AAV patients and HV in age or gender.  AAV patients had a median duration 
of disease of 71.5 months, mean eGFR of 53 mL / min / 1.73 m2 and low levels of 
proteinuria.  The majority of AAV patients were on immunosuppressant medication 
with a combination of prednisolone and azathioprine or mycophenolate mofetil.   
 






Age (years) 69.0 [62.8 -  
75.3] 
70.5 [66.8 - 
74.0] 
0.557 
Gender (M:F) 35:18 14:16 0.085 
ANCA specificity 
(PR3:MPO) 














4.4 [1.4 - 9.9] -- -- 
 Steroids [n (%)] 39 (73.6) -- -- 
 MMF [n (%)] 14 (26.4) -- -- 
Azathioprine [n 
(%)] 
19 (35.8) -- -- 
No treatment [n 
(%)] 
4 (7.5) -- -- 
Data is displayed as median [interquartile range] apart from renal 
function that is displayed as mean [standard deviation]. 
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3.3 CD4+CD28null T-cell proportion and absolute count 
In order to assess the proportion of CD4+CD28null T-cells within the CD4 
compartment, whole blood was stained with CD3, CD4 and CD28 antibodies as 
described in Chapter 2.  The gating strategy is shown in Figure 3.1.  A fluorescence-
minus-one (FMO) control was used for all experiments in order to assist with gating.  
CD3+CD4- T-cells were assessed as a surrogate marker of CD8+ T-cells and shall be 
referred to as CD8 for the remainder of the thesis. 
 
 
3.3.1 AAV patients display a higher proportion of CD4+CD28null T-cells 
compared to HV 
AAV patients displayed a significantly higher percentage of CD4+CD28null T-cells 
compared to HV (median 11.3 [IQR 3.7 - 19.7] vs. 6.7 [2.4 - 8.8]; p=0.022) (Figure 3.1).  
However there was no difference in CD4+CD28null absolute cell count between AAV 
and HV (Figure 3.2, Panel D).  There was no statistically significant difference in the 
percentage of CD8CD28null T-cells between AAV patients and HV (60.0 [41.0 - 73.6] vs. 
50.7 [40.5 - 62.9]; p=0.121).    
CMV Modulation of the Immune System in AAV 116 
 
 
Figure 3.1 CD4+CD28null and CD8CD28null T-cell expression in AAV and HV 
Whole blood was stained with CD3, CD4 and CD28 or isotype control monoclonal 
antibodies and CD4+CD28null and CD8CD28null T-cells were identified as shown here in a 
representative patient sample:  forward and side scatter was used to gate on lymphocytes 
(panel A); single cells were gated based on forward scatter height and area parameters 
(panel B); CD3+CD4+ and CD3+CD4- (CD8) cells were next identified (panel C); an FMO 
control was used to assist with CD28 gating as shown in panel D where the top panel has 
been stained with an isotype control and the bottom panel with CD28.  Panel E: AAV 
patients (n=53) (white boxes) have a statistically significant higher proportion of 
CD4+CD28null (left y axis) but not CD8CD28null T-cells (right y axis) compared to HV (n=30) 
(shaded boxes) (Mann-Whitney U test).  Median and Tukey boxplots are shown. 
19.8% 
40.9% 
CMV Modulation of the Immune System in AAV 117 
 
3.3.2 AAV patients have an inverted CD4:CD8 ratio compared to HV 
CD4 and CD8 T-cells were enumerated in whole blood (Figure 3.2).  AAV patients had a 
significantly lower CD4 count compared to HV, as previously reported [336], in keeping 
with an immunosuppressed state (430.4 cells / L [274.6 - 680.9] vs. 774.9 [590.4 - 
1126.3]; p<0.001).  Although AAV patients also displayed a lower CD8 count compared 
to HV (292.8 cells / L [179.7 - 548.1] vs. 426.8 [298.8 - 599.7]; p=0.019), the CD4:CD8 
ratio in AAV patients was inverted and significantly lower in AAV compared to HV (1.3 
[0.9 - 1.7] vs. 1.8 [1.6 - 2.0]; p=0.008).  The percentage of CD4+CD28null T-cells was 
negatively correlated to the CD4:CD8 ratio (Figure 3.2), suggesting that the CD4:CD8 
ratio, a marker of the immune risk profile [288], which has been associated with CMV 
past infection and frailty in the elderly [294], is adversely affected by the size of the 
CD4+CD28null T-cell expansion. 
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Figure 3.2 CD4 count and CD4:CD8 ratio in AAV patients versus HV 
Whole blood was stained with CD45, CD3 and CD4 monoclonal antibodies prior to the 
addition of counting beads.  Panels A, B and C display the gating strategy in a 
representative patient sample.  Panel D shows that AAV patients (n=53) (white boxes) 
had a statistically significant lower CD4 count compared to HV (n=30) (shaded boxes) 
(left y axis).  There was no difference in CD4+CD28null absolute cell count (right y axis).  
In Panel E, the CD4:CD8 ratio in AAV patients (white boxes) and HV (shaded boxes) is 
displayed.  The dotted line represents a CD4:CD8 ratio of 1.  In Panel F, the 
CD4+CD28null T-cell proportion is negatively correlated to the CD4:CD8 ratio (n=83). 
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3.4 CD4+CD28null T-cell phenotype and relationship to the CD4 CMV 
response 
In order to identify CMV responsive CD4+ T-cells and determine the cytokine secreting 
potential of CD4+CD28null T-cells, peripheral blood mononuclear cells (PBMC) were 
stimulated with CMV lysate in an overnight (16 hour) culture in the presence of 
monensin as detailed in Chapter 2. 
 
CD4+CD28null T-cells were identified as CMV responsive by the presence of IFN- 
staining following CMV lysate stimulation.  The specificity of this technique for CMV 
has been discussed in Section 2.6.6 (Figure 2.6).   
 
A significantly greater percentage of CD4+CD28null than CD4+CD28+ T-cells responded 
to CMV lysate (Figure 3.3).  There was no statistically significant difference between 
AAV and HV in the percentage of CD4+CD28null T-cells that responded to CMV lysate 
(AAV: 21.2 [IQR 8.3 - 35.9]; HV: 15.2 [6.0 - 42.6]; p=0.776).  The proportion of 
CD4+CD28null T-cells that were able to respond to CMV by IFN- production increased 
as the size of the CD4+CD28null T-cell compartment expanded indicating that 
individuals with greater expansions of CD4+CD28null have a greater proportion of 
CD4+CD28null T-cells able to respond to CMV and suggesting that CD4+CD28null T-cell 
expansion is not associated with loss of IFN- production (Figure 3.3, Panels C and D).   
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Figure 3.3 CD4+CD28null T-cell responsiveness to CMV lysate 
Panel A: Gating strategy shown in a representative patient sample.  PBMC were 
cultured overnight in the presence of CMV lysate (bottom row) or in culture medium 
alone (top row).  CD4+CD28null T-cells are displayed in purple and CD4+CD28+ T-cells 
in grey colour.  Panel B: A higher proportion of CD4+CD28null T-cells produced IFN- in 
response to CMV lysate compared to CD4+CD28+ T-cells (AAV (n=53) white boxes, HV 
(n=30) shaded boxes).  Median and Tukey boxplots are shown; Wilcoxon matched pairs 
signed rank test employed for statistical comparisons.  Panels C and D display the 
correlation between the size of the CD4+CD28null T-cell compartment and the 
proportion of CD4+CD28null T-cells that responded to CMV lysate by IFN- production 
after overnight culture (Spearman’s rank test) in HV and AAV respectively.     
CD4+CD28null: 13.6% 
CD4+CD28+: 1.1% 
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3.4.1 The size of CD4+CD28null T-cell expansions is closely linked to the 
overall CMV response in the CD4 compartment 
Given the fact that the origin of CD4+CD28null T-cells remains a subject of controversy 
in the literature [171, 184], measured variables including demographic parameters, 
renal function, the total CMV response in the CD4 compartment, CMV IgG titre and 
plasma levels of soluble markers of inflammation and endothelial dysfunction were 
related to the percentage of CD4+CD28null T-cells.  On univariable analysis, age, the 
percentage of CD8CD28null T-cells, plasma IP-10 (the ligand for CXCR3) and the overall 
CMV response in the CD4 compartment (proportion of IFN- positive CD4 T-cells 
following overnight culture with CMV lysate) were significantly associated with the size 
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Table 3.2 Univariable analysis of factors associated with the size of the 
CD4+CD28null T-cell expansion in AAV patients (n=53) 
Variable R value p value 
Age 0.346 0.011 
Gender 0.164 0.241 
eGFR 0.009 0.951 
Creatinine -0.069 0.625 
uACR -0.107 0.445 
Total CMV response in CD4 compartment 
(Percentage of IFN- + cells)* 
0.791 <0.001 
CD4 count -0.209 0.134 
CD4 : CD8 ratio -0.263 0.057 
CD8CD28null % 0.525 <0.001 
CMV IgG titre
a
 0.072 0.608 
CRP
a
 -0.024 0.868 
sICAM-1
a
 -0.162 0.251 
sVCAM-1
a
 -0.157 0.265 
Fractalkine
a
 0.132 0.353 
IP-10
a
 0.380 0.005 
RANTES
a
 0.061 0.665 
E-Selectin
a
 0.125 0.379 
P-Selectin
a
 0.226 0.107 
IFN-
a
 0.044 0.759 
TNF-
a
 0.017 0.905 
IL-2
a
 -0.041 0.771 
MCP-1
a
 0.169 0.232 
IL-6
a
 0.040 0.780 
IL-12
a
 0.122 0.387 
IL-17
a
 0.030 0.834 
IL-10
a
 0.043 0.764 
* Following overnight culture with CMV lysate; 
a 
Measured in plasma 
uACR: urinary albumin creatinine ratio 
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A multivariable linear regression model was designed in order to determine which 
variables were independently associated with the size of the CD4+CD28null T-cell 
expansion in AAV patients after controlling for relevant covariates.  All variables with a 
p value ≤ 0.1 on univariable analysis were entered in a multivariable linear regression 
model (Table 3.3).  The size of the CD4 CMV specific compartment, plasma IP-10 and 
the proportion of CD8CD28null T-cells remained independently associated with the 
size of the CD4+CD28null T-cell expansion after controlling for possible confounders 
whilst age was not significant (Table 3.3).  Graphical representation revealed a close 
linear relationship between CD4+CD28null T-cells proportion and the proportion of 
IFN- positive CD4 T-cells following CMV lysate stimulation (Figure 3.4) suggesting, 
together with the multivariable analysis results, that the size of the CD4+CD28null T-
cell expansion is largely determined by the size of the overall CMV response in the CD4 
compartment supporting the existing link in the literature between CMV infection and 
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Table 3.3 Multivariable analysis of factors associated with the size of the 
CD4+CD28null T-cell expansion in AAV patients 
Variable Univariable analysis Multivariable analysis 
p value B value [95% CI] p value 
IFN- + % in CD4 compartment* <0.001 1.03 [0.73, 1.32] < 0.001 
Age 0.011 0.18 [-0.05, 0.41] 0.120 
CD4 : CD8 ratio 0.057 -0.98 [-2.68, 0.72] 0.253 
CD8CD28null % <0.001 0.15 [0.03, 0.28] 0.014 
Plasma IP-10 0.005 0.01 [0.001, 0.01] 0.021 
* Following overnight culture with CMV lysate 
Multivariable model included all variables with a p value ≤ 0.1 on univariable analysis. 
R value: 0.861 
R Square: 0.742 
 
 
Figure 3.4 Correlation of CD4+CD28null T-cell proportion with the overall CD4 CMV 
response in AAV  
The size of the overall CD4 CMV specific compartment identified by IFN- production 
following overnight culture in the presence of CMV lysate and monensin, closely 
correlated with the proportion of CD4+CD28null T-cells in the CD4 compartment 
(Spearman’s rank test) (n=53). 
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3.4.2 Cytokine production by CD4+CD28null T-cells 
The cytokine secreting potential of CD4+CD28null T-cells in response to CMV lysate 
was assessed following overnight culture in the presence of monensin followed by 
fixation / permeabilisation and intracellular staining for IFN-, TNF-, IL-2, IL-5 and IL-
10 as detailed in Section 2.6.5.  An anti-CD154 monoclonal antibody conjugated to PE 
was also added in the overnight culture in order to identify activated T-cells.  Staining 
from a representative patient sample is shown in Figure 3.5 including appropriate 
positive and negative controls.   
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Figure 3.5 Cytokine expression in CD4+CD28null T-cells – representative staining  
Staining from a representative patient sample for IFN-, TNF-, IL-2, IL-5, IL-10 and the activation 
marker CD154 following overnight culture in medium alone (1st column), CMV lysate (2nd column) 
or SEB as a positive control (3rd column).  Plots gated on CD4+CD28null T-cells.  The IL-10 positive 
control was LPS instead of SEB as indicated and all CD4 T-cells are shown for that sample. 
0% 46.6% 14.4% 
0% 15.8% 6.4% 
0% 1.1% 1.2% 
0.4% 0.9% 0.6% 
0% 0.3% 1.3% 
0.8% 26.6% 13.8% 
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CD4+CD28null T-cells from AAV patients produced mainly IFN- and TNF- following 
stimulation with CMV lysate (IFN-: 21.2 % [IQR 8.2 - 36.9]; TNF-: 7.0 [2.5 - 12.9]).  On 
the contrary, a much lower percentage was capable of IL-2 (0.4 [0.1 - 1.1]), IL-5 (0.6 
[0.3 - 1.2]) and IL-10 (0.2 [0.1 - 0.5]) production.  Interestingly, CD154 was detected on 
fewer cells than IFN- suggesting loss of CD154 during overnight culture.  There was no 
difference between AAV and HC in the profile of the cytokines produced by 





Figure 3.6 Cytokine expression in CD4+CD28null T-cells in AAV and HV   
The proportion of CD4+CD28null T-cells expressing IFN-, TNF-, IL-2, IL-5, IL-10 and 
the activation marker CD154 in AAV patients (n=53) (white boxes) and HV (n=30) 
(shaded boxes) after overnight co-culture with monensin, CD154 monoclonal antibody 
conjugated to PE and CMV lysate stimulation is shown. 
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3.4.3 Polyfunctionality of CD4+CD28null T-cells 
Polyfunctionality of CD4+CD28null T-cells was assessed by quantifying the percentage 
of CMV responsive CD4+CD28null T-cells, identified by expression of IFN-, that were 
also capable of producing TNF- and IL-2 following overnight stimulation with CMV 
lysate and comparing that to the functionality of CD4+CD28+ T-cells.  The 
CD4+CD28null T-cell compartment contained significantly less polyfunctional cells 
within the IFN- positive CMV responsive compartment compared to CD4+CD28+ T-
cells (AAV: CD4+CD28null 0.96 [IQR 0.16 - 2.31] versus CD4+CD28+ 5.19 [2.69 - 9.34]; 
p<0.001) (Figure 3.7).  Therefore although a much greater proportion of CD4+CD28null 
T-cells were CMV responsive compared to their CD4+CD28+ counterparts, the 
CD4+CD28+ T-cell compartment contained a much higher proportion of polyfunctional 
CMV responsive T-cells as judged by their ability to secrete TNF- and IL-2 in addition 
to IFN-suggesting that CD4+CD28+ CMV specific T-cells may confer a more robust 
immune response in the control of CMV infection.  There was no difference in the 
proportions of polyfunctional CD4+CD28null or CD4+CD28+ T-cells between AAV 
patients and HV.    









Figure 3.7 Polyfunctionality of CMV responsive CD4+CD28null T-cells 
Polyfunctionality of CMV responsive CD4+CD28null T-cells was assessed by stimulating 
PBMC with CMV lysate in an overnight culture in the presence of monensin.  CMV 
responsive CD4 T-cells were identified by IFN- expression.  The proportion of T-cells 
also capable of expressing TNF- and IL-2 within the CMV responsive compartment as 
shown in a representative patient sample in Panel A was determined for CD4+CD28null 
(purple) and CD4+CD28+ T-cells (grey).  In Panel B, the proportions of polyfunctional 
CMV responsive T-cells within the CD4+CD28null and CD4+CD28+ compartments were 
compared (Wilcoxon matched pairs signed rank test) in AAV patients (n=53) (white 
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3.4.4 Inhibitory receptor expression by CD4+CD28null T-cells 
Expression of the inhibitory receptors PD-1, TIM-3, LAG-3 and CTLA-4 has been 
associated with T-cell functional exhaustion and sequential loss of cytokine production 
[303, 337].  In order to further explore the functionality of CD4+CD28null T-cells, the 
expression of these inhibitory receptors was assessed following overnight culture of 
PBMC in the presence of CMV lysate.  The proportion of CD4+CD28null T-cells 
expressing each of these receptors was compared to that of CD4+CD28+ T-cells in both 
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Figure 3.8 Inhibitory receptor expression in CD4+CD28null T-cells – representative 
plots   
PBMC were stimulated overnight with CMV lysate and stained with surface and 
intracellular markers the next day in order to identify expression of the inhibitory 
receptors PD-1, TIM-3, LAG-3 and CTLA-4 on CD4+CD28null (purple) and CD4+CD28+ 
(grey) T-cells.  Fluorescence minus one (FMO) experiments were also carried out 
where an isotype control was employed in place of the target antibody in order to 
assist with gating.  The corresponding FMO experiment for each marker is shown in 
the top plot. 
   
 
A significantly higher percentage of AAV CD4+CD28null T-cells compared to 
CD4+CD28+ T-cells expressed the inhibitory receptors PD-1 (9.5 [IQR 4.2 - 28.8] vs. 3.8 
[2.8 - 7.1]; p<0.001) and TIM-3 (1.3 [0.9 - 2.5] vs. 0.6 [0.4 - 0.8]; p<0.001).  There was 
no difference in the percentage of CD4+CD28null and CD4+CD28+ T-cells expressing 
CD4+CD28+: 4.3% CD4+CD28+: 0.6% CD4+CD28+: 19.0% CD4+CD28+: 18.8% 
CD4+CD28null: 22.9% CD4+CD28null: 2.6% CD4+CD28null: 17.9% CD4+CD28null: 3.9% 
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LAG-3 (14.4 [7.1 - 24.2] vs. 16.2 [9.2 - 22.2]; p=0.685) whereas a lower percentage of 
CD4+CD28null T-cells expressed CTLA-4 compared to CD4+CD28+ T-cells (9.4 [5.3 - 
17.4] vs. 20.1 [15.5 - 25.7]; p<0.001).  This pattern did not differ between AAV and HV.  
However, AAV patients overall tended to possess more CD4 T-cells expressing 
inhibitory receptors compared to HV (Figure 3.9). 
 
 
Figure 3.9 Inhibitory receptor expression in CD4+CD28null T-cells  
The inhibitory receptor expression of PD-1 (Panel A), TIM-3 (Panel B), LAG-3 (Panel C) 
and CTLA-4 (Panel D) was compared between CD4+CD28null T-cells and CD4+CD28+ T-
cells (Wilcoxon matched pairs signed rank test) and AAV (n=53) (white boxes) and HV 
(n=30) (shaded boxes) (Mann-Whitney U test).  
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Given the fact that CD4+CD28null T-cells displayed a lower degree of polyfunctionality 
and were more likely to express PD-1 and TIM-3 compared to their CD4+CD28+ 
counterparts, the expression of PD-1 and TIM-3 was compared between polyfunctional 
CD4+CD28null CMV specific T-cells and CD4+CD28null CMV specific T-cells capable of 
IFN-production only.  Polyfunctional CMV specific CD4+CD28null T-cells were less 
likely to express TIM-3 compared to less functional CD4+CD28null T-cells whereas 
there was no difference in PD-1 expression (Figure 3.10), suggesting that expression of 
TIM-3 but not PD-1 on CD4+CD28null T-cells is associated with reduced 
polyfunctionality.    
 
 
Figure 3.10 Expression of inhibitory receptors and polyfunctionality  
The expression of the inhibitory receptors PD-1 and TIM-3 was compared between 
polyfunctional CD4+CD28null T-cells, identified as IFN- positive T-cells capable of TNF-
and IL-2 production, and CD4+CD28null T-cells capable only of IFN- production 
(Wilcoxon matched pairs signed rank test).  Scatter dot plots with medians and IQR are 
shown. 
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3.4.5 T helper phenotype 
The phenotype of CD4+CD28null T-cells was further explored by comparing the 
expression of the Th1 transcription factor T-bet in CD4+CD28null and CD4+CD28+ T-
cells.  In parallel, expression of the transcription factor BLIMP-1 was assessed (Figure 
3.11).  In chronic infections high expression of BLIMP-1 in CD8 T-cells has been shown 
to promote expression of inhibitory receptors and exhaustion whereas T-bet 
expression promotes functional effector responses [337].    
 
Figure 3.11 Expression of T-bet and BLIMP-1 – representative sample 
Following overnight culture and stimulation with CMV lysate the expression of 
transcription factors T-bet and BLIMP-1 was assessed in CD4+CD28null (purple) and 
CD4+CD28+ (grey) T-cells as shown in this representative patient sample.  FMO 
controls were employed to aid gating as shown in the top row.  In addition, a myeloma 
cell line (U266), shown in the 3rd column, was stained with BLIMP-1 or isotype control 
as a positive control as myeloma cells constitutively express BLIMP-1.  CD138 was used 
to identify plasma cells shown in green. 
CD4+CD28+: 8.5% CD4+CD28+: 0.5% 
CD4+CD28null: 84.6% CD4+CD28null: 0.5% 
CMV Modulation of the Immune System in AAV 135 
 
A large proportion of CD4+CD28null T-cells from both AAV patients and HV expressed 
T-bet compared to a relatively small percentage of CD4+CD28+ T-cells (Figure 3.12, 
Panel A).  In AAV patients, 71.1 % of CD4+CD28null T-cells [IQR 53.4 - 81.4] expressed 
T-bet compared to 4.0 % of CD4+CD28+ T-cells [2.6 - 9.2] (p<0.001).  Furthermore, the 
proportion of CD4+CD28null T-cells expressing T-bet was correlated to the size of the 
CD4+CD28null T-cell expansion (r=0.773, p<0.001) in an exponential relationship 
(Figure 3.12, Panel B) suggesting that expression of T-bet on CD4+CD28null T-cells 
increases as this subset expands.  Conversely, BLIMP-1 expression was minimal in 
comparison to T-bet expression, although CD4 T-cells from AAV patients had a slightly 
higher expression of BLIMP-1 compared to HV (Figure 3.12, Panel A) mirroring the 
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Figure 3.12  Expression of T-bet and BLIMP-1 – summary results  
The proportion of CD4+CD28null and CD4+CD28+ T-cells expressing T-bet or BLIMP-1 
was assessed in AAV patients (n=53) (white boxes) and HV (n=30) (grey boxes) (Panel 
A).  A greater proportion of CD4+CD28null T-cells expressed T-bet compared to 
CD4+CD28+ T-cells in AAV and HV.  CD4+CD28null T-cells were more likely to express 
T-bet than BLIMP-1 in both AAV and HV.  CD4 T-cells from AAV patients were more 
likely to express BLIMP-1 compared to HV.  Comparisons within AAV patients and 
within HV were performed using Wilcoxon matched pairs signed rank test whilst 
comparisons across AAV patients and HV were performed using the Mann-Whitney U 
test.  In panel B, as the size of the CD4+CD28null T-cell expansion increased 





CMV Modulation of the Immune System in AAV 137 
 
Given the fact that a high proportion of CD4+CD28null T-cells were found to express 
the Th1 transcription factor T-bet, the T helper subtype of CD4+CD28null T-cells was 
confirmed in a subset of AAV patients (n=17) and HV (n=6).  Whole blood was stained 
for CXCR3, CCR4 and CCR6 (Figure 3.13) in order to identify Th1 (CXCR3+ CCR6-), Th17 
(CCR4+ CCR6+), Th1Th17 (CXCR3+ CCR6+) and Th2 (CCR4+CCR6-) T-cells [338].   
 
In keeping with T-bet expression, CD4+CD28null T-cells exhibited a Th1 type signature 
as identified by CXCR3 expression and minimal expression of CCR6 and CCR4.  
CD4+CD28null T-cells were significantly more likely to exhibit a Th1 pattern compared 
to CD4+CD28+ T-cells whereas the opposite was true for Th1Th17, Th17 and Th2 
signatures (Figure 3.13).  There was no difference in this pattern between AAV patients 
and HV.  The high expression of CXCR3 by CD4+CD28null T-cells was in agreement with 
the plasma level of IP-10, the ligand for CXCR3, that was found to be independently 
associated with the size of the CD4+CD28null T-cell expansion on multivariable analysis 
(Table 3.3). 
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Figure 3.13 T helper phenotype of CD4+CD28null T-cells  
Whole blood was stained with CXCR3, CCR4 and CCR6 antibodies in order to identify Th1, 
Th1Th17, Th17 and Th2 signatures in CD4+CD28null (purple) and CD4+CD28+ (grey) T-cells 
as seen in a representative patient sample in Panel A where the top row plots are gated on 
CD4+CD28null T-cells (purple) and the bottom row plots on CD4+CD28+ (grey) T-cells.  
Panel B shows summary results in AAV patients (n=17) (white boxes) and HV (n=6) (shaded 
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3.5 Discussion 
CD4+CD28null T-cells in AAV patients were found to mainly produce IFN- and TNF- in 
response to CMV lysate, in keeping with a Th1 subtype and in agreement with a 
previous report that described CD4+CD28null T-cells to be major sources of IFN- and 
TNF- within granulomas in patients with GPA [35].  In contrast, these cells produced 
relatively small amounts of IL-2 and negligible IL-5 and IL-10.  The Th1 phenotype of 
CD4+CD28null T-cells was further confirmed by staining for the chemokine receptor 
CXCR3 and the Th1 transcription factor T-bet that were present in the majority of 
CD4+CD28null T-cells.  Furthermore CD4+CD28null T-cells did not express CCR4 or 
CCR6 seen in Th2 (CXCR3-CCR4+CCR6-) and Th17 cells (CXCR3-CCR4+CCR6+) 
respectively.    
 
The proportion of CMV responsive T-cells amongst CD4+CD28null T-cells increased as 
the CD4+CD28null T-cell compartment expanded.  Moreover, the magnitude of the 
CD4 CMV response displayed a very close linear correlation to the CD4+CD28null T-cell 
percentage and on multivariable analysis was the best independent determinant of the 
size of the CD4+CD28null T-cell expansion in AAV patients in disease remission.   
 
Several studies have highlighted that the bimodal ‘carrier’ pattern of CD4+CD28null T-
cells can be explained by past infection with CMV.  In that respect Hooper et al. 
showed that in rheumatoid arthritis patients, CD4+CD28null T-cell expansions were 
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only present in CMV seropositive individuals [168].  Similarly, Morgan et al. described 
that significant expansions of CD4+CD28null T-cells were only present in CMV 
seropositive AAV patients [112].   
 
CD4+CD28null T-cells expand with age and as CMV seroprevalence also increases with 
age it can often be difficult to disentangle the two from each other [184].  
Furthermore, other researchers have suggested alternate antigens that may be 
responsible for the generation of CD4+CD28null T-cells such as heat shock proteins 
(HSP) [178, 200].  In these experiments, CD4+CD28null T-cells from patients with 
unstable angina, reacted to HSP60 but not CMV by upregulation of IFN- and perforin 
mRNA, casting doubt on the antigen specificity of these cells [200].   
 
The data presented here lend strong support to the existing evidence in the literature 
that suggests CMV infection is the driving force behind CD4+CD28null T-cell expansion.  
Interestingly, age was not associated with the size of the CD4+CD28null T-cell 
compartment after controlling for relevant confounders suggesting that the total CMV 
CD4 response defines the CD4+CD28null T-cell expansion independently from age and 
is more important than age itself in that respect, at least in an immunosuppressed 
patient population with an inflammatory disease.   
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A limitation of this study in terms of defining the CMV specificity of CD4+CD28null T-
cells is that only CMV seropositive patients were included.  This however was 
deliberate as significant CD4+CD28null T-cell expansions greater than 2% of the CD4 
compartment are only present in the setting of CMV seropositivity [112] and the 
primary objective of this chapter was to phenotype this cell type in AAV rather than 
prove that they are CMV specific.  For this reason CD4+CD28null cells were also not 
challenged with alternative antigens during the course of this work.   
 
Previous experiments have shown that CD4+CD28null T-cells proliferate in response to 
CMV antigens but not in response to other antigens like varicella zoster, tetanus toxoid 
and tuberculin purified protein derivative [112, 184], although as mentioned earlier 
reactivity to HSP60 has been demonstrated [200].  Bason and colleagues have shown 
that a short sequence of HSP60 shares homology with two CMV encoded proteins and 
that CMV infection induces antibodies that are able to bind HSP60 and cause 
endothelial damage [236].  It would be interesting to determine whether CMV specific 
CD4+CD28null T-cells are also able to recognise both CMV antigens and HSP60 and 
whether dual recognition is associated with increased cytotoxicity.      
 
The phenotype of CD4+CD28null T-cells was similar in AAV patients in remission and 
age matched healthy volunteers.  AAV patients had a significantly higher proportion of 
CD4+CD28null T-cells within their CD4 compartment although there was no difference 
in the absolute count as AAV patients were lymphopoenic, as expected.  AAV patients 
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are heavily immunosuppressed and therefore it is possible that subclinical CMV 
reactivation is more frequent in these patients compared to healthy people thereby 
leading to an exaggerated proportionate expansion of CD4+CD28null T-cells. 
 
In order to determine whether CD4+CD28null T-cells possess aspects of functionally 
exhausted cells, their capacity to produce multiple cytokines was assessed.  A lower 
proportion of CD4+CD28null T-cell CMV specific cells were polyfunctional as judged by 
production of all three IFN-, TNF- and IL-2 cytokines compared to their CD4+CD28+ 
CMV specific counterparts.  In a bone marrow transplantation study patients that 
possessed polyfunctional CD8 T-cells were protected from CMV reactivation [339].  
CD4 T-cells capable of producing multiple cytokines are thought to be more effective 
than single-cytokine producing cells [304] in part due to their ability to sustain CD8 
responses by IL-2 secretion [340].  Although much less is known about the importance 
of polyfunctional CD4 T-cells in the control of CMV reactivation, recently it has been 
shown that following lung transplantation CMV specific CD4 T-cells able to co-produce 
IFN-, TNF- and IL-2 conferred protection from subsequent CMV viraemia whereas 
single producers of IFN- were detrimental [341].  Taken together with the current 
findings this suggests that the balance between CD4+CD28+ and CD4+CD28null CMV 
specific T-cells may be important in the control of CMV reactivation.  There is currently 
no information in the literature on the effect of polyfunctional responses on subclinical 
CMV reactivation and hence this was further explored in the studies described in 
Chapter 5. 
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In an effort to explore potential functional exhaustion in CD4+CD28null T-cells further, 
their expression of inhibitory receptors and the transcription factor BLIMP-1 that are 
implicated in functional exhaustion was evaluated and compared to their CD4+CD28+ 
counterparts.  A greater proportion of CD4+CD28null T-cells expressed PD-1 and TIM-3 
compared to CD4+CD28+ cells although the expression of CTLA-4 was noted to be 
higher on CD4+CD28+ T-cells.  There was no difference in the expression of LAG-3 or 
BLIMP-1 between CD28null and CD28+ cells and it is noteworthy that the expression of 
BLIMP-1 in CD4+CD28null T-cells was negligible.  The transcriptional pathways that 
regulate functional exhaustion in CD4 T-cells are incompletely understood and it is 
likely that substantial heterogeneity exists amongst potentially exhausted CD4 T-cells 
[342].  Given that CD4+CD28null T-cells were more likely to express PD-1 and TIM-3 
and exhibited reduced polyfunctionality compared to CD4+CD28+ cells, the proportion 
of polyfunctional CMV specific CD4+CD28null that expressed PD-1 or TIM-3 was 
compared to that of IFN- only producing CD4+CD28null T-cells.  Single producers of 
IFN- were more likely to express the inhibitory receptor TIM-3 compared to 
polyfunctional CD4+CD28null T-cells whereas no difference was noted in PD-1 
expression.  This indicates that the expression of TIM-3 but not PD-1 on CD4+CD28null 
T-cells is associated with reduced functionality and identifies a subset of potentially 
exhausted less functional T-cells within the CD4+CD28null T-cell compartment.   
 
TIM-3 has been linked to functional exhaustion and reduced functionality of T-cells in 
cancer [343] and hepatitis B infection [344] but has not been previously identified as a 
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marker of reduced function on CMV specific T-cells.  This is of potential clinical 
importance both in the context of CMV reactivation and as expansions of 
CD4+CD28null T-cells have been previously linked to increased infections in patients 
with AAV [112] and reduced responsiveness to the influenza vaccine [300, 317].  
However, it should be noted that the proportion of TIM-3 expressing CD4+CD28null T-
cells was very low casting uncertainty onto the biological significance of this molecule 
in the control of functional anti-CMV responses.  Indeed, expression of TIM-3 as well as 
other inhibitory receptors such as PD-1 may alternatively reflect recent lymphocytic 
activation by way of recent encounter with CMV antigens.   
 
 
In summary, the work presented in this chapter has confirmed that CD4+CD28null T-
cells in AAV represent a CMV responsive, Th1 proinflammatory subset.  The data here 
has strengthened the association between CMV infection and CD4+CD28null T-cells by 
showing that the size of the CMV CD4 response determines the magnitude of the 
CD4+CD28null T-cell expansion in AAV patients and has indicated that CMV specific 
CD4+CD28+ T-cells are more polyfunctional compared to CMV specific CD4+CD28null 
T-cells.  Finally, for the first time, TIM-3 expression on the surface of CMV specific 
CD4+CD28null T-cells has been identified as a marker of a functionally exhausted 
subset of CD4+CD28null T-cells.  
 








ASSOCIATION BETWEEN CD4+CD28null T-CELL 
EXPANSIONS AND CARDIOVASCULAR RISK IN 
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Chapter 4 Association between CD4+CD28null T-cell expansions and 
cardiovascular disease risk in AAV 
4.1 Introduction 
CD4+CD28null T-cells have been persistently implicated in cardiovascular disease 
(CVD).  They have been found to preferentially infiltrate unstable plaques [227], are 
present in higher proportions in unstable compared to stable angina patients and are 
thought to be involved in the pathophysiology of endothelial damage due to their 
potent production of IFN-[226].  In vitro, they have been shown to exhibit perforin 
dependent cytotoxic activity against human umbilical vein endothelial cells [228].  In 
addition, CD4+CD28null T-cells have been shown to be associated with endothelial 
dysfunction, identified by flow mediated vasodilatation, in rheumatoid arthritis (RA) 
patients [175] and have also been implicated in early atherosclerotic damage, 
identified by increased carotid artery intima-media thickness, in RA [175], chronic 
kidney disease (CKD) [179, 180] and haemodialysis patients [181]. 
 
Cardiovascular disease is a leading cause of mortality in AAV [93] and CD4+CD28null T-
cells have previously been linked with increased mortality in this patient group [112].  
In addition, CMV seropositivity has been associated with increased arterial stiffness, an 
established marker of CVD risk, in patients with CKD [285].    
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The data presented in Chapter 3 confirmed that expansions of CD4+CD28null T-cells in 
AAV patients are CMV responsive and exhibit a Th1, pro-inflammatory phenotype.  The 
work presented in this chapter aimed to: 
 
 Determine the impact of CD4+CD28null T-cells on CVD risk in AAV by assessing 
their relationship to arterial stiffness and blood pressure parameters and 
 Explore the mechanisms via which CD4+CD28null T-cells may contribute to 
CVD in inflammatory disease by assessing their expression of endothelial 
receptors and markers of cytotoxicity in patients with AAV 
 
Blood pressure and arterial stiffness parameters were measured on 53 CMV 
seropositive patients with stable AAV in remission.  CD4+CD28null T-cells were 
enumerated on the same day by whole blood staining as detailed in Chapter 2.  The 
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4.2 CD4+CD28null T-cell expansions correlate with increased systolic blood 
pressure and pulse pressure 
The size of the CD4+CD28null T- cell expansion was significantly correlated to systolic 
blood pressure measured peripherally and centrally (Figure 4.1, Panels A and C). No 
correlation was seen between CD4+CD28null T-cell percentage and diastolic blood 
pressure or mean arterial pressure (MAP) (Figure 4.1, Panels B and D). 
 
Figure 4.1 CD4+CD28null T-cell expansions and blood pressure parameters.  Correlations 
(Spearman rank test) are shown between the size of the CD4+CD28null T-cell expansion in 
CMV seropositive AAV patients in remission (n=53) and peripheral systolic blood pressure (A), 
peripheral diastolic blood pressure (B), aortic systolic pressure (C) and mean arterial pressure 
(D). 
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Pulse pressure, the difference between systolic and diastolic blood pressure, is a 
surrogate marker of arterial stiffness and is increased in atherosclerosis and 
arteriosclerosis.  It is has been shown to be a better predictor of cardiovascular 
outcomes compared to mean arterial pressure and diastolic blood pressure [345, 346].  
The percentage of CD4+CD28null T-cells in AAV was significantly correlated with both 
peripheral and central pulse pressure in that patients with larger expansions of 
CD4+CD28null T-cells exhibited a higher pulse pressure (Figure 4.2). 
 
 
Figure 4.2 CD4+CD28null T-cells and pulse pressure   
Correlations (Spearman rank test) are shown for CD4+CD28null T-cells from CMV 
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4.3 The CD4+CD28null T-cell percentage is independently associated with 
increased arterial stiffness 
Next, the percentage of CD4+CD28null T-cells in AAV patients was related to the gold 
standard measure of arterial stiffness, pulse wave velocity (PWV).  Aortic PWV is a 
powerful independent predictor of all-cause mortality and cardiovascular events in 
ESRD, hypertensive subjects, diabetic patients and the general population [347, 348].  
Carotid to femoral aortic PWV was measured as described in Chapter 2.  In keeping 
with the observed relationship between CD4+CD28null T-cells and pulse pressure, the 
size of the CD4+CD28null T-cell expansion was found to be correlated with increased 
PWV (Figure 4.3). 
 
 
Figure 4.2 CD4+CD28null T-cells and pulse wave velocity   
Correlation (Spearman rank test) is shown for CD4+CD28null T-cells from CMV 
seropositive AAV patients in remission (n=53) and pulse wave velocity. 
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Univariable analysis revealed that PWV was associated with several other factors that 
could potentially confound the observed association with CD4+CD28null T-cell 
percentage (Table 4.1).   
 
Table 4.1 Factors associated with PWV on univariable analysis (n=53) 
Variable Univariable analysis 
R 
Square 
B value [95% CI] p value 
Age (years) 0.183 0.131 [0.053, 0.208] 0.001 
Gender 0.004 0.393 [-1.313, 2.100] 0.645 
Creatinine mol/L 0.021 0.008 [-0.008, 0.025] 0.305 
eGFR (mL/min/1.73m2) 0.026 -0.023 [-0.062, 0.017] 0.252 
Urinary Albumin Creatinine Ratio 
(ACR) 
0.056 0.019 [-0.003, 0.041] 0.088 
Peripheral Pulse Pressure (mmHg) 0.163 0.084 [0.030, 0.137] 0.003 
Central Pulse Pressure (mmHg) 0.126 0.077 [0.019, 0.135] 0.010 
Mean Arterial Pressure (mmHg) 0.102 0.088 [0.015, 0.161] 0.020 
Systolic Blood Pressure (mmHg) 0.191 0.079 [0.033, 0.124] 0.001 
Diastolic Blood Pressure (mmHg) 0.027 0.056 [-0.039, 0.150] 0.243 
Aortic Systolic Pressure (mmHg) 0.162 0.074 [0.026, 0.122] 0.003 
CD4+CD28null T-cell proportion 
(%) 
0.182 0.091 [0.037, 0.146] 0.001 
C-reactive protein 0.008 1.169 x 10-7 [0.000, 0.000] 0.520 
RANTES 0.004 -2.048 x 10-5 [0.000, 0.000] 0.676 
sICAM-1 0.005 5.27 x 10-7 [0.000, 0.000] 0.625 
sVCAM-1 0.004 1.18 x 10-6 [0.000, 0.000] 0.638 
IL-2 0.066 0.007 [0.000, 0.015] 0.065 
MCP-1 0.016 -0.002 [-0.007, 0.003] 0.366 
Fractalkine 0.009 0.020 [-0.039, 0.078] 0.5060 
E-selectin 0.001 3.34 x 10-6 [0.000, 0.000] 0.866 
IFN- 0.036 -0.004 [-0.010, 0.002] 0.179 
IL-10 0.025 0.089 [-0.068, 0.245] 0.260 
IL-6 0.004 0.002 [-0.007, 0.011] 0.649 
TNF- 0.083 0.015 [0.001, 0.029] 0.039 
IP-10 0.006 -0.001 [-0.002, 0.001] 0.586 
P-selectin 0.015 9.66 x 10-6 [0.000, 0.000] 0.395 
IL-17 0.015 -0.003 [-0.011, 0.004] 0.389 
IL-12 0.001 0.008 [-0.059, 0.074] 0.818 
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In order to determine whether the size of the CD4+CD28null T-cell expansion was 
independently associated with increased PWV, variables linked to PWV with a p value 
less than or equal to 0.1 on univariable analysis were entered in a multivariable linear 
regression model (Table 4.2).  The CD4+CD28null T-cell percentage was independently 
associated with PWV after controlling for relevant confounders. The only other factor 
that remained significantly associated with PWV was age.   
 
In order to avoid collinearity, only one blood pressure parameter was added at each 
iteration of the model.  Table 4.2 shows the final model with MAP.  The CD4+CD28null 
T-cell percentage remained independently associated with PWV with minimal changes 
in the overall R square, B values and p values when peripheral pulse pressure, central 
pulse pressure, peripheral systolic blood pressure or central aortic blood pressure 
were substituted for MAP.  Similarly, the final model shown in Table 4.2 includes TNF-
 but not IL-2 in order to avoid significant collinearity.  There was no change when 
TNF- was substituted for IL-2 and the size of the CD4+CD28null T-cell expansion 
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p value B value [95% CI] p value 
CD4+CD28null T-cell 
proportion 
0.001 0.066 [0.013, 0.119] 0.016 
Age 0.001 0.080 [0.006, 0.155] 0.035 
Urinary ACR 0.088 0.013 [-0.007, 0.033] 0.196 
Mean arterial pressure 
(MAP) 
0.020 0.053 [-0.016, 0.122] 0.128 
TNF- 0.039 0.010 [-0.002, 0.022] 0.086 
Multivariable model included all variables with a p value ≤ 0.1 on univariable analysis. 
R value: 0.635 




4.4 CD4+CD28null T-cell expression of endothelial receptors and markers 
of cytotoxicity 
Given the observed association between CD4+CD28null T-cell percentage and 
increased arterial stiffness, the expression of the endothelial receptors CX3CR1 
(receptor for fractalkine), CD49d (receptor for VCAM-1) and CD11b (receptor for ICAM-
1) was assessed on CD4+CD28null T-cells and compared to the expression of these 
receptors on CD4+CD28+ T-cells.  In parallel, the expression of the intracellular 
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cytotoxic molecules granzyme B and perforin was assessed as a marker of cytotoxic 
potential.  These experiments were performed on cryopreserved PBMC in a random 
subset of AAV patients (n=10).   
 
A large percentage of CD4+CD28null T-cells expressed all three endothelial receptor 
molecules compared to CD4+CD28+ T-cells (51.6 [IQR 42.7 - 64.4] vs. 5.0 [1.7 - 6.3]; 
p=0.006).  Similarly, the majority of CD4+CD28null T-cells were cytotoxic, as defined by 
the expression of both granzyme B and perforin, compared to a very low proportion of 
CD4+CD28+ T-cells (74.5 [63.5 - 92.7] vs. 2.9 [1.8 - 5.4]; p=0.016; Wilcoxon matched 
pairs signed rank test) (Figure 4.3).     
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Figure 4.3 Expression of endothelial receptors and markers of cytotoxicity   
Cryopreserved PBMC from 10 AAV patients were thawed and stained for expression of 
the endothelial receptors CX3CR1, CD49d and CD11b as well as the intracellular 
cytotoxic molecules granzyme B and perforin.  Panel A shows staining from a 
representative patient sample where CD4+CD28null T-cells are shown in purple and 
CD4+CD28+ T-cells in grey.  In Panel B the proportion of CD4+CD28null T-cells 
expressing all 3 endothelial receptors and in Panel C the proportion expressing both 
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Next, the expression of the activating natural killer cell receptor NKG2D on 
CD4+CD28null T-cells and its co-expression with CX3CR1, CD49d, CD11b and the 
cytotoxic molecules granzyme B and perforin was assessed as NKG2D has previously 
been implicated in endothelial cytotoxicity [225].  This again was performed in a 
random subset of AAV patients (n=10). 
 
A much higher percentage of CD4+CD28null T-cells expressed NKG2D compared to 
their CD4+CD28+ counterparts (27.4 [IQR 12.8 - 44.9] vs. 2.8 [0.8 - 5.1]; p=0.002) 
(Figure 4.4).  In addition, the majority of the NKG2D positive CD4+CD28null T-cell 
compartment expressed CX3CR1 (82.7% [75.0 - 90.4]) and pre-formed cytotoxic 
molecules granzyme B and perforin (85.7 [68.8 - 97.2]).  A large percentage of NKG2D+ 
CD4+CD28null T-cells were dual positive for CD49d and CD11b expression (38.2 [20.8 - 
51.9]).   
 
  




Figure 4.4 NKG2D staining in CD4+CD28null T-cells  
Cryopreserved PBMC from 10 AAV patients were thawed and stained with surface and 
intracellular markers to identify NKG2D positive cells within the CD4+CD28null T-cell 
compartment and investigate their phenotype in terms of CX3CR1 expression (Panel 
B), CD49d CD11b double expression (Panel C) and granzyme B perforin double 
expression (Panel D).  CD4+CD28null T-cells are depicted in purple, CD4+CD28+ cells in 
grey and NKG2D+ CD4+CD28null cells in red (Panels A-D).  Panel E shows summary 
results comparing the proportion of CD4+CD28null T-cells and CD4+CD28+ T-cells 
expressing NKG2D and proportions of NKG2D+ CD4+CD28null T-cells co-expressing 
CX3CR1, CD49d and CD11b as well as granzyme B and perforin.   
 




CD4+CD28+: 1.6% 84.6% 
51.4% 97.9% 
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4.5  Discussion  
Having shown that CD4+CD28null T-cells in AAV are CMV responsive, pro-inflammatory 
T-cells, work presented in this chapter aimed to characterise these cells further in 
terms of their cytotoxic potential and expression of endothelial homing receptors and 
investigate their relevance in contributing to cardiovascular risk in patients with AAV 
where cardiovascular disease (CVD) is a major source of morbidity and mortality.   
 
The size of the CD4+CD28null T-cell expansion in AAV patients in remission was shown 
to be correlated with multiple measures of blood pressure and arterial stiffness.  In 
addition, after controlling for relevant confounding variables such as age, mean arterial 
pressure, proteinuria and levels of systemic inflammation, the CD4+CD28null T-cell 
percentage was independently associated with carotid to femoral PWV, the gold 
standard measure of arterial stiffness and a well-established surrogate marker of 
cardiovascular outcomes. 
 
The data presented in Chapter 3 showed that CD4+CD28null T-cells in AAV patients are 
Th1 proinflammatory cells by virtue of their abundant secretion of IFN- and TNF- 
and expression of T-bet and CXCR3.  These observations are extended here to show 
that the majority of CD4+CD28null T-cells possess the endothelial homing receptors 
CX3CR1, CD49d and CD11b on their surface.  Furthermore, the majority of 
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CD4+CD28null T-cells were found to contain the pre-formed cytotoxic molecules 
granzyme B and perforin.   
 
The chemokine receptor CXCR3 is known to be responsible for the specific recruitment 
of Th1 cells to inflammatory sites [349].  In addition, its ligand, IP-10 and the CX3CR1 
ligand, fractalkine, are expressed by activated endothelial cells and in vitro 
experiments have shown that following stimulation with CMV antigens, CMV effector 
cells are able to produce soluble factors that induce endothelial activation and 
production of IP-10 and fractalkine, migrate in an IP-10 / fractalkine dependent fashion 
and induce endothelial cell lysis [287].  The endothelium is a target tissue for CMV 
infection [350, 351] and therefore endothelial receptors on CMV specific cells may 
serve to target them to areas of potential reactivation.    
 
Taken together, the data presented here suggests that expression of CXCR3, CX3CR1, 
CD49d and CD11b enables CD4+CD28null T-cells to target areas of inflamed 
endothelium through their respective ligands IP-10, fractalkine, VCAM-1 and ICAM-1 
leading to perforin and granzyme B mediated endothelial cell lysis and vascular 
damage.  Interestingly, the plasma concentration of IP-10 was found to be 
independently associated with the size of the CD4+CD28null T-cell expansion during 
the studies presented in Chapter 3 in keeping with possible endothelial upregulation of 
IP-10 in the setting of large CD4+CD28null T-cell expansions.     
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In addition, CD4+CD28null T-cells in AAV patients were found to express NKG2D an 
activating receptor usually found in natural killer cells as well as activated CD8 and CD4 
T-cells and implicated in the targeting and lysis of glomerular endothelial cells [225].  
NKG2D positive CD4+CD28null T-cells in turn were almost all CX3CR1 positive and 
almost always contained pre-formed granzyme B and perforin cytotoxic molecules.   
 
Data presented in the previous chapter showed that in AAV patients, both the 
proportion of T-bet expressing and IFN- producing CD4+CD28null T-cells increase as 
the size of the CD4+CD28null T-cell expansion increases.  This is also likely to be 
relevant in the mediation of vascular damage by this T-cell subset as T-bet deficient 
mice display a lack of infiltration at pathologic sites and are protected from a wide 
range of inflammatory diseases [352, 353] whilst both T-bet and IFN- are essential in 
the generation of angiotensin II mediated vascular dysfunction [354].   
 
CD4+CD28null T-cell expansions have been linked with measures of early 
atherosclerotic damage such as increased carotid artery intima media thickness and 
endothelial dysfunction in patients with CKD and RA [175, 180, 181].  To date there has 
only been one study evaluating the contribution of CD4+CD28null T-cells to arterial 
stiffness in HIV infected women where the proportion of CD4+CD28null T-cells was 
shown to correlate with decreased carotid artery distensibility as assessed by B-mode 
ultrasound [355].  CMV seropositivity on the other hand has previously been 
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associated with increased arterial stiffness in CKD patients [285] but the way in which 
this effect is mediated is not clear. 
 
The data presented in this thesis so far show that in CMV seropositive patients with an 
inflammatory disease CD4+CD28null T-cell expansions are comprised of CMV 
responsive, proinflammatory T-cells that possess multiple endothelial homing 
receptors and markers of cytotoxicity and have the capacity to potentially target and 
lyse endothelial cells by the production of granzyme B and perforin.  Furthermore in 
the same cohort of patients, large expansions of these cells are independently linked 
to increased arterial stiffness likely accounting for the increased mortality seen in 
patients with AAV that possess increased expansions of CD4+CD28null T-cells.  This 
implicates CMV in the exacerbation of vascular damage in inflammatory disease 
mediated by CD4+CD28null T-cells and opens new therapeutic opportunities not only 
in AAV but also in other inflammatory conditions such as CKD and RA where similar 
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Chapter 5 The potential for valaciclovir to prevent CMV mediated 
adverse modulation of the immune system in ANCA 
Associated VASculitis (CANVAS): a randomised controlled 
open label proof of concept clinical trial 
5.1 Introduction 
Multiple lines of evidence suggest that chronic CMV infection, and its association with 
an expanded population of CD4+CD28null T-cells, is linked to negative outcomes in 
several inflammatory conditions such as ANCA associated vasculitis (AAV), rheumatoid 
arthritis (RA), systemic lupus erythematosus  (SLE), chronic kidney disease (CKD) as 
well as in cardiovascular disease and older individuals [112, 171, 173-175, 191, 287, 
356].  Central to the rationale for the present study is the hypothesis that this is 
achieved, at least in part, by subclinical reactivation of the virus from latency resulting 
in a CMV mediated expansion of CD4+CD28null T-cells.  The data presented in the 
previous chapters have shown that CD4+CD28null T-cells in AAV are largely CMV 
specific, Th-1, proinflammatory cells, that possess receptors which can target the 
endothelium and that the size of their expansion directly correlates with increased 
arterial stiffness, an established marker of cardiovascular risk.  It is therefore important 
and clinically relevant to determine whether anti-CMV therapy has the potential to 
control possible subclinical CMV reactivation in latency and ameliorate these CMV 
induced changes on the immune system. 
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Utilising AAV as a model for inflammatory disease, the CANVAS proof of concept 
clinical trial (EudraCT 2012-001970-28, NCT01633476) presented here aimed to test 
the hypothesis that episodes of subclinical CMV reactivation in inflammatory 
conditions lead to an expansion of the CD4+CD28null T-cell compartment.  To that end, 
the trial was designed to test whether a 6 month treatment with oral valaciclovir in 
CMV seropositive AAV patients in disease remission, can control subclinical CMV 
reactivation and whether by controlling subclinical CMV reactivation the size of the 
CD4+CD28null T-cell expansion can be ameliorated as well as whether this can lead to 
an improvement in other associated CMV driven changes to the immune system. 
 
The trial protocol was approved by the relevant regulatory bodies and is outlined in 
Section 2.3.  Patients were randomised to 2g QDS of oral valaciclovir (dose was 
reduced according to renal function, Table 2.4) or no additional treatment in an open 
label fashion for 6 months followed by an additional follow-up period of 6 months.                  
 
5.2 Recruitment and patient flow 
The CONSORT flow diagram (Figure 5.1) shows the flow of patients within the clinical 
trial from assessment of eligibility to randomisation.  In summary, 200 AAV patients 
were assessed for eligibility.  Seventy-nine patients were initially deemed eligible for 
inclusion into the clinical trial.  One of the main reasons for the lower number of 
eligible patients, compared to the estimated number of 125 prior to commencement 
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of the trial, was an increase in the use of annual or 6-monthly rituximab for 
maintenance of clinical remission that precluded inclusion into the trial as patients 
could not have had rituximab within the last 12 months (see exclusion criteria in Table 
2.3).  A substantial amendment was successfully submitted to the REC and MHRA to 
reduce the length of time from treatment with the T-cell depleting agent 
cyclophosphamide to inclusion in the trial, from 12 months to 6 months, as previous 
data in SLE had shown return of lymphocyte counts to pre-treatment values as early as 
6 months following cyclophosphamide treatment [357].  An additional nine eligible 
patients were identified following this change. 
 
Forty-nine patients declined to participate in the clinical trial although a number of 
those agreed to participate in the cross-sectional element of the study that involved a 
single visit (Chapters 3 and 4).  The most common reason that patients did not want to 
participate was not wanting to take an extra tablet mainly due to apprehension of 
potential side effects and in particular fear of loss of kidney function as a result of the 
valaciclovir treatment.  The second most common reason was the number of visits 
associated with the clinical trial.  Thirty-nine patients were consented to participate in 
the clinical trial (44% of fully eligible patients).  However, one patient had a family 
emergency shortly after consenting and was therefore not randomised as they were 
unable to participate.  The remaining 38 patients were randomised to receive either 
valaciclovir or no additional therapy using the PC-CRTU independent telephone based 
randomisation system as described in Section 2.3.5. 













Figure 5.1 CONSORT flow diagram for the CANVAS clinical trial 
 
 
5.3 Protocol compliance 
There was good adherence to the study protocol during the course of the trial.  There 
were no protocol breaches.  Out of a total of 494 study visits only 27 visits were missed 
by study participants (5.5%).  Two patients randomised to the control arm (CT022 and 
CT026) were only able to attend the baseline and month 6 visits.  These two patients 
200 patients assessed for eligibility 
79 eligible patients identified 
88 eligible patients identified 
Amendment to exclusion 
criteria 
49 patients declined 
39 patients consented 
1 patient excluded from 
randomisation 
38 patients randomised 
Treatment – 19 patients Control – 19 patients 
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were therefore not included in the analysis of the tertiary outcome (Section 5.7) and 
the change in CMV IgG titre exploratory outcome (Section 5.8.6) but were included in 
all other analyses.   
 
The dose of valaciclovir was adjusted according to creatinine clearance.  The median 
dose of valaciclovir prescribed was 6g / day (1.5g QDS) (range 3 – 8g / day; 1.5g BD – 
2g QDS).  Compliance with the prescribed trial medication was assessed in a random 
selection of 9 patients randomised to the treatment arm by counting the number of 
tablets returned at each month visit and comparing it to the number of tablets 
dispensed and the prescribed dose.  The median compliance with prescribed trial 
medication in this selection of patients assessed was 94.4% (IQR 88.0 – 95.8) across 
the duration of the treatment period.  This selection of patients included patients that 
might have had a temporary break in treatment. 
 
All patients randomised to the treatment arm completed the study in full.  However, 
one patient (CT035) elected to stop taking the tablet within 2 weeks of 
commencement whilst an additional patient (CT033) developed acute kidney injury, 
which led to discontinuation of the study drug within one month of commencement.  
Both patients completed subsequent trial visits fully although the study drug was not 
restarted.  One patient (CT006) elected to stop the trial medication for 2 weeks during 
an episode of a chest infection at month 3 of the study.  A further patient (CT031) had 
a 1-week break in treatment in month 2 due to a hospital admission unrelated to the 
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study drug and a 2-week break in treatment during month 4 associated with an 
episode of depression again unrelated to the study drug.  All primary analyses were 
carried out using the intention to treat principle as pre-specified in the published 
clinical trial protocol [325]. 
 
5.4 Patient characteristics 
All patients randomised to the clinical trial, in keeping with the eligibility criteria, were 
in disease remission with no documented relapses in the last 6 months.  All patients 
had received high dose corticosteroids and cyclophosphamide or rituximab (with or 
without plasma exchange) for induction of remission, followed by low dose 
corticosteroids, azathioprine, mycophenolate mofetil (MMF) or methotrexate as 
maintenance of remission therapy.  Three patients had discontinued 
immunosuppression at the time of commencing the trial (Table 5.1).   
 
There were no significant differences between treatment and control groups in terms 
of age, gender, ethnicity, immunosuppressant medication or duration of disease (Table 
5.1).  Control patients had a higher proportion of CD4+CD28null T-cells at the pre-
randomisation visit compared to patients randomised to treatment although this did 
not attain statistical significance.  This discrepancy was noted at an interim Trial 
Steering Committee (TSC) meeting. Given the potential bias this may have caused at 
the end of the study, statistical advice given by the TSC statistical advisor suggested 
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the analysis plan be designed to assess proportionate rather than absolute value 
reduction for secondary, tertiary and exploratory outcomes.      
   
 
Table 5.1 Characteristics of patients randomised to the clinical trial 









Age (years) 67.4 (10.2) 66.0 (11.5) 68.8 (8.8) 0.412 
Gender (M:F) 25:13 12:7 13:6 0.732 
Ethnicity  
(% Caucasian) 
92.1 84.2 100.0 0.230 
ANCA specificity 
(PR3:MPO) 
27:10 12:6 15:4 0.476 
Disease chronicity 
(months)* 
71.5 (38.0 – 
144.0) 
87.0 (34.0 – 
138.5) 






56 (20) 53 (22) 59 (18) 0.339 
Immunosuppression 
(% on steroids) 
73.7 68.4 78.9 0.714 
Immunosuppression 
(% on MMF) 
26.3 26.3 26.3 1.000 
Immunosuppression 
(% on azathioprine) 
36.8 31.6 42.1 0.501 
Immunosuppression 
(% on no treatment) 
7.9 10.5 5.3 1.000 
CD4+CD28- % at 
pre-randomisation 
visit* 
13.5 (3.6 – 
21.3) 
10.9 (2.5 – 
15.8) 
19.1 (7.5 – 
25.1) 
0.102 
Values presented as mean (SD) apart from * that is presented as median (IQR) 
 
Eleven patients had their immunosuppression modified during the clinical trial period 
(Table 5.2).  Such modifications were equally split between the two groups.  The 
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majority of those instances related to a reduction or cessation of immunosuppression 
due to immunosuppressive treatment related complications such as infection.  None of 
the participants had an episode of disease relapse during the trial.    
 







CT031 Month 2 MMF paused for 2 weeks Infection 
CT021 Month 5 
Month 9 
Patient initiated temporary 
increase in prednisolone dose 
Infection 
CT005 Month 8 Azathioprine changed to MMF To enable commencement 
of allopurinol for severe 
gout 
CT006 Month 8 Azathioprine paused for 3 months Shingles 
CT035 Month 8 Temporary increase in 
prednisolone dose 
Infection 
CT005 Month 10 Temporary increase in 
prednisolone dose 
Severe polyarticular gout 
CT027 Month 10 Azathioprine stopped Squamous cell carcinoma 
Control Group 
CT019 Month 2 Temporary course of prednisolone 
and MMF dose reduced 
Infection 
CT030 Month 3 Azathioprine dose reduced Maintenance therapy dose 
reduction 
CT028 Month 4 Azathioprine stopped Renal mass – under 
investigation 
CT026 Month 7 Temporary increase in 
prednisolone dose 
Infection 
CT034 Month 9 MMF dose reduced  Recurrent infections 
MMF=Mycophenolate mofetil, ID=Clinical Trial Patient Identification  
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5.5 Primary Outcome 
The primary outcome of the clinical trial was the proportion of patients with CMV 
reactivation in blood or urine as assessed by qPCR.  All primary analyses were 
performed using the UHB Virology Laboratory validated cut-off of 200 CMV viral DNA 
copies / mL.  Additional secondary analyses were performed with a cut-off of 20 viral 
copies / mL which is the lower limit of quantitation of the assay.  A sensitivity analysis 
was performed on the proportion of reactivation episodes amongst all samples 
assayed.  CMV reactivation episodes are shown in Table 5.3.  The remainder of 
patients not shown on the table did not have any detectable CMV reactivation 
episodes for the duration of the clinical trial.        
 
There were 12 reactivation episodes (>200 viral copies / mL) in 8 patients (21.1% of the 
study group) over the 12-month study period.  In all of these reactivations episodes 
CMV DNA was detected only in the urine and not in plasma.  An additional 27 
reactivation episodes of minimal intensity (between 20 and 200 viral copies / mL) in 
total were observed in 15 patients (39.5% of the study group).  CMV DNA was detected 
just in urine in 15 of these episodes, just in plasma in 10, and in both urine and plasma 
in 2 cases.  All patients who had a reactivation of > 200 viral copies / mL had further 
episodes of minimal intensity reactivation.  There was no correlation between CMV 
reactivation in the urine and renal function.  All episodes were asymptomatic.    
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Primary analysis of CMV reactivation episodes (> 200 viral copies / mL) between month 
1 and month 6 (i.e. the duration of treatment), was consistent with valaciclovir 
treatment successfully blocking CMV reactivation completely in the treatment group 
with 4 patients reactivating in the control group (21.1%) and none in the treatment 
group (p=0.037).  During the 6 month follow up period after cessation of treatment, 
patients in the treatment group reactivated at similar rates to the control group and by 
the end of the 12-month period there was no difference in the overall proportion of 
patients with CMV reactivation in the control group (21.1%) versus the treatment 




       
 
 
Figure 5.2 Kaplan-Meier curve analysis of the primary outcome showing time to 
reactivation (>200 viral copies / mL; primary analysis) in the treatment (n=19) (red line) 
and control (n=19) (black line) groups 
Curves were compared using the Gehan-Breslow-Wilcoxon statistic.  Panels A, B, C 
show the treatment period (Month 1 – Month 6), follow-up period after cessation of 
treatment only (Month 7 – Month 12) and overall study period (Month 1 – Month 12), 
respectively.  The gridline in panel C indicates the end of treatment.    
p=0.037 p=0.338 p=0.449 
C A B 
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A secondary analysis of the primary outcome was also performed in order to consider 
those CMV reactivation episodes of minimal intensity (20 – 200 viral copies / mL).  On 
an intention to treat analysis, more control patients reactivated (>20 viral copies / mL) 
compared to treatment patients during the treatment period (Month 1 – Month 6) 
(control 31.6% vs. treatment 10.5%; p=0.110), although this difference did not reach 
statistical significance.  However, two patients in the treatment group (CT035 and 
CT033) stopped taking the drug at 2 weeks and at 1 month respectively as mentioned 
earlier.  Indeed, two out of the three reactivation episodes in the treatment group 
during the treatment period occurred in patient CT035 following cessation of the study 
drug at 2 weeks.  The third episode occurred in patient CT031 who had a 2-week break 
in treatment during month 4 and reactivated at the month 5 time point.  On a per 
protocol analysis that did not include the 2 patients that had stopped treatment by 
month 1, there was a statistically significant difference in the proportion of patients 
reactivating CMV (>20 viral copies / mL) between the two groups during the treatment 
period (control 31.6% vs. treatment 5.3%; p=0.041).  In addition, the only episode of 
CMV reactivation in the treatment group occurred in patient CT031 following a 2 week 
break in treatment as described above (Figure 5.3).  As with the primary analysis, 
















Figure 5.3 Kaplan-Meier curve analysis of the primary outcome showing time to 
reactivation (>20 viral copies / mL; secondary analysis) in the treatment (n=19) (red 
line) and control (n=19) (black line) groups 
Curves were compared using the Gehan-Breslow-Wilcoxon statistic.  Panels A, B, C 
show the treatment period (Month 1 – Month 6), follow-up period after cessation of 
treatment only (Month 7 – Month 12) and overall study period (Month 1 – Month 12) 
respectively (all intention to treat).  The gridline in panel C indicates the end of 
treatment.  Panel D shows the results of the per protocol analysis during the treatment 




A sensitivity analysis was also performed to consider the proportion of samples that 
were positive for CMV reactivation amongst all plasma and urine samples assayed 
during the treatment period.  Contingency tables were constructed and the treatment 
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p=0.110 p=0.757 p=0.508 
p=0.041 
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group was compared to the control group using the Fisher’s exact test (Table 5.4).  
Missing samples were taken into account by excluding them from the denominator.  
Utilising the 200 viral copies / mL threshold, there were 6 reactivation instances out of 
a possible of 205 in the control group and 0 instances out of a possible of 227 in the 
treatment group during the treatment period (p=0.011).  Considering all reactivation 
episodes greater than 20 viral copies / mL, the numbers were 16 out of 205 and 3 out 
of 227 for the control and treatment groups respectively (p=0.002).  This analysis was 
performed on an intention to treat basis and included all patients randomised to the 
treatment arm.  Finally, during the treatment period, taking into account all episodes 
>20 viral copies / mL, the median CMV viral DNA copy number was 741.5 copies / mL 
(IQR: 66.8 – 2791.0) in the control group compared to just 85.0 copies / mL (IQR: 29.0 – 
141.0) in the treated patients.  As mentioned earlier, it is important to note that the 3 
reactivation episodes of minimal intensity (20 – 200 viral copies / mL) that occurred in 
the treatment group during the treatment period all occurred either after cessation of 
treatment or following a break in treatment.  Taken together this data shows that 
valaciclovir treatment successfully blocked CMV reactivation during the treatment 
period.  Following cessation of therapy, CMV reactivation resumed at the same rate as 





CMV Modulation of the Immune System in AAV 177 
 
Table 5.4 Contingency table showing number of reactivation episodes during the 
treatment period 
 Treatment Control 
Number of samples with > 200 viral copies / mL 0 6 
Number of samples with > 20 viral copies / mL 3 16 
Total number of samples assayed (plasma and 
urine) 
227 205 




5.6 Secondary Outcomes  
Given the central role of CD4+CD28null T-cells as mediators of CMV driven 
inflammation and in order to test the hypothesis that subclinical CMV reactivation 
drives the expansion of CD4+CD28null T-cells, one of the main secondary outcomes of 
the clinical trial was change in the proportion of CD4+CD28null T-cells from baseline to 
6 months.  Other pre-specified secondary outcomes were change in the concentration 
of soluble markers of inflammation (CRP, IFN-, TNF-, IL-2, IL-6, IL-10, IL-17) from 
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5.6.1 Secondary Outcome – Change in the proportion of CD4+CD28null T-cells 
from baseline to 6 months 
The CD4+CD28null T-cell percentage within the CD4 compartment was measured via 
flow cytometry after staining whole blood with fluorochrome labelled monoclonal 
antibodies for CD3, CD4 and CD28 as detailed in Section 2.6.2.  A fluorescence minus 
one (FMO) control for CD28 staining was run with every experimental sample in order 
to aid gating.  The gating strategy has been discussed in Chapter 3 (Figure 3.1).   
 
The assay was validated for use in the clinical trial as detailed in Section 2.7.  An aliquot 
of Cytofix CD4 positive control with a known CD3+CD4+ expression was assayed with 
each experimental assay run to provide quality assurance and verify that each assay 
was completed successfully.   
 
The absolute values of CD4+CD28null T-cell percentages at the start (baseline) and at 
the end (month 6) of the treatment period for treated and control patients are shown 
in Figure 5.5.  These were analysed using paired ratio t tests as described in Section 
2.9.1, in order to test for statistically significant trends in the ratio of CD4+CD28null T-
cell percentage between month 6 and baseline in the treatment and control groups.  
Data is reported as geometric mean of ratios with 95% confidence intervals (CI), where 
a value of less than 1 denotes a reduction in the ratio of the percentage of 
CD4+CD28null T-cells (month 6 to baseline) and a value greater than 1 an increase.   
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There was a statistically significant reduction in the CD4+CD28null T-cell percentage 
month 6 to baseline ratio in treated patients, of 23.0 (geometric mean of ratios 0.770, 
95% CI [0.611 - 0.970], p=0.029).  In contrast, there was no statistically significant 
change in the CD4+CD28null T-cell percentage ratio in the control patients (0.946 
[0.814 - 1.110], p=0.449) indicating that blocking subclinical CMV reactivation in the 




Figure 5.5 Secondary outcome – change in CD4+CD28null T-cell percentage during 
treatment period 
Panels A and B show absolute values of CD4+CD28null T-cell percentages at baseline 
(M0) and month 6 (M6) for treatment (n=19) and control (n=19) patients respectively.  
There was a significant proportionate reduction in CD4+CD28null T-cell percentage at 
the end of the treatment period in treated patients but not controls.   
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5.6.2 Secondary Outcome – Change in concentration of soluble markers of 
inflammation from baseline to 6 months 
In order to determine whether blocking subclinical CMV reactivation also led to an 
improvement in soluble markers of inflammation, plasma CRP, IFN-, TNF-, IL-2, IL-6, 
IL-10, and IL-17 were measured using Luminex technology at the start and end of 
treatment as detailed in Section 2.6.3.  Paired ratio t tests were used to detect 
statistically significant trends between the baseline and month 6 measurements in the 
treatment and control groups as previously described.   
 
There was a statistically significant reduction in the ratio of month 6 to baseline 
concentration of IL-2 in the treated patients, of 81.6% (geometric mean of ratios 0.184, 
95% CI [0.049 - 0.693], p=0.015), whereas no statistically significant change was 
observed in the control patients (0.831 [0.522 - 1.323], p=0.414).  There was also a 
reduction in the ratio of month 6 to baseline concentration of IFN- in the treated 
patients, of 81.6% (0.183 [0.033 - 1.011], p=0.051), whereas again no change was seen 
in control patients (1.166 [0.657 - 2.071], p=0.580) (Figure 5.6).  There were no 
statistically significant differences in the ratios of the month 6 to baseline 
concentration values for TNF-, IL-6, IL-10, IL-17 or CRP in either of the groups (Figure 
5.7).  Summary data of month 6 to baseline ratios for all plasma markers of 
inflammation measured as part of the secondary outcome are shown in Table 5.5.    
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Figure 5.6 Secondary outcome – change in plasma concentration of markers of 
inflammation  
Panels A and B show absolute values of IL-2 and panels C and D of IFN- concentration 
at baseline (M0) and month 6 (M6) for treatment (n=19) and control (n=19) patients 
respectively.  At the end of the treatment period there was a statistically significant 
proportionate reduction in the plasma level of IL-2, as well as a trend towards a 
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Table 5.5 Results of paired ratio t tests for soluble markers of inflammation 
assayed for the clinical trial secondary outcome 









95% CI p value 
IL-2 0.184 [0.049 - 
0.693] 
0.015 0.831 [0.522 - 
1.323] 
0.414 
IFN- 0.183 [0.033 - 
1.011] 
0.051 1.166 [0.657 - 
2.071] 
0.580 
TNF- 0.612 [0.343 - 
1.093] 
0.092 0.859 [0.501 - 
1.472] 
0.560 
IL-6 0.478 [0.187 -
1.220] 
0.115 0.914 [0.636 - 
1.314] 
0.610 
IL-10 0.682 [0.344 - 
1.354] 
0.256 0.811 [0.541 - 
1.214] 
0.290 
IL-17 0.339 [0.087 - 
1.327] 
0.113 0.405 [0.101 - 
1.622] 
0.188 
CRP 1.304 [0.632 – 
2.691] 
0.451 0.887 [0.465 – 
1.690] 
0.700 
M6 = month 6, M0 = baseline, CI = confidence intervals     
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Figure 5.7 Secondary outcome – change in plasma concentration of markers of inflammation.  Panels show absolute values for concentration of 
plasma markers at baseline (M0) and month 6 (M6).  Panels A, C, E, G and I show values for TNF-, IL-6, IL-10, IL-17 and CRP in the treated patients 
whilst panels B, D, F, H and J show absolute values for the concentration of the same markers at M0 and M6 for the control patients. 
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5.6.3 Safety 
5.6.3.1  Adverse events 
Adverse events (AE) were documented for both treatment and control patients for the 
duration of the study irrespective of assessed relatedness at the time of reporting 
(Table 5.6).  Overall, the study drug was well tolerated.  There was no difference in the 
number of observed episodes of infection during the clinical trial period between 
treated and control patients.  The majority of infections were either lower or upper 
respiratory tract infections.  In addition, there was one episode of shingles in a control 
patient who received a one week course of aciclovir by their GP during month 2 of the 
study.  There was also an episode of shingles in a treatment patient that developed 2 
months following cessation of the study drug.  This was also treated with a course of 
aciclovir treatment by the GP.        
 
There were significantly more gastrointestinal tract (GI) related AEs reported in the 
treatment group compared to control patients.  This is in keeping with the known side-
effect profile of valaciclovir.  The majority of GI related AEs were episodes of 
diarrhoea, nausea and vomiting, and to a lesser extent abdominal pain, dry mouth and 
weight loss.  All reported GI related events were mild in severity and short lived and 
did not lead to discontinuation of the study drug by the participants or the research 
team.  In addition, 14 out of the 36 GI related observed AEs in the treatment group 
occurred in 2 patients with a known long-standing history of chronic diarrhoea and 
were assessed as not being related to the study medication at the time of reporting. 
CMV Modulation of the Immune System in AAV 185 
 
Table 5.6 Adverse events reported during the clinical trial period 






p value (treatment 
vs. control) 
Total number of infections 84 43 41 0.827 
Total number of GI related AEs 49 36 13 0.002 
Total number of 
musculoskeletal AEs 
36 23 13 0.100 
Number of patients with new 
or worsening respiratory AEs 
22 11 11 1.000 
Number of patients with new 
or worsening cardiac AEs 
5 3 2 1.000 
Number of patients with new 
or worsening neuropsychiatric 
AEs 
14 8 6 0.501 
Number of patients 
experiencing bleeding or 
bruising 
9 4 5 1.000 
Number of patients reporting 
new or worsening lethargy 
12 6 6 1.000 
 Number of patients with new 
ocular / visual AEs 
6 3 3 1.000 
Number of patients with new 
ENT related AEs 
3 2 1 1.000 
Episodes of acute kidney injury 3 2 1 1.000 
Episodes of anaemia 3 2 1 1.000 
Liver dysfunction episodes 1 1 0 1.000 
GI = gastrointestinal tract  
 
 
One patient elected to stop the study drug after 2 weeks of treatment due to a 
perceived increase in long-standing breathlessness.  Although this episode was 
assessed as not related to the study drug, the study medication was not restarted as 
per the patient’s wishes.  There was no difference in the frequency of respiratory AEs 
between treatment and control patients.   
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Other AEs were equally split between the treatment and control patients (Table 6.6).  
Of note, a squamous cell carcinoma was diagnosed in a treatment patient and a renal 
mass was identified in a control patient during the study period. 
 
There were 3 episodes of acute kidney injury (AKI) in 3 patients during the study 
period.  One of those occurred in a treatment patient several months after cessation of 
the study drug in the context of a hospital admission for severe polyarticular gout and 
was assessed as not related to the study drug.  Another AKI episode occurred in a 
control patient in the context of a hospital admission associated with pulmonary 
emboli.  A further episode of AKI occurred in a treatment patient within 1 month of 
commencing the study drug.  Creatinine rose to a value of 176 mol/L (baseline 70 
mol/L).  This was associated with symptoms of neurotoxicity (drowsiness, 
unsteadiness and mild dysarthria) and anaemia in keeping with valaciclovir toxicity and 
the drug’s known side effect profile.  The study drug was promptly stopped on review 
at the month 1 visit.  All symptoms resolved following cessation of valaciclovir and 
renal function returned to baseline over the course of 2 weeks.  The episode was 
managed on an outpatient basis and the study drug was not restarted. 
 
One episode of mild derangement in liver function occurred in a patient randomised to 
the treatment arm during the treatment period.  Alanine transaminase (ALT) rose to a 
maximum value of 55 IU/L.  This occurred following commencement of cinnarizine for 
long-standing inner ear dysfunction.  The ALT level returned to normal following 
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discontinuation of cinnarizine without stopping the study drug.  The transient mild ALT 
rise was assessed as not related to the study medication. 
 
5.6.3.2  Transient rise in mean cell volume 
An incidental macrocytosis was consistently observed amongst the patients that 
received the study drug.  Mean cell volume (MCV) gradually increased in valaciclovir 
treated patients, reaching a plateau at month 5 (Figure 5.8).  Following cessation of the 
study drug at month 6, MCV gradually reduced and reached normal values by the end 
of the study period.  This pattern was not observed in the control patients.  The 
macrocytosis associated with the study drug was asymptomatic and not accompanied 
by any change in haemoglobin or other full blood count indices.  Upon recognition of 
this AE in the first few patients, vitamin B12, folic acid and thyroid function tests were 
routinely checked in all treatment patients that developed a macrocytosis.  There was 
no associated thyroid dysfunction, vitamin B12 or folate deficiency.  There was an 
inverse relationship between renal function and peak MCV (Figure 5.8, Panel B), 
although this observation was not statistically significant. 
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Figure 5.8 Transient macrocytosis in the treatment group 
Panel A shows mean MCV (mean cell volume) in treated (n=19) (red) and control 
(n=17) (black) patients.  Panel B shows a scatter plot of eGFR versus peak MCV 




5.6.3.3  Serious adverse events 
A total of 12 serious adverse events (SAEs) were reported during the study period (see 
also DSUR in Appendix 9).  All SAEs were assessed as not related to the study drug and 
SAEs were evenly split between the treatment and control groups (Table 5.7).  One 
treatment patient had a total of 5 SAEs due to hospital admissions for recurrent 
infective exacerbations of bronchiectasis in keeping with their known past medical 
history and background frequency of infective exacerbations of bronchiectasis. 
 
 


















r = - 0.346
p = 0.147























CMV Modulation of the Immune System in AAV 189 
 
Table 5.7 Serious adverse events reported during the clinical trial period 







Respiratory infection 7 5 2 
Gastrointestinal tract 
infection 
1 0 1 
Arthritis 1 1 0 
Arrhythmia 1 0 1 
Epistaxis 1 0 1 




5.7 Tertiary Outcome – Persistence of valaciclovir effect on the proportion 
of CD4+CD28null T-cells 
The persistence of the effect of blocking subclinical CMV reactivation on CD4+CD28null 
T-cell proportions was assessed by comparing the CD4+CD28null T-cell percentage 
within the CD4 compartment at 6 months and 12 months for treatment and control 
groups.  Data was transformed and analysed using paired ratio t tests as described 
above.  No statistically significant differences were detected in the month 12 to month 
6 ratios of CD4+CD28null T-cell percentage in either of the groups (Treatment: 
geometric mean of ratios 0.893, 95% CI [0.682 - 1.171], p=0.393; Control: 1.146 [0.930 
- 1.412], p=0.186). 
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In order to consider change in CD4+CD28null T-cell percentage across the duration of 
the study, a repeated measures ANOVA analysis was carried out with Dunnett’s 
multiple comparison test as a post-hoc analysis, comparing baseline to month 6 and 
month 6 to month 12 CD4+CD28null T-cell percentage ratios.  The absolute 
CD4+CD28null percentage values are shown in Figure 6.9 and the summary data in 
Table 5.8.  The only statistically significant comparison was a reduction in the 
CD4+CD28null T-cell percentage ratio in the treatment group between baseline and 
month 6 (treatment period) in keeping with the findings already presented for the 
secondary outcome and indicating that blocking subclinical CMV reactivation with 
valaciclovir led to a sustained reduction in the proportion of CD4+CD28null T-cells in 




Figure 5.9 Change in CD4+CD28null T-cell proportion across the study period 
Left and right panels show absolute values of CD4+CD28null T-cell percentages at 
baseline (M0), month 6 (M6) and month 12 (M12) for treatment (n=19) and control 
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Table 5.8 Repeated measures ANOVA analysis for CD4+CD28null T-cell percentage 
change across study period 









95% CI Adjusted 
p value 
Overall   0.065   0.267 
M6:M0 0.770 [0.599 - 
0.990] 
0.041 0.987 [0.827 - 
1.177]  
0.975 
M12:M6 0.893 [0.695 - 
1.149] 
0.489 1.146 [0.902 - 
1.455] 
0.309 
Adjusted p values based on Dunnett’s post-hoc multiple comparison test 
 
 
5.8 Exploratory Outcomes 
In order to determine whether blocking CMV reactivation with valaciclovir led to an 
improvement in other associated CMV driven changes to the immune system 
exploratory outcomes included change in CD8CD28null T-cells, CD4:CD8 ratio, soluble 
markers of endothelial dysfunction and CMV IgG titre.  Change in the absolute count of 
CD4+CD28null, CD8CD28null and IFN- producing CD4+CD28null T-cells following 
overnight stimulation with CMV lysate was also assessed.   
 
5.8.1 Change in CD4+CD28null T-cell counts from baseline to 6 months 
In keeping with the observed reduction in the proportion of CD4+CD28null T-cells in 
the treatment arm (secondary outcome), there was a reduction in the month 6 to 
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baseline ratio of the CD4+CD28null cell count of 27.0% in the treated patients 
(geometric mean of ratios 0.730, 95% CI [0.574 - 0.929], p=0.013), whereas no change 
was observed in the control patients (0.934 [0.7504 - 1.163], p=0.523) (Figure 5.10).   
 
 
Figure 5.10 Exploratory outcome – change in CD4+CD28null T-cell count during 
treatment period 
Panels A and B show absolute values of CD4+CD28null T-cell counts at baseline (M0) 
and month 6 (M6) for treatment (n=19) and control (n=19) patients respectively.  
There was a statistically significant proportionate reduction in the absolute 
CD4+CD28null T-cell count in treated patients but not in controls. 
 
 
5.8.2 Change in CD8CD28null T-cell percentage and absolute count from 
baseline to 6 months 
There was no significant change in the CD8CD28null T-cell percentage month 6 to 
baseline ratio in either of the two groups (Treatment: 0.921 [0.826 - 1.027], p=0.131; 
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Control: 0.984 [0.927 - 1.046], p=0.591) (Figure 5.11).  There was however a 
statistically significant reduction in the CD8CD28null cell count ratio in the treatment 
group of 20.7% (0.793 [0.642 - 0.979], p=0.033) with no observed change in control 




Figure 5.11 Exploratory outcome – change in CD8CD28null T-cell proportion and 
absolute count during treatment period  
Panels A and B show absolute values of CD8CD28null percentages and panels C and D 
absolute values of CD8CD28null cell counts at baseline (M0) and month 6 (M6) for 
treatment (n=19) and control (n=19) patients respectively.  There was no change in the 
percentage of CD8CD28null T-cells in either treated or control patients.  In treated 
patients there was a proportionate reduction in the absolute count of CD8CD28null T-
cells across the treatment period that was not observed in controls.  
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5.8.3 Change in the CD4:CD8 ratio from baseline to 6 months 
An inverted CD4:CD8 ratio is one of the characteristics of the ‘immune risk profile’ 
(IRP) [288, 289, 291].  Given the fact that CMV is implicated in the development of the 
IRP [294] and the CD4+CD28null T-cell percentage was found to be associated with a 
reduced CD4:CD8 ratio in AAV patients (Chapter 3, Figure 3.2), change in the CD4:CD8 
ratio across the treatment period was assessed.  Blocking subclinical CMV reactivation 
with valaciclovir was associated with an improvement (i.e. an increase) in the CD4:CD8 
ratio in the treated patients of 0.256 (95% CI 0.001 – 0.511, p=0.050) with no change 
observed in control patients (- 0.162 [- 0.566 – 0.242], p=0.411) (Figure 5.12). 
 
 
Figure 5.12 Change in CD4:CD8 ratio during treatment period 
At the end of the 6 month treatment period there was an increase in the CD4:CD8 
ratio corresponding to an improvement in this marker of the IRP in the treated (n=19) 
patients whilst no change was observed in controls (n=19). 
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5.8.4 Change in CD4+CD28null CMV specific T-cells from baseline to 6 months 
Analysis of CD4+CD28null T-cells capable of producing IFN- following overnight 
stimulation with CMV lysate, revealed a statistically significant reduction in the 
CD4+CD28null IFN-+ percentage ratio between month 6 and baseline of 25.3% as well 
as a reduction in the CD4+CD28null IFN- cell count ratio of 45.0% in the treatment 
group (geometric mean of ratios 0.747 and 0.550, 95% CIs [0.565 - 0.989 and 0.358 - 
0.856], p value 0.043 and 0.010).  There was no significant change in the control 
patients (1.122 and 1.016, 95% CI [0.755 - 1.669] and [0.605 - 1.707], p value 0.548 and 
0.949) (Figure 5.13).  This was in agreement with the observed reduction in overall 
CD4+CD28null T-cell in the treated patients (secondary outcome) and indicated that 
blocking CMV reactivation with valaciclovir in the treated patients led to a targeted 
reduction in CMV specific CD4+CD28null T-cells.   
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Figure 5.13 Exploratory outcome – change in CMV specific CD4+CD28null T-cell 
proportion and absolute count during treatment period 
Panels A and B show absolute values of CD4+CD28null IFN-+ percentages and panels 
D and E absolute values of CD4+CD28null IFN-+ cell counts following overnight 
stimulation with CMV lysate at baseline (M0) and month 6 (M6) for treatment (n=19) 
and control (n=19) patients respectively.  There was a proportionate reduction in both 
CD4+CD28null IFN- percentage and absolute count across the treatment period in the 
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5.8.5 Change in soluble markers of endothelial damage from baseline to 6 
months 
Soluble markers of endothelial dysfunction (RANTES, sVCAM-1, sICAM-1, P-selectin, E-
selectin, Fractalkine, IP-10, MCP-1 and IL-12) were measured using Luminex 
technology at the start and end of treatment as detailed in Section 2.6.3 in order to 
determine whether blockage of CMV reactivation with valaciclovir would have an 
effect on the levels of these markers.  Paired ratio t tests were used to detect 
statistically significant trends between the baseline and month 6 measurements in the 
treatment and control groups.   
 
The only statistically significant change observed was in the level of P-selectin that 
decreased by 15% (p=0.046) in the treated patients whereas no statistically significant 
difference was observed in controls (Figure 5.14) (Table 5.9).  There was no statistically 
significant change in the ratio of month 6 to baseline concentration of RANTES, 
sVCAM-1, sICAM-1, E-selectin, Fractalkine, IP-10, MCP-1 or IL-12 in either of the groups 









Figure 5.14 Exploratory outcome – Change plasma concentration of markers of 
endothelial dysfunction (P-selectin) 
Absolute values are shown for treatment (n=19) and control (n=19) patients at 
baseline (M0) and month 6 (M6).  There was a statistically significant proportionate 
reduction in the levels of P-selectin in the treated patients but not in controls. 
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Figure 5.15  Exploratory 
outcome – change in 
plasma concentration of 
markers of endothelial 
dysfunction  
Panels A, C, E, G, I, K, M 
and O show absolute 
values for concentration 
of RANTES, IL-12, IP-10, 
fractalkine, sVCAM-1, 
sICAM-1, MCP-1 and E-
selectin respectively for 
baseline (M0) and month 
6 (M6) in treated 
patients.  Panels B, D, F, 
H, J, L, N and P show 
values for control 
patients. 
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Table 5.9 Results of paired ratio t tests for soluble markers of endothelial 
dysfunction 
 Treatment Control 
Marker Geometric 
mean of ratios 
(M6:M0) 
95% CI p value Geometric 
mean of ratios 
(M6:M0) 
95% CI p value 
RANTES 0.602 [0.336 - 1.078] 0.084 0.832 [0.472 - 1.467] 0.504 
P-selectin 0.850 [0.726 - 0.996] 0.046 0.859 [0.718 - 1.027] 0.090 
E-selectin 1.037 [0.839 - 1.281] 0.723 1.019 [0.884 - 1.176] 0.783 
sVCAM-1 1.058 [0.942 - 1.141] 0.129 1.030 [0.969 - 1.095] 0.320 
sICAM-1 1.012 [0.945 - 1.084] 0.720 1.000 [0.924 - 1.082] 0.997 
Fractalkine 1.036 [0.829 - 1.295] 0.741 0.980 [0.733 - 1.311] 0.886 
IP-10 1.063 [0.940 - 1.202] 0.312 1.018 [0.878 - 1.181] 0.803 
MCP-1 1.088 [0.956 - 1.237] 0.188 0.924 [0.808 - 1.057] 0.232 
IL-12 0.452 [0.177 - 1.157] 0.093 0.879 [0.556 - 1.389] 0.560 
M6 = month 6, M0 = baseline, CI = confidence intervals 
 
 
5.8.6  Change in CMV IgG titre levels 
Given the fact that CMV IgG titre has been linked with adverse outcomes [278], a pre-
specified exploratory outcome was whether valaciclovir treatment for 6 months can 
lead to a reduction in CMV IgG titres.  To determine this, plasma samples were 
collected from clinical trial participants monthly over the duration of the trial and 
analysed at the end of the study as outlined in Section 2.6.8.  Because initial titre levels 
varied widely between patients and in order to avoid skewing of the data by occasional 
patients with high titre values, the data was normalised by expressing it as a 
percentage at each month relative to the baseline that was given a value of 100%.      
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The CMV IgG titre percentage levels in control patients remained fairly static for the 
duration of the clinical trial period (Figure 5.16, Panel B).  In contrast, CMV IgG titre 
percentage levels gradually reduced in the treatment group, although this became 
more evident from month 5 onwards in keeping with the half-life of IgG (Figure 5.16, 
Panel A).  The CMV IgG percentage titre sharply increased for participant CT005 (red 
arrow) and CT031 (green arrow) during the treatment period, in contrast to the rest of 
the treatment group (Figure 5.16, Panel A).  Interestingly, CT005 had a CMV 
reactivation episode at baseline prior to commencing treatment (Table 5.3) suggesting 
a temporal delay between CMV reactivation and rise in CMV IgG titre.  Participant 
CT031 on the other hand had a 1-week break in treatment during month 2 which was 
followed by a gradual rise in CMV IgG titre and a further 2-week break in treatment 
during month 4 that was followed by a CMV reactivation episode of low intensity 
(Table 5.3) and a further spike in CMV IgG titre in month 7 (Figure 5.16).  Similar spikes 
in CMV IgG titre were noted following CMV reactivation in control patients.    
 
Repeated measures ANOVA revealed a statistically significant change overall in the 
CMV IgG titre percentage change during the study period in the treatment group 
(p=0.040) but not in the control patients (p=0.813).  Furthermore, on post-hoc analysis 
there was a statistically significant negative linear trend in the treated patients (post-
test for linear trend, slope -1.305, p<0.001) but not in controls (post-test for linear 
trend, slope 0.218, p=0.521) indicating that blocking subclinical CMV reactivation with 
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valaciclovir led to a statistically significant reduction in CMV IgG titre in the treated 




Figure 5.16 Panels A and B show summary data of CMV IgG titre percentage change 
in treatment (n=19) and control (n=17) patients respectively 
The red and green arrows in Panel A refer to participant CT005 and CT031 respectively 
that displayed a rise in CMV IgG titre following episodes of CMV reactivation.  Panel C 
shows mean IgG titre percentage values in treated (red) and control (black) patients.  
The IgG titre gradually declined over the course of the study in treated patients but not 
in controls.   
Control
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5.8.6.1 Correlation between reduction in CMV IgG titre and CD4+CD28null T-cell 
parameters 
Having observed a reduction in CD4+CD28null T-cell proportion, CD4+CD28null T-cell 
absolute count and CMV IgG titre in the treated patients, further analysis was carried 
out to determine whether these changes were appropriately correlated in the same 
patients.  In order to achieve this, linear regression analysis was performed between 
the month 6 to baseline CD4+CD28null T-cell proportion or absolute count log ratio 
and the slope of the CMV IgG titre change from baseline to month 12 (Figure 5.17).  
CMV IgG titre slope was examined across the entire study period due to the observed 
delay in titre reduction in treated patients.   
 
The change in CD4+CD28null T-cell proportion as well as absolute count was directly 
related to the change in CMV IgG titre as shown in Figure 5.17.  This association was 
statistically significant in the treated patients but not in controls suggesting that 
blocking subclinical CMV reactivation with valaciclovir therapy resulted in a reduction 
in the CD4+CD28null T-cell expansion which was mirrored by a drop in CMV IgG titre 
adding validity to the results reported earlier in this chapter.  Interestingly, although 
not statistically significant, the change in CD4+CD28null T-cell absolute count appeared 
to be related to the change in CMV IgG titre also in the control patients (Figure 5.17, 
Panel D). This probably reflects the influence of subclinical CMV reactivation, or 
absence of, on the CD4+CD28null T-cell compartment and CMV IgG titre as further 
discussed below in Section 5.9.      
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Figure 5.17 Correlation between CMV IgG titre and CD4+CD28null T-cell parameters 
Linear regression analysis was carried out between the CD4+CD28null T-cell proportion 
(A, B) or CD4+CD28null T-cell absolute count (C, D) month 6 (M6) to baseline (M0) log 
ratio and the CMV IgG titre slope change in treated (n=19) (A, C) and control (n=17) (B, 
D) patients.  Regression lines with 95% confidence intervals are shown. 
 
 
5.8.7 Change in pulse wave velocity across the study period 
Given the association between CD4+CD28null T-cell expansion and cardiovascular 
disease as well as the independent association between CD4+CD28null T-cells and 
increased arterial stiffness as measured by pulse wave velocity, observed in Chapter 4, 
the final exploratory outcome of the clinical trial arm aimed to determine whether 
treatment with valaciclovir for 6 months could lead to an improvement in arterial 
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stiffness.  Arterial stiffness was measured by carotid femoral PWV as detailed in 
Chapter 2 at baseline, at the end of the 6 month treatment and at the end of the study 
at 12 months.   
 
Figure 5.18 (Panel A) shows PWV adjusted for a mean arterial pressure (MAP) of 90 
mmHg for control and treated patients.  There was a statistically significant increase in 
PWV in the control patients but not the treated patients across the study period 
suggesting that controlling subclinical CMV reactivation and reducing the size of the 
CD4+CD28null T-cell expansion might have had a protective effect in the treated 
patients.  Furthermore, the absolute count of CD4+CD28null T-cells at baseline 
significantly correlated with the change in PWV (adjusted for MAP of 90 mmHg) across 
the study period in that patients with higher numbers of CD4+CD28null T-cells at 
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Figure 5.18 Change in pulse wave velocity across the study period 
Panel A shows the change in PWV (adjusted for MAP 90 mmHg) across the study 
period for control (n=19) (black) and treatment (n=19) (red) patients.  There was an 
overall increase in PWV in the control patients (p=0.016) but not the treated ones 
(p=0.827) with the statistically significant difference in the control patients lying 
between the baseline and month 6 time points (ANOVA with post-hoc Dunnett’s 
multiple comparison test comparing M12 and M6 to the baseline values).  In panel B, 
the CD4+CD28null absolute cell count at baseline was correlated to the magnitude of 
the change in PWV (adjusted for MAP 90 mmHg) from baseline to month 12 (r=0.334, 
p=0.047; Pearson’s correlation).    
 
 
5.9 CMV reactivation and expansion of the CD4+CD28null T-cell 
compartment in the control patients 
In order to further evaluate the impact of subclinical CMV reactivation on the size of 
the CD4+CD28null T-cell compartment, the change in the size of the CD4+CD28null T-
cell expansion across the entire study period was assessed in the control patients 
(n=19) in relation to CMV reactivation.  Patients that reactivated CMV at least once 
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exhibited an overall increase in CD4+CD28null T-cell percentage (0.9 [IQR -1.1 - 2.0]) 
compared to those that did not (-1.6 [-8.9 - 0.4]; p=0.038) (Figure 5.19, Panel A).  
Furthermore, the overall change in CD4+CD28null T-cell percentage over the study 
period was correlated with the number of reactivation episodes observed (r=0.537, 




Figure 5.19 CMV reactivation and change in CD4+CD28null T-cells in controls  
The change in CD4+CD28null T-cell proportion between the pre-baseline visit (PB) and 
month 12 (M12) in control patients (n=19) was assessed in relation to CMV 
reactivation between the baseline and month 12 visits.  Patients that reactivated CMV 
at least once versus those that did not reactivate at all are shown in Panel A (Mann 
Whitney U test).  In Panel B the correlation between the total number of reactivation 
episodes and the change in the CD4+CD28null T-cell compartment is shown 
(Spearman’s rank test). 
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Next, the CD4+CD28null T-cell proportion was evaluated monthly across the study 
period using cryopreserved PBMC samples from 3 control patients that reactivated 
CMV during follow up.  Figure 5.20 shows the CD4+CD28null T-cell percentage plotted 
against CMV viral copy number and CMV IgG titre.  A temporal relationship was 
observed between episodes of CMV reactivation and changes in the size of the 
CD4+CD28null T-cell compartment as well as the CMV IgG titre.  Measurable CMV 
reactivation was preceded by an increase in CD4+CD28null T-cell proportion and was 
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Figure 5.20 CD4+CD28null tracking experiments in control patients with CMV 
reactivation 
The change in CD4+CD28null T-cell proportion was tracked across the study period 
(pre-baseline (PB) to month 12) in 3 different control patients that reactivated CMV in 
order to relate the onset of CMV reactivation (right y axes) to changes in 
CD4+CD28null T-cell proportion and CMV IgG titre (left y axes).  An increase in 
CD4+CD28null T-cell percentage preceded measurable CMV reactivation.  CMV 
reactivation was followed by an increase in CMV IgG titre in some but not all episodes 
of reactivation.  
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5.10 CMV reactivation and polyfunctionality 
The data discussed in Chapter 3 revealed that CD4+CD28null T-cells, despite being 
markedly pro-inflammatory, were less polyfunctional in terms of IFN-, TNF- and IL-2 
co-expression following overnight stimulation with CMV lysate compared to their 
CD4+CD28+ counterparts.  The effect of relative proportions of polyfunctional cells on 
the risk of CMV reactivation was therefore evaluated.  Patients free from CMV 
reactivation over the 12 month study period had a higher baseline ratio of CD4+CD28+ 
to CD4+CD28null CMV specific T-cells (Figure 5.21, Panel A).  In addition, this ratio was 
negatively correlated to the total number of reactivation episodes over the 12 month 
study period (Figure 5.21, Panel B).   
 
Finally, patients that reactivated CMV at least once had a lower baseline proportion of 
polyfunctional CD4+CD28+ CMV specific T-cells (Figure 5.21, Panel C), defined as 
CD4+CD28+IFN-+ cells also capable of TNF- and IL-2 co-expression following 
overnight stimulation with CMV lysate suggesting that the possession of polyfunctional 
CD4+CD28+ CMV specific T-cells is important in keeping CMV controlled and avoiding 
episodes of subclinical CMV reactivation.    
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Figure 5.21 Effect of polyfunctionality on risk of CMV reactivation (n=38) 
Panel A: Patients that reactivated CMV at least once over the course of the study had a 
lower ratio of CD4+CD28+:CD4+CD28null CMV specific T-cells at baseline, identified by 
IFN- expression following overnight stimulation with CMV lysate (Mann Whitney U 
test).  Panel B: The ratio of CD4+CD28+:CD4+CD28null CMV specific T-cells at baseline 
was negatively correlated with the total number of CMV reactivation episodes over the 
study period (Spearman’s rank test).  Panel C: Patients that reactivated CMV at least 
once over the course of the study had a lower proportion of polyfunctional 
CD4+CD28+ CMV specific T-cells, identified as CD4+CD28+IFN-+ T-cells capable of 
TNF- and IL-2 co-expression following overnight stimulation with CMV lysate 
compared to patients that did not reactivate. 
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5.11 Discussion 
There is very little information in the literature on the prevalence and magnitude of 
potential CMV reactivation during latency in immunosuppressed patients with 
inflammatory conditions.  The data presented here show that significant subclinical 
CMV reactivation does indeed occur in CMV seropositive AAV patients in disease 
remission and that 37% of patients will reactivate CMV at least once over a period of 
12 months based on reactivation rates in the control patients.  All detectable episodes 
were asymptomatic, of low titre and were mainly seen in patients’ urine.      
 
Six months treatment with valaciclovir was successful in blocking CMV reactivation in 
AAV patients.  In turn, blocking CMV reactivation in treated patients led to a consistent 
reduction in several parameters of CMV-specific cell mediated immunity compared to 
controls that showed no change in any of these assessments.  Specifically, the 
proportion as well as absolute count of CD4+CD28null T-cells was reduced after 6 
months of valaciclovir therapy in treated patients but not in controls.  In addition, the 
absolute count of CD8CD28null T-cells as well as the proportion and absolute count of 
CD4+CD28null CMV-specific T-cells were reduced in treatment but not in control 
patients.  The fact that blocking CMV reactivation with valaciclovir in treated patients 
led to a decrease in these cell populations indicates that expansion of such T-cell 
subsets is driven by episodes of subclinical CMV reactivation.   
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This is supported by the supplementary analysis in the control patients where subjects 
that reactivated CMV showed an increase in their CD4+CD28null T-cell percentage.  
The increase in CD4+CD28null T-cell percentage in control patients was also found to 
be correlated with the number of reactivation episodes over the study period.  
Detailed analysis of the change in CD4+CD28null T-cell percentage on a per month 
basis in a subset of control patients that reactivated CMV showed that a rise in 
CD4+CD28null T-cell percentage preceded the onset of documented reactivation.  
 
The reduction in CMV-specific CD4+CD28null T-cells capable of producing IFN- 
following overnight stimulation with CMV lysate in treated patients was accompanied 
by a reduction in IL-2 and IFN-plasma levels that was not seen in controls.  The 
plasma marker of endothelial dysfunction P-selectin was also reduced only in treated 
patients.  P-selectin is expressed on inflamed endothelium and is implicated in vascular 
inflammation where proinflammatory Th1 T-cells bearing its ligand PSGL-1 (P-selectin 
glycoprotein ligand 1) under control of the transcription factor T-bet are able to bind 
to it and induce endothelial damage [353, 358].  As such, a reduction in P-selectin and 
Th1 mediated cytokines seen here may translate to an improvement in vascular 
inflammation.  There was a suggestion from the serial pulse wave velocity 
measurements undertaken during the trial that arterial stiffness increased in the 
control patients but remained static in the treated patients during the first 6 months of 
the study.  However, the trial was not designed to detect a difference in pulse wave 
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velocity between treated and control patients and therefore this remains to be 
adequately investigated in future studies. 
 
Blocking subclinical CMV reactivation with valaciclovir also led to a sustained reduction 
in CMV IgG titre levels.  There was a temporal delay associated with this, which is in 
keeping with the findings presented in Figure 5.15 (Panel A), where CMV reactivation 
preceded a rise in IgG titre that could be detected in peripheral blood.  Similarly, the 
effect of blocking CMV reactivation with valaciclovir treatment on the CMV IgG titre 
became clear only at month 5 and persisted for several months following treatment 
cessation likely as a result of the long half-life of IgG [359].   
 
Importantly, the decline in CMV IgG titre in treated patients was mirrored by a 
decrease in CD4+CD28null T-cell percentage and absolute counts as these changes 
were correlated when plotted against each other.  In addition, changes to CMV IgG 
titre levels have been shown to correspond to episodes of reactivation [360-362].  
Hence, a declining CMV IgG titre in the treated patients likely reflects another marker 
of evidence of blocked CMV reactivation in addition to the PCR results and the fact 
that the CMV IgG titre correlated with a drop in CD4+CD28null T-cell indices of similar 
magnitude adds further validity to the data.  
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Valaciclovir was well tolerated with mainly gastrointestinal symptoms reported by 
treated patients in keeping with the drug’s known side effect profile.  There was an 
episode of significant valaciclovir toxicity associated with acute kidney injury in one 
patient.  This was picked up at the month 1 safety assessment, however on discussion 
with the patient the symptoms had started from the 2nd week of taking the drug.  
Future clinical trials should therefore include a safety assessment also at 2 weeks as 
significant toxicity, where it occurs, is likely to be encountered within the first few 
weeks of commencing treatment. 
 
As discussed, there was a consistent effect of valaciclovir treatment leading to a block 
of CMV reactivation which was associated with a reduction in CD4+CD28null T-cells 
and other subsets of CMV-specific and associated cell mediated immunity, plasma 
levels of markers of inflammation and endothelial dysfunction and plasma CMV IgG 
titres.  Importantly, this treatment effect was consistently found across 4 different 
techniques that were used in the assessment of these outcomes namely, qPCR, flow 
cytometry, LUMINEX and ELISA.  The clinical trial was powered to detect a difference in 
reactivation rates between treated and control patients.  Hence 2-way ANOVA 
analyses comparing repeated measure assessments between treated and control 
patients for the secondary and exploratory outcomes were not carried out.  However, 
the fact that a reduction in all secondary and exploratory outcomes of CMV mediated 
changes to the immune system was persistently seen in the treated patients only and 
not in the control group is in keeping with validity of these findings.  The results of the 
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trial are very encouraging.  However, there is a need to replicate these findings in a 
larger clinical trial adequately powered to detect statistically significant changes in 
these parameters with 2-way ANOVA analyses.  
 
There are some learning points from this study that can be applied to a future larger 
clinical trial.  There was a discrepancy noted in the CD4+CD28null T-cell percentage 
between patients randomised to the treatment versus the control arm although this 
difference was not statistically significant.  A CD4+CD28null cell percentage 
stratification cut-off of 40% was incorporated into the randomisation algorithm.  
However, there were only a couple of patients with CD4+CD28null cell percentages 
greater than 40% so follow up clinical trials should utilise a lower stratification cut-off 
in order to achieve better balance between treated and control patients.   
 
Furthermore, given the longevity of CD4+CD28null T-cells and the delay in the 
reduction of CMV IgG titre observed in this trial, it is possible that a longer duration of 
anti-viral treatment is necessary to attain larger reductions in these pro-inflammatory 
T-cells rather than the modest reductions observed in this present study.  Future trials 
should therefore employ a duration of treatment of 12 months in order to assess 
whether this can be achieved and also evaluate clinically meaningful outcomes such as 
change in arterial stiffness that are likely to require a longer treatment and follow up 
period to detect significant such changes.   
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In summary, this proof of concept clinical trial presented here shows that CMV 
reactivation regularly occurs in AAV CMV seropositive patients in remission and can be 
safely blocked with valaciclovir treatment.  The data shows for the first time that 
subclinical CMV reactivation drives the expansion of CD4+CD28null T-cells and that this 
and other associated CMV induced changes to the immune system can be ameliorated 
with valaciclovir treatment in patients with AAV, in agreement with the study 
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Chapter 6 General Discussion 
 
The two leading causes of morbidity and mortality in AAV are infection and 
cardiovascular disease [93].  Previous research has shown that large expansions of 
proinflammatory CD4+CD28null T-cells in AAV patients are only present in CMV 
seropositive individuals and are associated with increased infection, reduced renal 
function and increased mortality [112].  CMV and CD4+CD28null T-cells have also been 
described as having a significant bearing on immunosenescence and are associated 
with reduced immune responses to heterologous antigen [297] and influenza 
vaccination [300].  In addition CMV seropositivity and CD4+CD28null T-cell expansions 
have been linked to vascular pathology [287] and an increased risk of cardiovascular 
disease in patients with inflammatory conditions such as chronic kidney disease (CKD), 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) [156, 175, 180]. 
 
This thesis examined the hypothesis that subclinical CMV reactivation is the driver 
behind the observed expansion of CD4+CD28null T-cells in inflammatory disease.  Part 
of the work carried out aimed to explore the mechanisms via which the harmful effects 
of this cell subset are mediated in patients with AAV.  In addition, a proof of concept 
open label randomised controlled clinical trial of 6 months oral valaciclovir or no 
additional therapy in CMV seropositive AAV patients in remission was designed and 
implemented during the course of this PhD.  The trial tested the hypothesis of whether 
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blocking subclinical CMV reactivation with valaciclovir can halt or reduce the expansion 
of CD4+CD28null T-cells and ameliorate associated CMV induced immune 
dysregulation.  Further work aimed to explore the mechanisms involved in the control 
of subclinical CMV reactivation. 
 
6.1  Subclinical CMV reactivation drives the expansion of CD4+CD28null T-
cells 
The first of its kind proof of concept clinical trial carried out during the course of this 
work has shown that firstly, valaciclovir blocks subclinical CMV reactivation in CMV 
seropositive AAV patients and secondly, that this in turn leads to a reduction in the 
proportion of CD4+CD28null T-cells in treated patients only.  Other favourable changes 
such as reduction in inflammatory and endothelial dysfunction markers and reduction 
in CMV IgG titres were also seen in the treated patients but not in controls indicating 
that blocking CMV reactivation with valaciclovir ameliorates associated CMV adverse 
modulation of the immune system in AAV.  Finally, valaciclovir therapy was safe and 
well tolerated.   
 
As discussed, CMV is implicated in the immunosenescence that is increasingly been 
recognised with advancing age but may also play a part in immune dysregulation in the 
setting of inflammatory disease leading to weakened immune responses.  One possible 
mechanism in which this may occur is via ‘memory inflation’ whereby expansion of 
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proinflammatory subsets such as CD4+CD28null T-cells is mirrored by a shrinkage of 
the naïve CD4 T-cell compartment associated with a reduced ability to mount effective 
responses to new antigens.   
 
Work carried out during this thesis has shown that the size of the CD4+CD28null T-cell 
compartment in AAV patients is reciprocally related to the CD4:CD8 ratio suggesting 
that limiting CD4+CD28null T-cell expansion by blocking subclinical CMV reactivation 
may also have favourable outcomes in terms of improving the ‘immune risk profile’ in 
patients with AAV.  Indeed, valaciclovir treatment in the clinical trial was associated 
with an improvement in the CD4:CD8 ratio in treated patients whereas no change was 
seen in control patients, although these findings need to be confirmed in a larger 
study. 
 
6.2 Phenotype of CD4+CD28null T-cells in AAV and mechanisms of vascular 
damage 
Several reports exist on the type of surface and intracellular markers possessed by 
CD4+CD28null T-cells in different inflammatory conditions and in healthy individuals.  
However a comprehensive analysis of the phenotype of CD4+CD28null T-cells in AAV 
has not been previously undertaken.  The studies presented here have shown 
CD4+CD28null T-cells in AAV to be CMV responsive Th1 cells with a proinflammatory 
potential expressing mainly IFN- and TNF-.  Further analysis of their cell surface 
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chemokine receptor pattern showed for the first time that such cells in AAV co-express 
CXCR3, CX3CR1, CD49d and CD11b suggesting that they are able to traffic to and bind 
activated endothelial cells.  Surface expression of NKG2D and possession of 
intracellular perforin and granzyme B that have been shown to enable endothelial cell 
lysis were also seen.  Finally, the size of the expansion of CD4+CD28null T-cells in CMV 
seropositive AAV patients was independently associated with increased arterial 
stiffness as measured by carotid to femoral pulse wave velocity suggesting 
involvement of this cell subset in the pathophysiology of atherosclerosis in CMV 
seropositive patients.   
 
Other researchers have previously shown that during in vitro co-culture experiments, 
peripheral blood mononuclear cells (PBMC) from CMV seropositive individuals with a 
high proportion of CMV specific CD4 T-cells induce higher levels of upregulation of 
fractalkine, VCAM-1 and ICAM-1 (the ligands for CX3CR1, CD49d and CD11b identified 
on CD4+CD28null T-cells in this thesis) on endothelial cell monolayers and exhibit 
higher levels of PBMC adherence and endothelial damage compared to PBMC from 
individuals with a low proportion of CMV specific CD4 T-cells [363].  Endothelial cell 
activation was dependent on IFN- and TNF- production by CMV specific cells and in 
other experiments the ligand for CXCR3, IP10, was also shown to be upregulated on 
activated endothelium and be critical for the adherence of CMV effector CD4 T-cells 
onto endothelial cell monolayers [287].     
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Taking this together with the data from this thesis it is proposed that in AAV patients 
subclinical CMV reactivation drives the expansion of proinflammatory CMV specific 
CD4+CD28null T-cells that are targeted to endothelial cells through co-expression of 
unique chemokine receptors.  Through production of Th1 cytokines these cells induce 
endothelial activation and via release of cytotoxic perforin and granzyme B participate 
in endothelial damage exacerbating atherosclerosis and arteriosclerosis and leading to 
an increased incidence of cardiovascular disease. 
 
 
6.3  Control of subclinical CMV reactivation requires polyfunctional CD4 
responses 
The mechanisms that control subclinical CMV reactivation remain unclear.  Given the 
link between subclinical CMV reactivation and CD4+CD28null T-cell expansion 
demonstrated by this thesis, it is important to consider how viral control is maintained 
in this situation.  Work undertaken here has identified TIM-3 as a marker of exhausted 
CD4+CD28null T-cells with reduced functionality.  Furthermore, CMV specific 
CD4+CD28+ cells were identified as having increased functionality compared to 
CD4+CD28null T-cells.   
 
Analysis of the clinical trial CMV reactivation results revealed that patients reactivating 
CMV at least once during the course of the study had a lower ratio of CMV specific 
CD4+CD28+ to CMV specific CD4+CD28null T-cells at baseline and that the number of 
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viral reactivation episodes was also inversely correlated with this ratio indicating for 
the first time the importance of polyfunctional CD4+CD28+ CMV specific T-cells in the 
control of subclinical CMV reactivation.  Furthermore, patients that reactivated CMV at 
least once during the study also had a lower percentage of polyfunctional CD4+CD28+ 
CMV specific T-cells at baseline further highlighting the importance of multiple-
cytokine producing T-cells in the control of subclinical reactivation.  It will be 
interesting to see in subsequent studies whether controlling subclinical CMV 
reactivation changes the pattern of cytokine production in CMV specific T-cells in a 
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6.4  Conclusion 
In conclusion, the studies undertaken during this PhD have shown for the first time 
that subclinical CMV reactivation drives the expansion of CD4+CD28null T-cells in a 
patient group with an inflammatory disease.  CD4+CD28null T-cells were shown to be 
endothelial homing cytotoxic T-cells and were independently associated with 
increased arterial stiffness, a well-established marker of increased cardiovascular risk.  
It is proposed here that CD4+CD28null T-cells through expression of chemokine 
receptors bind to respective ligands on activated endothelial cells leading to vascular 
damage which ultimately culminates to the observed increased risk of cardiovascular 
disease seen in association with CMV and this proinflammatory subset.  Finally, 
blocking subclinical CMV reactivation with valaciclovir in AAV patients led to a 
reduction in CD4+CD28null T-cells.  This opens exciting potential therapeutic avenues 
for patients with AAV but also other inflammatory conditions such as chronic kidney 
disease and rheumatoid arthritis where such CMV driven changes have been 
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6.5  Future work 
Chronic kidney disease (CKD) is a global public health concern with an estimated 
prevalence of over 10% of the population in Western Europe and the United States 
[364].  People with CKD are much more likely to die from cardiovascular disease (CVD) 
rather than progress to end-stage renal failure and the risk of CVD in CKD increases 
inexorably with declining renal function.  Furthermore this increased risk cannot be 
fully attributed to conventional atherosclerotic risk factors and it is likely that 
increased arterial stiffness is one of the major contributors to this adverse outcome 
[348]. 
 
Previous work has shown that CMV seropositive patients CKD have increased arterial 
stiffness [285].  In addition, CD4+CD28null T-cell expansions in CKD correlate with 
measures of early atherosclerotic damage and CMV seropositivity with prevalence of 
atherosclerotic disease [173, 180, 181].  Given the findings of this thesis we have 
hypothesised that subclinical CMV reactivation drives the expansion of cytotoxic 
CD4+CD28null T-cells in patients with CKD leading to increased arterial stiffness, a key 
contributor of increased CVD in CKD.  As such subclinical CMV reactivation and the 
expansion of CD4+CD28null T-cells may represent a potentially modifiable factor in the 
treatment of the increased cardiovascular risk in CKD.  We are currently in the process 
of submitting a grant application to carry out an interventional study in patients with 
CKD of 12 months treatment with valaciclovir in order to determine whether blocking 
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subclinical CMV reactivation and ameliorating the CD4+CD28null T-cell expansion in 
















CMV Modulation of the Immune System in AAV 228 
 
References 
1. Berden, A., et al., Diagnosis and management of ANCA associated vasculitis. BMJ, 
2012. 344: p. e26. 
2. McKinney, E.F., et al., The immunopathology of ANCA-associated vasculitis. Semin 
Immunopathol, 2014. 36(4): p. 461-78. 
3. Morgan, M.D., et al., Anti-neutrophil cytoplasm-associated glomerulonephritis. J Am 
Soc Nephrol, 2006. 17(5): p. 1224-34. 
4. Jennette, J.C. and R.J. Falk, Small-vessel vasculitis. N Engl J Med, 1997. 337(21): p. 
1512-23. 
5. Jennette, J.C., et al., Nomenclature of systemic vasculitides. Proposal of an 
international consensus conference. Arthritis Rheum, 1994. 37(2): p. 187-92. 
6. Jennette, J.C., et al., 2012 revised International Chapel Hill Consensus Conference 
Nomenclature of Vasculitides. Arthritis Rheum, 2013. 65(1): p. 1-11. 
7. Watts, R.A., et al., Renal vasculitis in Japan and the UK--are there differences in 
epidemiology and clinical phenotype? Nephrol Dial Transplant, 2008. 23(12): p. 3928-
31. 
8. Watts, R.A., et al., Epidemiology of systemic vasculitis: a ten-year study in the United 
Kingdom. Arthritis Rheum, 2000. 43(2): p. 414-9. 
9. Scott, D.G. and R.A. Watts, Epidemiology and clinical features of systemic vasculitis. 
Clin Exp Nephrol, 2013. 17(5): p. 607-10. 
10. Abdou, N.I., et al., Wegener's granulomatosis: survey of 701 patients in North America. 
Changes in outcome in the 1990s. J Rheumatol, 2002. 29(2): p. 309-16. 
11. Mahr, A., et al., Prevalences of polyarteritis nodosa, microscopic polyangiitis, 
Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic 
population in 2000: a capture-recapture estimate. Arthritis Rheum, 2004. 51(1): p. 92-
9. 
12. Watts, R.A., et al., Epidemiology of vasculitis in Europe. Ann Rheum Dis, 2001. 60(12): 
p. 1156-7. 
13. Hoffman, G.S., et al., Wegener granulomatosis: an analysis of 158 patients. Ann Intern 
Med, 1992. 116(6): p. 488-98. 
14. Reinhold-Keller, E., et al., An interdisciplinary approach to the care of patients with 
Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum, 2000. 
43(5): p. 1021-32. 
15. Stone, J.H. and G. Wegener's Granulomatosis Etanercept Trial Research, Limited versus 
severe Wegener's granulomatosis: baseline data on patients in the Wegener's 
granulomatosis etanercept trial. Arthritis Rheum, 2003. 48(8): p. 2299-309. 
16. Gaudin, P.B., et al., The pathologic spectrum of pulmonary lesions in patients with anti-
neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-
myeloperoxidase. Am J Clin Pathol, 1995. 104(1): p. 7-16. 
17. van der Woude, F.J., et al., Autoantibodies against neutrophils and monocytes: tool for 
diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet, 1985. 
1(8426): p. 425-9. 
18. Niles, J.L., et al., Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic 
antibodies in the diagnosis of rapidly progressive glomerulonephritis. J Am Soc 
Nephrol, 1991. 2(1): p. 27-36. 
19. Radice, A. and R.A. Sinico, Antineutrophil cytoplasmic antibodies (ANCA). 
Autoimmunity, 2005. 38(1): p. 93-103. 
CMV Modulation of the Immune System in AAV 229 
 
20. Kain, R., et al., Molecular mimicry in pauci-immune focal necrotizing 
glomerulonephritis. Nat Med, 2008. 14(10): p. 1088-96. 
21. Kain, R., et al., High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil 
cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol, 2012. 23(3): p. 556-66. 
22. Falk, R.J., et al., Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to 
degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A, 1990. 
87(11): p. 4115-9. 
23. Xiao, H., et al., Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase 
cause glomerulonephritis and vasculitis in mice. J Clin Invest, 2002. 110(7): p. 955-63. 
24. Huugen, D., et al., Aggravation of anti-myeloperoxidase antibody-induced 
glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. 
Am J Pathol, 2005. 167(1): p. 47-58. 
25. Schreiber, A., et al., Bone marrow-derived cells are sufficient and necessary targets to 
mediate glomerulonephritis and vasculitis induced by anti-myeloperoxidase antibodies. 
J Am Soc Nephrol, 2006. 17(12): p. 3355-64. 
26. Schreiber, A., et al., C5a receptor mediates neutrophil activation and ANCA-induced 
glomerulonephritis. J Am Soc Nephrol, 2009. 20(2): p. 289-98. 
27. Xiao, H., et al., C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc 
Nephrol, 2014. 25(2): p. 225-31. 
28. Xiao, H., et al., The role of neutrophils in the induction of glomerulonephritis by anti-
myeloperoxidase antibodies. Am J Pathol, 2005. 167(1): p. 39-45. 
29. Xiao, H., et al., Alternative complement pathway in the pathogenesis of disease 
mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol, 2007. 170(1): p. 
52-64. 
30. Huugen, D., et al., Inhibition of complement factor C5 protects against anti-
myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int, 2007. 
71(7): p. 646-54. 
31. Flint, J., M.D. Morgan, and C.O. Savage, Pathogenesis of ANCA-associated vasculitis. 
Rheum Dis Clin North Am, 2010. 36(3): p. 463-77. 
32. Kallenberg, C.G., et al., Anti-neutrophil cytoplasmic antibodies: current diagnostic and 
pathophysiological potential. Kidney Int, 1994. 46(1): p. 1-15. 
33. Brouwer, E., et al., Predominance of IgG1 and IgG4 subclasses of anti-neutrophil 
cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and 
clinically related disorders. Clin Exp Immunol, 1991. 83(3): p. 379-86. 
34. Morgan, M.D., et al., Patients with Wegener's granulomatosis demonstrate a relative 
deficiency and functional impairment of T-regulatory cells. Immunology, 2010. 130(1): 
p. 64-73. 
35. Komocsi, A., et al., Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major 
source of interferon-gamma and tumor necrosis factor-alpha in Wegener's 
granulomatosis. Am J Pathol, 2002. 160(5): p. 1717-24. 
36. Lamprecht, P., et al., CD28 negative T cells are enriched in granulomatous lesions of the 
respiratory tract in Wegener's granulomatosis. Thorax, 2001. 56(10): p. 751-7. 
37. Abdulahad, W.H., et al., Persistent expansion of CD4+ effector memory T cells in 
Wegener's granulomatosis. Kidney Int, 2006. 70(5): p. 938-47. 
38. Berden, A.E., et al., Cellular immunity in Wegener's granulomatosis: characterizing T 
lymphocytes. Arthritis Rheum, 2009. 60(6): p. 1578-87. 
39. Lockwood, C.M., et al., Long-term remission of intractable systemic vasculitis with 
monoclonal antibody therapy. Lancet, 1993. 341(8861): p. 1620-2. 
CMV Modulation of the Immune System in AAV 230 
 
40. Schmitt, W.H., et al., Treatment of refractory Wegener's granulomatosis with 
antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int, 2004. 65(4): p. 
1440-8. 
41. Muller, A., et al., Localized Wegener's granulomatosis: predominance of CD26 and IFN-
gamma expression. J Pathol, 2000. 192(1): p. 113-20. 
42. Schonermarck, U., et al., Circulating cytokines and soluble CD23, CD26 and CD30 in 
ANCA-associated vasculitides. Clin Exp Rheumatol, 2000. 18(4): p. 457-63. 
43. Wang, G., et al., High plasma levels of the soluble form of CD30 activation molecule 
reflect disease activity in patients with Wegener's granulomatosis. Am J Med, 1997. 
102(6): p. 517-23. 
44. Lamprecht, P., et al., Differences in CCR5 expression on peripheral blood CD4+CD28- T-
cells and in granulomatous lesions between localized and generalized Wegener's 
granulomatosis. Clin Immunol, 2003. 108(1): p. 1-7. 
45. Ordonez, L., et al., CD45RC isoform expression identifies functionally distinct T cell 
subsets differentially distributed between healthy individuals and AAV patients. PLoS 
One, 2009. 4(4): p. e5287. 
46. Abdulahad, W.H., P. Lamprecht, and C.G. Kallenberg, T-helper cells as new players in 
ANCA-associated vasculitides. Arthritis Res Ther, 2011. 13(4): p. 236. 
47. Abdulahad, W.H., et al., Skewed distribution of Th17 lymphocytes in patients with 
Wegener's granulomatosis in remission. Arthritis Rheum, 2008. 58(7): p. 2196-205. 
48. Nogueira, E., et al., Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are 
elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant, 2010. 
25(7): p. 2209-17. 
49. Laan, M., et al., Neutrophil recruitment by human IL-17 via C-X-C chemokine release in 
the airways. J Immunol, 1999. 162(4): p. 2347-52. 
50. Panettieri, R.A., Jr., et al., Activation of cAMP-dependent pathways in human airway 
smooth muscle cells inhibits TNF-alpha-induced ICAM-1 and VCAM-1 expression and T 
lymphocyte adhesion. J Immunol, 1995. 154(5): p. 2358-65. 
51. Jovanovic, D.V., et al., IL-17 stimulates the production and expression of 
proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J 
Immunol, 1998. 160(7): p. 3513-21. 
52. Marinaki, S., et al., Persistent T-cell activation and clinical correlations in patients with 
ANCA-associated systemic vasculitis. Nephrol Dial Transplant, 2006. 21(7): p. 1825-32. 
53. Abdulahad, W.H., et al., Urinary CD4+ effector memory T cells reflect renal disease 
activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum, 
2009. 60(9): p. 2830-8. 
54. Moosig, F., et al., Costimulatory molecules in Wegener's granulomatosis (WG): lack of 
expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 
(CD86) on T cells. Clin Exp Immunol, 1998. 114(1): p. 113-8. 
55. Bauer, S., et al., Activation of NK cells and T cells by NKG2D, a receptor for stress-
inducible MICA. Science, 1999. 285(5428): p. 727-9. 
56. Holmen, C., et al., Circulating inflammatory endothelial cells contribute to endothelial 
progenitor cell dysfunction in patients with vasculitis and kidney involvement. J Am Soc 
Nephrol, 2005. 16(10): p. 3110-20. 
57. Capraru, D., et al., Expansion of circulating NKG2D+ effector memory T-cells and 
expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's 
granulomatosis. Clin Immunol, 2008. 127(2): p. 144-50. 
58. Jayne, D.R. and N. Rasmussen, Treatment of antineutrophil cytoplasm autoantibody-
associated systemic vasculitis: initiatives of the European Community Systemic 
Vasculitis Clinical Trials Study Group. Mayo Clin Proc, 1997. 72(8): p. 737-47. 
CMV Modulation of the Immune System in AAV 231 
 
59. De Groot, K., et al., Randomized trial of cyclophosphamide versus methotrexate for 
induction of remission in early systemic antineutrophil cytoplasmic antibody-associated 
vasculitis. Arthritis Rheum, 2005. 52(8): p. 2461-9. 
60. Faurschou, M., et al., Brief Report: long-term outcome of a randomized clinical trial 
comparing methotrexate to cyclophosphamide for remission induction in early systemic 
antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum, 2012. 
64(10): p. 3472-7. 
61. de Groot, K., et al., Pulse versus daily oral cyclophosphamide for induction of remission 
in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann 
Intern Med, 2009. 150(10): p. 670-80. 
62. Harper, L., et al., Pulse versus daily oral cyclophosphamide for induction of remission in 
ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis, 2012. 71(6): p. 955-
60. 
63. Jones, R.B., et al., Rituximab versus cyclophosphamide in ANCA-associated renal 
vasculitis. N Engl J Med, 2010. 363(3): p. 211-20. 
64. Stone, J.H., et al., Rituximab versus cyclophosphamide for ANCA-associated vasculitis. 
N Engl J Med, 2010. 363(3): p. 221-32. 
65. Booth, A., et al., Prospective study of TNFalpha blockade with infliximab in anti-
neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol, 
2004. 15(3): p. 717-21. 
66. Laurino, S., et al., Prospective study of TNFalpha blockade with adalimumab in ANCA-
associated systemic vasculitis with renal involvement. Nephrol Dial Transplant, 2010. 
25(10): p. 3307-14. 
67. Morgan, M.D., et al., Addition of infliximab to standard therapy for ANCA-associated 
vasculitis. Nephron Clin Pract, 2011. 117(2): p. c89-97. 
68. Stone, J.H., et al., Etanercept combined with conventional treatment in Wegener's 
granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum, 2001. 
44(5): p. 1149-54. 
69. Jayne, D.R., et al., Randomized trial of plasma exchange or high-dosage 
methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol, 
2007. 18(7): p. 2180-8. 
70. Walsh, M., et al., Long-term follow-up of patients with severe ANCA-associated 
vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is 
unclear. Kidney Int, 2013. 84(2): p. 397-402. 
71. Pepper, R.J., et al., Intravenous cyclophosphamide and plasmapheresis in dialysis-
dependent ANCA-associated vasculitis. Clin J Am Soc Nephrol, 2013. 8(2): p. 219-24. 
72. Langford, C.A., et al., Use of a cyclophosphamide-induction methotrexate-maintenance 
regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate 
of relapse. Am J Med, 2003. 114(6): p. 463-9. 
73. Reinhold-Keller, E., et al., High rate of renal relapse in 71 patients with Wegener's 
granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis 
Rheum, 2002. 47(3): p. 326-32. 
74. Mukhtyar, C., et al., Outcomes from studies of antineutrophil cytoplasm antibody 
associated vasculitis: a systematic review by the European League Against Rheumatism 
systemic vasculitis task force. Ann Rheum Dis, 2008. 67(7): p. 1004-10. 
75. Samson, M., et al., Long-term outcomes of 118 patients with eosinophilic 
granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective 
trials. J Autoimmun, 2013. 43: p. 60-9. 
76. Knight, A., et al., Urinary bladder cancer in Wegener's granulomatosis: risks and 
relation to cyclophosphamide. Ann Rheum Dis, 2004. 63(10): p. 1307-11. 
CMV Modulation of the Immune System in AAV 232 
 
77. Talar-Williams, C., et al., Cyclophosphamide-induced cystitis and bladder cancer in 
patients with Wegener granulomatosis. Ann Intern Med, 1996. 124(5): p. 477-84. 
78. Jayne, D., et al., A randomized trial of maintenance therapy for vasculitis associated 
with antineutrophil cytoplasmic autoantibodies. N Engl J Med, 2003. 349(1): p. 36-44. 
79. Hiemstra, T.F., et al., Mycophenolate mofetil vs azathioprine for remission 
maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a 
randomized controlled trial. JAMA, 2010. 304(21): p. 2381-8. 
80. Pendergraft, W.F., 3rd, et al., Long-term maintenance therapy using rituximab-induced 
continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol, 
2014. 9(4): p. 736-44. 
81. Charles, P., et al., Rituximab for induction and maintenance treatment of ANCA-
associated vasculitides: a multicentre retrospective study on 80 patients. 
Rheumatology (Oxford), 2014. 53(3): p. 532-9. 
82. Besada, E., W. Koldingsnes, and J.C. Nossent, Long-term efficacy and safety of pre-
emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: 
results from a single centre. Rheumatology (Oxford), 2013. 52(11): p. 2041-7. 
83. Cartin-Ceba, R., et al., Rituximab for remission induction and maintenance in refractory 
granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. 
Arthritis Rheum, 2012. 64(11): p. 3770-8. 
84. Smith, R.M., et al., Rituximab for remission maintenance in relapsing antineutrophil 
cytoplasmic antibody-associated vasculitis. Arthritis Rheum, 2012. 64(11): p. 3760-9. 
85. Jayne, D.R., et al., Intravenous immunoglobulin for ANCA-associated systemic vasculitis 
with persistent disease activity. QJM, 2000. 93(7): p. 433-9. 
86. Walsh, M., A. Chaudhry, and D. Jayne, Long-term follow-up of relapsing/refractory 
anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte 
depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis, 2008. 67(9): p. 
1322-7. 
87. Birck, R., et al., 15-Deoxyspergualin in patients with refractory ANCA-associated 
systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am 
Soc Nephrol, 2003. 14(2): p. 440-7. 
88. Flossmann, O., et al., Deoxyspergualin in relapsing and refractory Wegener's 
granulomatosis. Ann Rheum Dis, 2009. 68(7): p. 1125-30. 
89. Schmitt, W.H., et al., Prolonged treatment of refractory Wegener's granulomatosis 
with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant, 
2005. 20(6): p. 1083-92. 
90. Bartolucci, P., et al., Efficacy of the anti-TNF-alpha antibody infliximab against 
refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 
(Oxford), 2002. 41(10): p. 1126-32. 
91. Jones, R.B., et al., A multicenter survey of rituximab therapy for refractory 
antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum, 2009. 
60(7): p. 2156-68. 
92. Ntatsaki, E., et al., BSR and BHPR guideline for the management of adults with ANCA-
associated vasculitis. Rheumatology (Oxford), 2014. 53(12): p. 2306-9. 
93. Flossmann, O., et al., Long-term patient survival in ANCA-associated vasculitis. Ann 
Rheum Dis, 2011. 70(3): p. 488-94. 
94. Morgan, M.D., et al., Increased incidence of cardiovascular events in patients with 
antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort 
study. Arthritis Rheum, 2009. 60(11): p. 3493-500. 
CMV Modulation of the Immune System in AAV 233 
 
95. Baber, U., et al., Risk for recurrent coronary heart disease and all-cause mortality 
among individuals with chronic kidney disease compared with diabetes mellitus, 
metabolic syndrome, and cigarette smokers. Am Heart J, 2013. 166(2): p. 373-380 e2. 
96. Tonelli, M., et al., Chronic kidney disease and mortality risk: a systematic review. J Am 
Soc Nephrol, 2006. 17(7): p. 2034-47. 
97. Di Angelantonio, E., et al., Chronic kidney disease and risk of major cardiovascular 
disease and non-vascular mortality: prospective population based cohort study. BMJ, 
2010. 341: p. c4986. 
98. Tervaert, J.W., Translational mini-review series on immunology of vascular disease: 
accelerated atherosclerosis in vasculitis. Clin Exp Immunol, 2009. 156(3): p. 377-85. 
99. Filer, A.D., et al., Diffuse endothelial dysfunction is common to ANCA associated 
systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis, 2003. 62(2): p. 162-7. 
100. Raza, K., et al., Suppression of inflammation in primary systemic vasculitis restores 
vascular endothelial function: lessons for atherosclerotic disease? Circulation, 2000. 
102(13): p. 1470-2. 
101. Booth, A.D., et al., Infliximab improves endothelial dysfunction in systemic vasculitis: a 
model of vascular inflammation. Circulation, 2004. 109(14): p. 1718-23. 
102. Booth, A.D., et al., Inflammation and arterial stiffness in systemic vasculitis: a model of 
vascular inflammation. Arthritis Rheum, 2004. 50(2): p. 581-8. 
103. de Leeuw, K., et al., Accelerated atherosclerosis in patients with Wegener's 
granulomatosis. Ann Rheum Dis, 2005. 64(5): p. 753-9. 
104. Chironi, G., et al., Increased prevalence of subclinical atherosclerosis in patients with 
small-vessel vasculitis. Heart, 2007. 93(1): p. 96-9. 
105. Faurschou, M., et al., Increased morbidity from ischemic heart disease in patients with 
Wegener's granulomatosis. Arthritis Rheum, 2009. 60(4): p. 1187-92. 
106. Goodson, N.J., et al., Mortality in early inflammatory polyarthritis: cardiovascular 
mortality is increased in seropositive patients. Arthritis Rheum, 2002. 46(8): p. 2010-9. 
107. del Rincon, I.D., et al., High incidence of cardiovascular events in a rheumatoid arthritis 
cohort not explained by traditional cardiac risk factors. Arthritis Rheum, 2001. 44(12): 
p. 2737-45. 
108. Solomon, D.H., et al., Cardiovascular morbidity and mortality in women diagnosed with 
rheumatoid arthritis. Circulation, 2003. 107(9): p. 1303-7. 
109. Wallberg-Jonsson, S., M.L. Ohman, and S.R. Dahlqvist, Cardiovascular morbidity and 
mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J 
Rheumatol, 1997. 24(3): p. 445-51. 
110. Manzi, S., et al., Age-specific incidence rates of myocardial infarction and angina in 
women with systemic lupus erythematosus: comparison with the Framingham Study. 
Am J Epidemiol, 1997. 145(5): p. 408-15. 
111. Ward, M.M., Premature morbidity from cardiovascular and cerebrovascular diseases in 
women with systemic lupus erythematosus. Arthritis Rheum, 1999. 42(2): p. 338-46. 
112. Morgan, M.D., et al., CD4+CD28- T cell expansion in granulomatosis with polyangiitis 
(Wegener's) is driven by latent cytomegalovirus infection and is associated with an 
increased risk of infection and mortality. Arthritis Rheum, 2011. 63(7): p. 2127-37. 
113. Kumar, H., T. Kawai, and S. Akira, Pathogen recognition by the innate immune system. 
Int Rev Immunol, 2011. 30(1): p. 16-34. 
114. Boehm, T., Design principles of adaptive immune systems. Nat Rev Immunol, 2011. 
11(5): p. 307-17. 
115. Makino, Y., et al., Predominant expression of invariant V alpha 14+ TCR alpha chain in 
NK1.1+ T cell populations. Int Immunol, 1995. 7(7): p. 1157-61. 
CMV Modulation of the Immune System in AAV 234 
 
116. Godfrey, D.I., et al., NKT cells: what's in a name? Nat Rev Immunol, 2004. 4(3): p. 231-
7. 
117. Janeway, C.A., Jr., B. Jones, and A. Hayday, Specificity and function of T cells bearing 
gamma delta receptors. Immunol Today, 1988. 9(3): p. 73-6. 
118. Koch, U. and F. Radtke, Mechanisms of T cell development and transformation. Annu 
Rev Cell Dev Biol, 2011. 27: p. 539-62. 
119. Kindt, T.J., et al., Kuby immunology. 2007. 
120. Taylor, J.M., et al., CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: 
which to choose and how to use. J Acquir Immune Defic Syndr, 1989. 2(2): p. 114-24. 
121. Syrjala, H., H.M. Surcel, and J. Ilonen, Low CD4/CD8 T lymphocyte ratio in acute 
myocardial infarction. Clin Exp Immunol, 1991. 83(2): p. 326-8. 
122. Sharpe, A.H. and G.J. Freeman, The B7-CD28 superfamily. Nat Rev Immunol, 2002. 2(2): 
p. 116-26. 
123. Karandikar, N.J., et al., Targeting the B7/CD28:CTLA-4 costimulatory system in CNS 
autoimmune disease. J Neuroimmunol, 1998. 89(1-2): p. 10-8. 
124. Salomon, B. and J.A. Bluestone, Complexities of CD28/B7: CTLA-4 costimulatory 
pathways in autoimmunity and transplantation. Annu Rev Immunol, 2001. 19: p. 225-
52. 
125. Sansom, D.M., CD28, CTLA-4 and their ligands: who does what and to whom? 
Immunology, 2000. 101(2): p. 169-77. 
126. Schwartz, R.H., T cell anergy. Annu Rev Immunol, 2003. 21: p. 305-34. 
127. Hutloff, A., et al., ICOS is an inducible T-cell co-stimulator structurally and functionally 
related to CD28. Nature, 1999. 397(6716): p. 263-6. 
128. Ishida, Y., et al., Induced expression of PD-1, a novel member of the immunoglobulin 
gene superfamily, upon programmed cell death. EMBO J, 1992. 11(11): p. 3887-95. 
129. Park, W., et al., Co-stimulatory pathways controlling activation and peripheral 
tolerance of human CD4+CD28- T cells. Eur J Immunol, 1997. 27(5): p. 1082-90. 
130. van Seventer, G.A., et al., Analysis of T cell stimulation by superantigen plus major 
histocompatibility complex class II molecules or by CD3 monoclonal antibody: 
costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. J Exp 
Med, 1991. 174(4): p. 901-13. 
131. Liu, Y., et al., Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J 
Exp Med, 1992. 175(2): p. 437-45. 
132. Tripathi, S.K. and R. Lahesmaa, Transcriptional and epigenetic regulation of T-helper 
lineage specification. Immunol Rev, 2014. 261(1): p. 62-83. 
133. Becattini, S., et al., T cell immunity. Functional heterogeneity of human memory CD4(+) 
T cell clones primed by pathogens or vaccines. Science, 2015. 347(6220): p. 400-6. 
134. Romagnani, S., Th1/Th2 cells. Inflamm Bowel Dis, 1999. 5(4): p. 285-94. 
135. Csernok, E., et al., Cytokine profiles in Wegener's granulomatosis: predominance of 
type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum, 1999. 42(4): p. 742-
50. 
136. Frostegard, J., et al., Cytokine expression in advanced human atherosclerotic plaques: 
dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. 
Atherosclerosis, 1999. 145(1): p. 33-43. 
137. Michie, C.A., et al., Lifespan of human lymphocyte subsets defined by CD45 isoforms. 
Nature, 1992. 360(6401): p. 264-5. 
138. Huehn, J., et al., Developmental stage, phenotype, and migration distinguish naive- 
and effector/memory-like CD4+ regulatory T cells. J Exp Med, 2004. 199(3): p. 303-13. 
139. Ahmed, R. and D. Gray, Immunological memory and protective immunity: 
understanding their relation. Science, 1996. 272(5258): p. 54-60. 
CMV Modulation of the Immune System in AAV 235 
 
140. Dutton, R.W., L.M. Bradley, and S.L. Swain, T cell memory. Annu Rev Immunol, 1998. 
16: p. 201-23. 
141. Sallusto, F., et al., Two subsets of memory T lymphocytes with distinct homing 
potentials and effector functions. Nature, 1999. 401(6754): p. 708-12. 
142. Moro-Garcia, M.A., R. Alonso-Arias, and C. Lopez-Larrea, When Aging Reaches CD4+ T-
Cells: Phenotypic and Functional Changes. Front Immunol, 2013. 4: p. 107. 
143. Taylor, J.J. and M.K. Jenkins, CD4+ memory T cell survival. Curr Opin Immunol, 2011. 
23(3): p. 319-23. 
144. Appay, V., et al., Memory CD8+ T cells vary in differentiation phenotype in different 
persistent virus infections. Nat Med, 2002. 8(4): p. 379-85. 
145. Appay, V., et al., Phenotype and function of human T lymphocyte subsets: consensus 
and issues. Cytometry A, 2008. 73(11): p. 975-83. 
146. Shahinian, A., et al., Differential T cell costimulatory requirements in CD28-deficient 
mice. Science, 1993. 261(5121): p. 609-12. 
147. Warrington, K.J., et al., CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 
stimulation. Blood, 2003. 101(9): p. 3543-9. 
148. Effros, R.B., et al., Decline in CD28+ T cells in centenarians and in long-term T cell 
cultures: a possible cause for both in vivo and in vitro immunosenescence. Exp 
Gerontol, 1994. 29(6): p. 601-9. 
149. Posnett, D.N., et al., Clonal populations of T cells in normal elderly humans: the T cell 
equivalent to "benign monoclonal gammapathy". J Exp Med, 1994. 179(2): p. 609-18. 
150. Choremi-Papadopoulou, H., et al., Downregulation of CD28 surface antigen on CD4+ 
and CD8+ T lymphocytes during HIV-1 infection. J Acquir Immune Defic Syndr, 1994. 
7(3): p. 245-53. 
151. Vallejo, A.N., et al., Aging-related deficiency of CD28 expression in CD4+ T cells is 
associated with the loss of gene-specific nuclear factor binding activity. J Biol Chem, 
1998. 273(14): p. 8119-29. 
152. Vallejo, A.N., et al., Modulation of CD28 expression: distinct regulatory pathways 
during activation and replicative senescence. J Immunol, 1999. 162(11): p. 6572-9. 
153. Schmidt, D., J.J. Goronzy, and C.M. Weyand, CD4+ CD7- CD28- T cells are expanded in 
rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest, 1996. 97(9): 
p. 2027-37. 
154. Schmidt, D., et al., The repertoire of CD4+ CD28- T cells in rheumatoid arthritis. Mol 
Med, 1996. 2(5): p. 608-18. 
155. Ugarte-Gil, M.F., et al., Circulating CD4+CD28null and extra-thymic CD4+CD8+ double 
positive T cells are independently associated with disease damage in systemic lupus 
erythematosus patients. Lupus, 2016. 25(3): p. 233-40. 
156. Lopez, P., et al., Senescent profile of angiogenic T cells from systemic lupus 
erythematosus patients. J Leukoc Biol, 2016. 99(3): p. 405-12. 
157. Thewissen, M., et al., Premature immunosenescence in rheumatoid arthritis and 
multiple sclerosis patients. Ann N Y Acad Sci, 2005. 1051: p. 255-62. 
158. Thewissen, M., et al., Analyses of immunosenescent markers in patients with 
autoimmune disease. Clin Immunol, 2007. 123(2): p. 209-18. 
159. Thewissen, M., et al., CD4+CD28null T cells in autoimmune disease: pathogenic 
features and decreased susceptibility to immunoregulation. J Immunol, 2007. 179(10): 
p. 6514-23. 
160. Miyazaki, Y., et al., Expansion of CD4+CD28- T cells producing high levels of interferon-
{gamma} in peripheral blood of patients with multiple sclerosis. Mult Scler, 2008. 14(8): 
p. 1044-55. 
CMV Modulation of the Immune System in AAV 236 
 
161. Markovic-Plese, S., et al., CD4+CD28- costimulation-independent T cells in multiple 
sclerosis. J Clin Invest, 2001. 108(8): p. 1185-94. 
162. Broux, B., et al., IL-15 amplifies the pathogenic properties of CD4+CD28- T cells in 
multiple sclerosis. J Immunol, 2015. 194(5): p. 2099-109. 
163. Broux, B., et al., CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of 
multiple sclerosis patients. J Autoimmun, 2012. 38(1): p. 10-9. 
164. Sun, Z., et al., Association of Graves' disease and prevalence of circulating IFN-gamma-
producing CD28(-) T cells. J Clin Immunol, 2008. 28(5): p. 464-72. 
165. Garcia de Tena, J., et al., Active Crohn's disease patients show a distinctive expansion of 
circulating memory CD4+CD45RO+CD28null T cells. J Clin Immunol, 2004. 24(2): p. 185-
96. 
166. Fasth, A.E., et al., T cell infiltrates in the muscles of patients with dermatomyositis and 
polymyositis are dominated by CD28null T cells. J Immunol, 2009. 183(7): p. 4792-9. 
167. Duftner, C., et al., Preferential type 1 chemokine receptors and cytokine production of 
CD28- T cells in ankylosing spondylitis. Ann Rheum Dis, 2006. 65(5): p. 647-53. 
168. Hooper, M., et al., Cytomegalovirus seropositivity is associated with the expansion of 
CD4+CD28- and CD8+CD28- T cells in rheumatoid arthritis. J Rheumatol, 1999. 26(7): p. 
1452-7. 
169. Ostrowski, S.R., et al., A low level of CD4+CD28+ T cells is an independent predictor of 
high mortality in human immunodeficiency virus type 1-infected patients. J Infect Dis, 
2003. 187(11): p. 1726-34. 
170. Kammerer, R., et al., Expansion of T cells negative for CD28 expression in HIV infection. 
Relation to activation markers and cell adhesion molecules, and correlation with 
prognostic markers. Med Microbiol Immunol, 1996. 185(1): p. 19-25. 
171. Dumitriu, I.E., The life (and death) of CD4+ CD28(null) T cells in inflammatory diseases. 
Immunology, 2015. 146(2): p. 185-93. 
172. Kovalcsik, E., et al., Proteasome-mediated reduction in proapoptotic molecule Bim 
renders CD4(+)CD28null T cells resistant to apoptosis in acute coronary syndrome. 
Circulation, 2015. 131(8): p. 709-20. 
173. Betjes, M.G., et al., A killer on the road: circulating CD4(+)CD28null T cells as 
cardiovascular risk factor in ESRD patients. J Nephrol, 2012. 25(2): p. 183-91. 
174. Betjes, M.G., W. Weimar, and N.H. Litjens, Circulating CD4(+)CD28null T Cells May 
Increase the Risk of an Atherosclerotic Vascular Event Shortly after Kidney 
Transplantation. J Transplant, 2013. 2013: p. 841430. 
175. Gerli, R., et al., CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in 
rheumatoid arthritis patients. Circulation, 2004. 109(22): p. 2744-8. 
176. Yadav, A.K., et al., Vitamin D deficiency, CD4+CD28null cells and accelerated 
atherosclerosis in chronic kidney disease. Nephrology (Carlton), 2012. 17(6): p. 575-81. 
177. Yadav, A.K. and V. Jha, CD4+CD28null cells are expanded and exhibit a cytolytic profile 
in end-stage renal disease patients on peritoneal dialysis. Nephrol Dial Transplant, 
2011. 26(5): p. 1689-94. 
178. Yadav, A.K., V. Kumar, and V. Jha, Heat shock proteins 60 and 70 specific 
proinflammatory and cytotoxic response of CD4+CD28null cells in chronic kidney 
disease. Mediators Inflamm, 2013. 2013: p. 384807. 
179. Yadav, A.K., A. Lal, and V. Jha, Association of circulating fractalkine (CX3CL1) and 
CX3CR1(+)CD4(+) T cells with common carotid artery intima-media thickness in patients 
with chronic kidney disease. J Atheroscler Thromb, 2011. 18(11): p. 958-65. 
180. Yadav, A.K., A. Lal, and V. Jha, Cytotoxic CD4+CD28 null T lymphocytes, systemic 
inflammation and atherosclerotic risk in patients with chronic kidney disease. Nephron 
Clin Pract, 2012. 120(4): p. c185-93. 
CMV Modulation of the Immune System in AAV 237 
 
181. Sun, Z., et al., Prevalence of circulating CD4+CD28null T cells is associated with early 
atherosclerotic damage in patients with end-stage renal disease undergoing 
hemodialysis. Hum Immunol, 2013. 74(1): p. 6-13. 
182. Vallejo, A.N., et al., Clonality and longevity of CD4+CD28null T cells are associated with 
defects in apoptotic pathways. J Immunol, 2000. 165(11): p. 6301-7. 
183. Wagner, U., et al., Clonally expanded CD4+CD28null T cells in rheumatoid arthritis use 
distinct combinations of T cell receptor BV and BJ elements. Eur J Immunol, 2003. 
33(1): p. 79-84. 
184. Maly, K. and M. Schirmer, The story of CD4+ CD28- T cells revisited: solved or still 
ongoing? J Immunol Res, 2015. 2015: p. 348746. 
185. Vallejo, A.N., C.M. Weyand, and J.J. Goronzy, T-cell senescence: a culprit of immune 
abnormalities in chronic inflammation and persistent infection. Trends Mol Med, 2004. 
10(3): p. 119-24. 
186. Valenzuela, H.F. and R.B. Effros, Divergent telomerase and CD28 expression patterns in 
human CD4 and CD8 T cells following repeated encounters with the same antigenic 
stimulus. Clin Immunol, 2002. 105(2): p. 117-25. 
187. Schirmer, M., et al., Resistance to apoptosis and elevated expression of Bcl-2 in clonally 
expanded CD4+CD28- T cells from rheumatoid arthritis patients. J Immunol, 1998. 
161(2): p. 1018-25. 
188. Weyand, C.M., et al., Functional properties of CD4+ CD28- T cells in the aging immune 
system. Mech Ageing Dev, 1998. 102(2-3): p. 131-47. 
189. Namekawa, T., et al., Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis 
Rheum, 1998. 41(12): p. 2108-16. 
190. Duftner, C., et al., High prevalence of circulating CD4+CD28- T-cells in patients with 
small abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol, 2005. 25(7): p. 1347-
52. 
191. Duftner, C., et al., Prevalence, clinical relevance and characterization of circulating 
cytotoxic CD4+CD28- T cells in ankylosing spondylitis. Arthritis Res Ther, 2003. 5(5): p. 
R292-300. 
192. Pieper, J., et al., Peripheral and site-specific CD4(+) CD28(null) T cells from rheumatoid 
arthritis patients show distinct characteristics. Scand J Immunol, 2014. 79(2): p. 149-
55. 
193. Barton, R.W., et al., The effect of anti-intercellular adhesion molecule-1 on phorbol-
ester-induced rabbit lung inflammation. J Immunol, 1989. 143(4): p. 1278-82. 
194. Namekawa, T., et al., Killer cell activating receptors function as costimulatory 
molecules on CD4+CD28null T cells clonally expanded in rheumatoid arthritis. J 
Immunol, 2000. 165(2): p. 1138-45. 
195. Groh, V., et al., Stimulation of T cell autoreactivity by anomalous expression of NKG2D 
and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A, 2003. 100(16): p. 
9452-7. 
196. Warrington, K.J., et al., CD4+,CD28- T cells in rheumatoid arthritis patients combine 
features of the innate and adaptive immune systems. Arthritis Rheum, 2001. 44(1): p. 
13-20. 
197. Dejaco, C., et al., NKG2D stimulated T-cell autoreactivity in giant cell arteritis and 
polymyalgia rheumatica. Ann Rheum Dis, 2013. 72(11): p. 1852-9. 
198. Zal, B., et al., Killer cell immunoglobulin receptor profile on CD4(+) CD28(-) T cells and 
their pathogenic role in non-dialysis-dependent and dialysis-dependent chronic kidney 
disease patients. Immunology, 2015. 145(1): p. 105-13. 
CMV Modulation of the Immune System in AAV 238 
 
199. Zal, B., et al., Differential pathways govern CD4+ CD28- T cell proinflammatory and 
effector responses in patients with coronary artery disease. J Immunol, 2008. 181(8): p. 
5233-41. 
200. Zal, B., et al., Heat-shock protein 60-reactive CD4+CD28null T cells in patients with 
acute coronary syndromes. Circulation, 2004. 109(10): p. 1230-5. 
201. Van Raemdonck, K., et al., CXCR3 ligands in disease and therapy. Cytokine Growth 
Factor Rev, 2015. 26(3): p. 311-27. 
202. Lima, X.T., et al., Frequency and characteristics of circulating CD4(+) CD28(null) T cells 
in patients with psoriasis. Br J Dermatol, 2015. 173(4): p. 998-1005. 
203. Zhang, X., et al., Tissue trafficking patterns of effector memory CD4+ T cells in 
rheumatoid arthritis. Arthritis Rheum, 2005. 52(12): p. 3839-49. 
204. Jones, B.A., M. Beamer, and S. Ahmed, Fractalkine/CX3CL1: a potential new target for 
inflammatory diseases. Mol Interv, 2010. 10(5): p. 263-70. 
205. Dong, L., et al., T Cell CX3CR1 Mediates Excess Atherosclerotic Inflammation in Renal 
Impairment. J Am Soc Nephrol, 2016. 27(6): p. 1753-64. 
206. Zhang, X., et al., Chemokine CX3CL1 and its receptor CX3CR1 are associated with 
human atherosclerotic lesion volnerability. Thromb Res, 2015. 135(6): p. 1147-53. 
207. Shah, R., et al., Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and 
Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J 
Kidney Dis, 2015. 66(2): p. 266-73. 
208. Garcia, G.E., et al., NF-kappaB-dependent fractalkine induction in rat aortic endothelial 
cells stimulated by IL-1beta, TNF-alpha, and LPS. J Leukoc Biol, 2000. 67(4): p. 577-84. 
209. Sawai, H., et al., Fractalkine mediates T cell-dependent proliferation of synovial 
fibroblasts in rheumatoid arthritis. Arthritis Rheum, 2007. 56(10): p. 3215-25. 
210. Sawai, H., et al., T cell costimulation by fractalkine-expressing synoviocytes in 
rheumatoid arthritis. Arthritis Rheum, 2005. 52(5): p. 1392-401. 
211. Yano, R., et al., Recruitment of CD16+ monocytes into synovial tissues is mediated by 
fractalkine and CX3CR1 in rheumatoid arthritis patients. Acta Med Okayama, 2007. 
61(2): p. 89-98. 
212. Bryl, E., et al., Down-regulation of CD28 expression by TNF-alpha. J Immunol, 2001. 
167(6): p. 3231-8. 
213. Fagiolo, U., et al., Increased cytokine production in mononuclear cells of healthy elderly 
people. Eur J Immunol, 1993. 23(9): p. 2375-8. 
214. O'Mahony, L., et al., Quantitative intracellular cytokine measurement: age-related 
changes in proinflammatory cytokine production. Clin Exp Immunol, 1998. 113(2): p. 
213-9. 
215. Bryl, E., et al., Modulation of CD28 expression with anti-tumor necrosis factor alpha 
therapy in rheumatoid arthritis. Arthritis Rheum, 2005. 52(10): p. 2996-3003. 
216. Rizzello, V., et al., Modulation of CD4(+)CD28null T lymphocytes by tumor necrosis 
factor-alpha blockade in patients with unstable angina. Circulation, 2006. 113(19): p. 
2272-7. 
217. Pawlik, A., et al., Therapy with infliximab decreases the CD4+CD28- T cell compartment 
in peripheral blood in patients with rheumatoid arthritis. Rheumatol Int, 2004. 24(6): p. 
351-4. 
218. Liaskou, E., et al., Loss of CD28 expression by liver-infiltrating T cells contributes to 
pathogenesis of primary sclerosing cholangitis. Gastroenterology, 2014. 147(1): p. 221-
232 e7. 
219. Pandya, J.M., et al., CD4+ and CD8+ CD28(null) T Cells Are Cytotoxic to Autologous 
Muscle Cells in Patients With Polymyositis. Arthritis Rheumatol, 2016. 68(8): p. 2016-
26. 
CMV Modulation of the Immune System in AAV 239 
 
220. Gilani, S.R., et al., CD28 down-regulation on circulating CD4 T-cells is associated with 
poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One, 2010. 5(1): p. 
e8959. 
221. Martens, P.B., et al., Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. 
Arthritis Rheum, 1997. 40(6): p. 1106-14. 
222. Giscombe, R., et al., Expanded T cell populations in patients with Wegener's 
granulomatosis: characteristics and correlates with disease activity. J Clin Immunol, 
1998. 18(6): p. 404-13. 
223. Schlesier, M., et al., Activated CD4+ and CD8+ T-cell subsets in Wegener's 
granulomatosis. Rheumatol Int, 1995. 14(5): p. 213-9. 
224. Eriksson, P., et al., Expansions of CD4+CD28- and CD8+CD28- T cells in granulomatosis 
with polyangiitis and microscopic polyangiitis are associated with cytomegalovirus 
infection but not with disease activity. J Rheumatol, 2012. 39(9): p. 1840-3. 
225. Shabir, S., et al., Cytomegalovirus-Associated CD4(+) CD28(null) Cells in NKG2D-
Dependent Glomerular Endothelial Injury and Kidney Allograft Dysfunction. Am J 
Transplant, 2016. 16(4): p. 1113-28. 
226. Liuzzo, G., et al., Perturbation of the T-cell repertoire in patients with unstable angina. 
Circulation, 1999. 100(21): p. 2135-9. 
227. Liuzzo, G., et al., Monoclonal T-cell proliferation and plaque instability in acute 
coronary syndromes. Circulation, 2000. 101(25): p. 2883-8. 
228. Nakajima, T., et al., T-cell-mediated lysis of endothelial cells in acute coronary 
syndromes. Circulation, 2002. 105(5): p. 570-5. 
229. Giubilato, S., et al., Expansion of CD4+CD28null T-lymphocytes in diabetic patients: 
exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes 
mellitus. Eur Heart J, 2011. 32(10): p. 1214-26. 
230. Pingiotti, E., et al., Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28 T 
cells in RA patients and correlation with atherosclerotic damage. Ann N Y Acad Sci, 
2007. 1107: p. 32-41. 
231. Pierer, M., et al., Association of anticytomegalovirus seropositivity with more severe 
joint destruction and more frequent joint surgery in rheumatoid arthritis. Arthritis 
Rheum, 2012. 64(6): p. 1740-9. 
232. van Leeuwen, E.M., et al., Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-
specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol, 
2004. 173(3): p. 1834-41. 
233. van Eden, W., R. van der Zee, and B. Prakken, Heat-shock proteins induce T-cell 
regulation of chronic inflammation. Nat Rev Immunol, 2005. 5(4): p. 318-30. 
234. Wick, G., M. Knoflach, and Q. Xu, Autoimmune and inflammatory mechanisms in 
atherosclerosis. Annu Rev Immunol, 2004. 22: p. 361-403. 
235. Zhu, J., et al., Increased serum levels of heat shock protein 70 are associated with low 
risk of coronary artery disease. Arterioscler Thromb Vasc Biol, 2003. 23(6): p. 1055-9. 
236. Bason, C., et al., Interaction of antibodies against cytomegalovirus with heat-shock 
protein 60 in pathogenesis of atherosclerosis. Lancet, 2003. 362(9400): p. 1971-7. 
237. Vomaske, J., J.A. Nelson, and D.N. Streblow, Human Cytomegalovirus US28: a 
functionally selective chemokine binding receptor. Infect Disord Drug Targets, 2009. 
9(5): p. 548-56. 
238. Chidrawar, S., et al., Cytomegalovirus-seropositivity has a profound influence on the 
magnitude of major lymphoid subsets within healthy individuals. Clin Exp Immunol, 
2009. 155(3): p. 423-32. 
239. Jamieson, B.D., et al., Generation of functional thymocytes in the human adult. 
Immunity, 1999. 10(5): p. 569-75. 
CMV Modulation of the Immune System in AAV 240 
 
240. Linton, P.J. and K. Dorshkind, Age-related changes in lymphocyte development and 
function. Nat Immunol, 2004. 5(2): p. 133-9. 
241. Wistuba-Hamprecht, K., et al., Age-associated alterations in gammadelta T-cells are 
present predominantly in individuals infected with Cytomegalovirus. Immun Ageing, 
2013. 10(1): p. 26. 
242. Ahlfors, K., IgG antibodies to cytomegalovirus in a normal urban Swedish population. 
Scand J Infect Dis, 1984. 16(4): p. 335-7. 
243. Soderberg-Naucler, C., O. Fornara, and A. Rahbar, Cytomegalovirus driven 
immunosenescence-An immune phenotype with or without clinical impact? Mech 
Ageing Dev, 2016. 158: p. 3-13. 
244. Cannon, M.J., D.S. Schmid, and T.B. Hyde, Review of cytomegalovirus seroprevalence 
and demographic characteristics associated with infection. Rev Med Virol, 2010. 20(4): 
p. 202-13. 
245. Staras, S.A., et al., Seroprevalence of cytomegalovirus infection in the United States, 
1988-1994. Clin Infect Dis, 2006. 43(9): p. 1143-51. 
246. Ho, M., Epidemiology of cytomegalovirus infections. Rev Infect Dis, 1990. 12 Suppl 7: p. 
S701-10. 
247. Steininger, C., Clinical relevance of cytomegalovirus infection in patients with disorders 
of the immune system. Clin Microbiol Infect, 2007. 13(10): p. 953-63. 
248. Soderberg-Naucler, C., K.N. Fish, and J.A. Nelson, Reactivation of latent human 
cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell, 
1997. 91(1): p. 119-26. 
249. Reeves, M., P. Sissons, and J. Sinclair, Reactivation of human cytomegalovirus in 
dendritic cells. Discov Med, 2005. 5(26): p. 170-4. 
250. Reeves, M.B., et al., Latency, chromatin remodeling, and reactivation of human 
cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci U S A, 
2005. 102(11): p. 4140-5. 
251. Tarrant-Elorza, M., C.C. Rossetto, and G.S. Pari, Maintenance and replication of the 
human cytomegalovirus genome during latency. Cell Host Microbe, 2014. 16(1): p. 43-
54. 
252. Taylor-Wiedeman, J., et al., Monocytes are a major site of persistence of human 
cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol, 1991. 72 ( Pt 9): p. 
2059-64. 
253. Emery, V.C., Investigation of CMV disease in immunocompromised patients. J Clin 
Pathol, 2001. 54(2): p. 84-8. 
254. Jackson, S.E., G.M. Mason, and M.R. Wills, Human cytomegalovirus immunity and 
immune evasion. Virus Res, 2011. 157(2): p. 151-60. 
255. Shellam, G.R., et al., Increased susceptibility to cytomegalovirus infection in beige 
mutant mice. Proc Natl Acad Sci U S A, 1981. 78(8): p. 5104-8. 
256. Barron, M.A., et al., Relationship of reconstituted adaptive and innate cytomegalovirus 
(CMV)-specific immune responses with CMV viremia in hematopoietic stem cell 
transplant recipients. Clin Infect Dis, 2009. 49(12): p. 1777-83. 
257. Stowe, R.P., et al., Chronic herpesvirus reactivation occurs in aging. Exp Gerontol, 2007. 
42(6): p. 563-70. 
258. Mehta, S.K., et al., Reactivation and shedding of cytomegalovirus in astronauts during 
spaceflight. J Infect Dis, 2000. 182(6): p. 1761-4. 
259. Stowe, R.P., et al., Immune responses and latent herpesvirus reactivation in spaceflight. 
Aviat Space Environ Med, 2001. 72(10): p. 884-91. 
260. Crough, T. and R. Khanna, Immunobiology of human cytomegalovirus: from bench to 
bedside. Clin Microbiol Rev, 2009. 22(1): p. 76-98, Table of Contents. 
CMV Modulation of the Immune System in AAV 241 
 
261. Neuenhahn, M., et al., Transfer of minimally manipulated CMV-specific T cells from 
stem cell or third-party donors to treat CMV infection after alloHSCT. Leukemia, 2017. 
262. Riddell, S.R., et al., Restoration of viral immunity in immunodeficient humans by the 
adoptive transfer of T cell clones. Science, 1992. 257(5067): p. 238-41. 
263. Walter, E.A., et al., Reconstitution of cellular immunity against cytomegalovirus in 
recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl 
J Med, 1995. 333(16): p. 1038-44. 
264. Cobbold, M., et al., Adoptive transfer of cytomegalovirus-specific CTL to stem cell 
transplant patients after selection by HLA-peptide tetramers. J Exp Med, 2005. 202(3): 
p. 379-86. 
265. Pourgheysari, B., et al., The cytomegalovirus-specific CD4+ T-cell response expands 
with age and markedly alters the CD4+ T-cell repertoire. J Virol, 2007. 81(14): p. 7759-
65. 
266. Derhovanessian, E., et al., Infection with cytomegalovirus but not herpes simplex virus 
induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. J 
Gen Virol, 2011. 92(Pt 12): p. 2746-56. 
267. Wills, M., et al., Report from the second cytomegalovirus and immunosenescence 
workshop. Immun Ageing, 2011. 8(1): p. 10. 
268. Weinberger, B., et al., Healthy aging and latent infection with CMV lead to distinct 
changes in CD8+ and CD4+ T-cell subsets in the elderly. Hum Immunol, 2007. 68(2): p. 
86-90. 
269. Bolovan-Fritts, C.A., R.N. Trout, and S.A. Spector, Human cytomegalovirus-specific 
CD4+-T-cell cytokine response induces fractalkine in endothelial cells. J Virol, 2004. 
78(23): p. 13173-81. 
270. Rauwel, B., et al., Release of human cytomegalovirus from latency by a KAP1/TRIM28 
phosphorylation switch. Elife, 2015. 4. 
271. Zagorowicz, E., et al., Cytomegalovirus Infection in Ulcerative Colitis is Related to 
Severe Inflammation and a High Count of Cytomegalovirus-positive Cells in Biopsy Is a 
Risk Factor for Colectomy. J Crohns Colitis, 2016. 
272. Nikitskaya, E.A., et al., Cytomegalovirus in Plasma of Acute Coronary Syndrome 
Patients. Acta Naturae, 2016. 8(2): p. 102-7. 
273. Tan, D.B., et al., Levels of CMV-reactive antibodies correlate with the induction of 
CD28(null) T cells and systemic inflammation in chronic obstructive pulmonary disease 
(COPD). Cell Mol Immunol, 2016. 13(4): p. 551-3. 
274. Betjes, M.G., W. Weimar, and N.H. Litjens, CMV seropositivity determines epoetin dose 
and hemoglobin levels in patients with CKD. J Am Soc Nephrol, 2009. 20(12): p. 2661-6. 
275. Delgado, J.F., et al., Influence of cytomegalovirus infection in the development of 
cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant, 
2015. 34(8): p. 1112-9. 
276. Desai, R., et al., Impact of Cytomegalovirus on Long-term Mortality and Cancer Risk 
After Organ Transplantation. Transplantation, 2015. 99(9): p. 1989-94. 
277. Opelz, G. and B. Dohler, Reduced rate of cardiovascular death after cytomegalovirus 
prophylaxis in renal transplant recipients. Transplantation, 2015. 99(6): p. 1197-202. 
278. Zhang, J., et al., High Human Cytomegalovirus IgG Level is Associated with Increased 
Incidence of Diabetic Atherosclerosis in Type 2 Diabetes Mellitus Patients. Med Sci 
Monit, 2015. 21: p. 4102-10. 
279. Spyridopoulos, I., et al., CMV seropositivity and T-cell senescence predict increased 
cardiovascular mortality in octogenarians: results from the Newcastle 85+ study. Aging 
Cell, 2016. 15(2): p. 389-92. 
CMV Modulation of the Immune System in AAV 242 
 
280. Cheng, J., et al., Cytomegalovirus infection causes an increase of arterial blood 
pressure. PLoS Pathog, 2009. 5(5): p. e1000427. 
281. Firth, C., et al., Cytomegalovirus infection is associated with an increase in systolic 
blood pressure in older individuals. QJM, 2016. 
282. Izadi, M., et al., Cytomegalovirus localization in atherosclerotic plaques is associated 
with acute coronary syndromes: report of 105 patients. Methodist Debakey Cardiovasc 
J, 2012. 8(2): p. 42-6. 
283. Courivaud, C., et al., Cytomegalovirus exposure and cardiovascular disease in kidney 
transplant recipients. J Infect Dis, 2013. 207(10): p. 1569-75. 
284. Haarala, A., et al., Relation of high cytomegalovirus antibody titres to blood pressure 
and brachial artery flow-mediated dilation in young men: the Cardiovascular Risk in 
Young Finns Study. Clin Exp Immunol, 2012. 167(2): p. 309-16. 
285. Wall, N.A., et al., Cytomegalovirus seropositivity is associated with increased arterial 
stiffness in patients with chronic kidney disease. PLoS One, 2013. 8(2): p. e55686. 
286. Bolovan-Fritts, C.A. and S.A. Spector, Endothelial damage from cytomegalovirus-
specific host immune response can be prevented by targeted disruption of fractalkine-
CX3CR1 interaction. Blood, 2008. 111(1): p. 175-82. 
287. van de Berg, P.J., et al., Cytomegalovirus-induced effector T cells cause endothelial cell 
damage. Clin Vaccine Immunol, 2012. 19(5): p. 772-9. 
288. Koch, S., et al., Cytomegalovirus infection: a driving force in human T cell 
immunosenescence. Ann N Y Acad Sci, 2007. 1114: p. 23-35. 
289. Koch, S., et al., Human cytomegalovirus infection and T cell immunosenescence: a mini 
review. Mech Ageing Dev, 2006. 127(6): p. 538-43. 
290. Pawelec, G., et al., Immunosenescence and Cytomegalovirus: where do we stand after 
a decade? Immun Ageing, 2010. 7: p. 13. 
291. Pawelec, G., et al., Cytomegalovirus and human immunosenescence. Rev Med Virol, 
2009. 19(1): p. 47-56. 
292. Savva, G.M., et al., Cytomegalovirus infection is associated with increased mortality in 
the older population. Aging Cell, 2013. 12(3): p. 381-7. 
293. Wikby, A., et al., Expansions of peripheral blood CD8 T-lymphocyte subpopulations and 
an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA 
immune study. Exp Gerontol, 2002. 37(2-3): p. 445-53. 
294. Wikby, A., et al., Changes in CD8 and CD4 lymphocyte subsets, T cell proliferation 
responses and non-survival in the very old: the Swedish longitudinal OCTO-immune 
study. Mech Ageing Dev, 1998. 102(2-3): p. 187-98. 
295. Luz Correa, B., et al., The inverted CD4:CD8 ratio is associated with cytomegalovirus, 
poor cognitive and functional states in older adults. Neuroimmunomodulation, 2014. 
21(4): p. 206-12. 
296. Fletcher, J.M., et al., Cytomegalovirus-specific CD4+ T cells in healthy carriers are 
continuously driven to replicative exhaustion. J Immunol, 2005. 175(12): p. 8218-25. 
297. Khan, N., et al., Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus 
impairs the response to a coresident EBV infection. J Immunol, 2004. 173(12): p. 7481-
9. 
298. Stowe, R.P., et al., Reactivation of herpes simplex virus type 1 is associated with 
cytomegalovirus and age. J Med Virol, 2012. 84(11): p. 1797-802. 
299. Ogunjimi, B., et al., Cytomegalovirus seropositivity is associated with herpes zoster. 
Hum Vaccin Immunother, 2015. 11(6): p. 1394-9. 
300. Trzonkowski, P., et al., Association between cytomegalovirus infection, enhanced 
proinflammatory response and low level of anti-hemagglutinins during the anti-
CMV Modulation of the Immune System in AAV 243 
 
influenza vaccination--an impact of immunosenescence. Vaccine, 2003. 21(25-26): p. 
3826-36. 
301. Derhovanessian, E., et al., Cytomegalovirus-associated accumulation of late-
differentiated CD4 T-cells correlates with poor humoral response to influenza 
vaccination. Vaccine, 2013. 31(4): p. 685-90. 
302. Turner, J.E., et al., Rudimentary signs of immunosenescence in Cytomegalovirus-
seropositive healthy young adults. Age (Dordr), 2014. 36(1): p. 287-97. 
303. Yi, J.S., M.A. Cox, and A.J. Zajac, T-cell exhaustion: characteristics, causes and 
conversion. Immunology, 2010. 129(4): p. 474-81. 
304. Kannanganat, S., et al., Multiple-cytokine-producing antiviral CD4 T cells are 
functionally superior to single-cytokine-producing cells. J Virol, 2007. 81(16): p. 8468-
76. 
305. Bronke, C., et al., Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected 
individuals progressing to AIDS with CMV end-organ disease. J Infect Dis, 2005. 191(6): 
p. 873-80. 
306. Kassu, A., et al., Regulation of virus-specific CD4+ T cell function by multiple 
costimulatory receptors during chronic HIV infection. J Immunol, 2010. 185(5): p. 3007-
18. 
307. Sester, U., et al., PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells 
correlates with viremia and reversible functional anergy. Am J Transplant, 2008. 8(7): 
p. 1486-97. 
308. Antoine, P., et al., Functional exhaustion of CD4+ T lymphocytes during primary 
cytomegalovirus infection. J Immunol, 2012. 189(5): p. 2665-72. 
309. Pera, A., et al., CMV induces expansion of highly polyfunctional CD4+ T cell subset 
coexpressing CD57 and CD154. J Leukoc Biol, 2016. 
310. Barton, E.S., et al., Herpesvirus latency confers symbiotic protection from bacterial 
infection. Nature, 2007. 447(7142): p. 326-9. 
311. White, D.W., R. Suzanne Beard, and E.S. Barton, Immune modulation during latent 
herpesvirus infection. Immunol Rev, 2012. 245(1): p. 189-208. 
312. Mekker, A., et al., Immune senescence: relative contributions of age and 
cytomegalovirus infection. PLoS Pathog, 2012. 8(8): p. e1002850. 
313. Cicin-Sain, L., et al., Cytomegalovirus infection impairs immune responses and 
accentuates T-cell pool changes observed in mice with aging. PLoS Pathog, 2012. 8(8): 
p. e1002849. 
314. Furman, D., et al., Cytomegalovirus infection enhances the immune response to 
influenza. Sci Transl Med, 2015. 7(281): p. 281ra43. 
315. Miles, D.J., et al., Cytomegalovirus infection induces T-cell differentiation without 
impairing antigen-specific responses in Gambian infants. Immunology, 2008. 124(3): p. 
388-400. 
316. Johnstone, J., et al., Immune biomarkers predictive of respiratory viral infection in 
elderly nursing home residents. PLoS One, 2014. 9(9): p. e108481. 
317. Derhovanessian, E., et al., Latent infection with cytomegalovirus is associated with 
poor memory CD4 responses to influenza A core proteins in the elderly. J Immunol, 
2014. 193(7): p. 3624-31. 
318. Goldeck, D., et al., Genetic Influence on the Peripheral Blood CD4+ T-cell Differentiation 
Status in CMV Infection. J Gerontol A Biol Sci Med Sci, 2016. 
319. Mori, T., et al., Incidence of cytomegalovirus reactivation in patients with inflammatory 
connective tissue diseases who are under immunosuppressive therapy. J Rheumatol, 
2004. 31(7): p. 1349-51. 
CMV Modulation of the Immune System in AAV 244 
 
320. Emery, V.C., et al., Quantitative effects of valacyclovir on the replication of 
cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus 
disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical 
Trials Group 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. 
J Infect Dis, 1999. 180(3): p. 695-701. 
321. Griffiths, P.D., et al., The effect of valaciclovir on cytomegalovirus viremia and viruria 
detected by polymerase chain reaction in patients with advanced human 
immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo 
Wellcome 123-014 International CMV Prophylaxis Study Group. J Infect Dis, 1998. 
177(1): p. 57-64. 
322. Reischig, T., et al., Valacyclovir for cytomegalovirus prophylaxis reduces the risk of 
acute renal allograft rejection. Transplantation, 2005. 79(3): p. 317-24. 
323. Reischig, T., et al., Valacyclovir prophylaxis versus preemptive valganciclovir therapy to 
prevent cytomegalovirus disease after renal transplantation. Am J Transplant, 2008. 
8(1): p. 69-77. 
324. Beswick, M., et al., Antiviral therapy can reverse the development of immune 
senescence in elderly mice with latent cytomegalovirus infection. J Virol, 2013. 87(2): p. 
779-89. 
325. Chanouzas, D., et al., Valaciclovir to prevent Cytomegalovirus mediated adverse 
modulation of the immune system in ANCA-associated vasculitis (CANVAS): study 
protocol for a randomised controlled trial. Trials, 2016. 17(1): p. 338. 
326. Chan, A.W., et al., SPIRIT 2013: new guidance for content of clinical trial protocols. 
Lancet, 2013. 381(9861): p. 91-2. 
327. Chan, A.W., et al., SPIRIT 2013 statement: defining standard protocol items for clinical 
trials. Ann Intern Med, 2013. 158(3): p. 200-7. 
328. Chan, A.W., et al., SPIRIT 2013 explanation and elaboration: guidance for protocols of 
clinical trials. BMJ, 2013. 346: p. e7586. 
329. Bonilla, F.A., Pharmacokinetics of immunoglobulin administered via intravenous or 
subcutaneous routes. Immunol Allergy Clin North Am, 2008. 28(4): p. 803-19, ix. 
330. Hickson, S.S., et al., Validity and repeatability of the Vicorder apparatus: a comparison 
with the SphygmoCor device. Hypertens Res, 2009. 32(12): p. 1079-85. 
331. Ng, K.P., et al., Allopurinol is an independent determinant of improved arterial stiffness 
in chronic kidney disease: a cross-sectional study. PLoS One, 2014. 9(3): p. e91961. 
332. Gibson, W., Structure and formation of the cytomegalovirus virion. Curr Top Microbiol 
Immunol, 2008. 325: p. 187-204. 
333. Dunn, W., et al., Functional profiling of a human cytomegalovirus genome. Proc Natl 
Acad Sci U S A, 2003. 100(24): p. 14223-8. 
334. Dolan, A., et al., Genetic content of wild-type human cytomegalovirus. J Gen Virol, 
2004. 85(Pt 5): p. 1301-12. 
335. Hayden, R.T., et al., Commutability of the First World Health Organization International 
Standard for Human Cytomegalovirus. J Clin Microbiol, 2015. 53(10): p. 3325-33. 
336. Jarrousse, B., et al., Increased risk of Pneumocystis carinii pneumonia in patients with 
Wegener's granulomatosis. Clin Exp Rheumatol, 1993. 11(6): p. 615-21. 
337. Wherry, E.J., T cell exhaustion. Nat Immunol, 2011. 12(6): p. 492-9. 
338. Acosta-Rodriguez, E.V., et al., Surface phenotype and antigenic specificity of human 
interleukin 17-producing T helper memory cells. Nat Immunol, 2007. 8(6): p. 639-46. 
339. Krol, L., et al., Signature profiles of CMV-specific T-cells in patients with CMV 
reactivation after hematopoietic SCT. Bone Marrow Transplant, 2011. 46(8): p. 1089-
98. 
CMV Modulation of the Immune System in AAV 245 
 
340. Boyman, O. and J. Sprent, The role of interleukin-2 during homeostasis and activation 
of the immune system. Nat Rev Immunol, 2012. 12(3): p. 180-90. 
341. Snyder, L.D., et al., Polyfunctional T-Cell Signatures to Predict Protection from 
Cytomegalovirus after Lung Transplantation. Am J Respir Crit Care Med, 2016. 193(1): 
p. 78-85. 
342. Crawford, A., et al., Molecular and transcriptional basis of CD4(+) T cell dysfunction 
during chronic infection. Immunity, 2014. 40(2): p. 289-302. 
343. Kong, Y., et al., PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in 
AML patients post allogeneic stem cell transplantation. Blood Cancer J, 2015. 5: p. 
e330. 
344. Nebbia, G., et al., Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in 
chronic hepatitis B virus infection. PLoS One, 2012. 7(10): p. e47648. 
345. Blacher, J., et al., Pulse pressure not mean pressure determines cardiovascular risk in 
older hypertensive patients. Arch Intern Med, 2000. 160(8): p. 1085-9. 
346. Franklin, S.S., et al., Does the relation of blood pressure to coronary heart disease risk 
change with aging? The Framingham Heart Study. Circulation, 2001. 103(9): p. 1245-9. 
347. Laurent, S., et al., Expert consensus document on arterial stiffness: methodological 
issues and clinical applications. Eur Heart J, 2006. 27(21): p. 2588-605. 
348. Chue, C.D., et al., Arterial stiffness in chronic kidney disease: causes and consequences. 
Heart, 2010. 96(11): p. 817-23. 
349. Bonecchi, R., et al., Differential expression of chemokine receptors and chemotactic 
responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med, 1998. 187(1): p. 
129-34. 
350. Seckert, C.K., et al., Liver sinusoidal endothelial cells are a site of murine 
cytomegalovirus latency and reactivation. J Virol, 2009. 83(17): p. 8869-84. 
351. Pampou, S., et al., Cytomegalovirus genome and the immediate-early antigen in cells of 
different layers of human aorta. Virchows Arch, 2000. 436(6): p. 539-52. 
352. Neurath, M.F., et al., The transcription factor T-bet regulates mucosal T cell activation 
in experimental colitis and Crohn's disease. J Exp Med, 2002. 195(9): p. 1129-43. 
353. Lord, G.M., et al., T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. 
Blood, 2005. 106(10): p. 3432-9. 
354. Kossmann, S., et al., Angiotensin II-induced vascular dysfunction depends on interferon-
gamma-driven immune cell recruitment and mutual activation of monocytes and NK-
cells. Arterioscler Thromb Vasc Biol, 2013. 33(6): p. 1313-9. 
355. Kaplan, R.C., et al., T cell activation predicts carotid artery stiffness among HIV-infected 
women. Atherosclerosis, 2011. 217(1): p. 207-13. 
356. Dumitriu, I.E., et al., CD4+ CD28 null T cells in coronary artery disease: when helpers 
become killers. Cardiovasc Res, 2009. 81(1): p. 11-9. 
357. Lacki, J.K., et al., The effect of intravenous cyclophosphamide pulse on peripheral blood 
lymphocytes in lupus erythematosus patients. Rheumatol Int, 1997. 17(2): p. 55-60. 
358. Underhill, G.H., et al., A crucial role for T-bet in selectin ligand expression in T helper 1 
(Th1) cells. Blood, 2005. 106(12): p. 3867-73. 
359. Mankarious, S., et al., The half-lives of IgG subclasses and specific antibodies in patients 
with primary immunodeficiency who are receiving intravenously administered 
immunoglobulin. J Lab Clin Med, 1988. 112(5): p. 634-40. 
360. Adler, S.P., J. Baggett, and M. McVoy, Transfusion-associated cytomegalovirus 
infections in seropositive cardiac surgery patients. Lancet, 1985. 2(8458): p. 743-7. 
361. Flo, R.W., et al., Longitudinal study of cytomegalovirus antibodies in individuals 
infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis, 1995. 
14(6): p. 504-11. 
CMV Modulation of the Immune System in AAV 246 
 
362. Sulowicz, W., et al., Cytomegalovirus infection in kidney transplant patients: clinical 
manifestations and diagnosis. Zentralbl Bakteriol, 1998. 287(4): p. 489-500. 
363. Bolovan-Fritts, C.A., R.N. Trout, and S.A. Spector, High T-cell response to human 
cytomegalovirus induces chemokine-mediated endothelial cell damage. Blood, 2007. 
110(6): p. 1857-63. 
364. Chronic Kidney Disease Prognosis, C., et al., Association of estimated glomerular 
filtration rate and albuminuria with all-cause and cardiovascular mortality in general 


















CMV Modulation of the Immune System in AAV 247 
 
Appendix 1 Publications and abstracts arising from this thesis at the 
time of submission 
 
Publications 
1. Chanouzas, D., Dyall L., Nightingale, P., Ferro, C., Moss, P., Morgan, M.D., 
Harper, L. Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the 
immune system in ANCA-associated vasculitis (CANVAS): study protocol for a 
randomised controlled trial. Trials, 2016. 17(1): p. 338. 
 
Abstracts 
1. Chanouzas, D., Sagmeister, M., Dyall, L., Nightingale, P., Ferro, C., Moss, P., 
Morgan, M.D., Harper, L.  Valaciclovir to prevent cytomegalovirus mediated 
adverse modulation of the immune system in ANCA associated vasculitis 
(CANVAS): results from a randomised controlled trial.  Accepted for poster 
presentation at American Society of Nephrology Congress, Nov 2016, Chicago. 
USA. 
2. Chanouzas, D., Dyall, L., Ferro, C., Moss, P., Morgan, M.D., Harper, L. 
CD4+CD28- T-cells are CMV specific cytotoxic endothelial targeting cells and are 
independently associated with increased arterial stiffness in renal disease.  
Accepted for poster presentation at American Society of Nephrology Congress, 
Nov 2016, Chicago, USA. 
3. Chanouzas, D., Dyall L., Dale, J., Moss, P., Morgan, M.D., Harper, L. CD4+CD28- 
T-cell expansions in ANCA-associated vasculitis and association with arterial 
stiffnes: baseline data from a randomised controlled trial.  Lancet, 2015. 385 
Suppl 1:S30. 
Presented as poster presentation at: 
Academy of Medical Sciences Spring Conference, Feb 2015, London 
Abstract 3 was also presented as oral presentation at: 
5th International Workshop on CMV and Immunosenescence, Nov 2014, 
Amsterdam, Holland 
CMV Modulation of the Immune System in AAV 248 
 






















CMV Modulation of the Immune System in AAV 250 
 
 
CMV Modulation of the Immune System in AAV 251 
 
 
CMV Modulation of the Immune System in AAV 252 
 
 
CMV Modulation of the Immune System in AAV 253 
 
 
CMV Modulation of the Immune System in AAV 254 
 
 
CMV Modulation of the Immune System in AAV 255 
 
 
CMV Modulation of the Immune System in AAV 256 
 
 
CMV Modulation of the Immune System in AAV 257 
 
 
CMV Modulation of the Immune System in AAV 258 
 
 
CMV Modulation of the Immune System in AAV 259 
 
 




CMV Modulation of the Immune System in AAV 261 
 
 
CMV Modulation of the Immune System in AAV 262 
 
 
CMV Modulation of the Immune System in AAV 263 
 
 
CMV Modulation of the Immune System in AAV 264 
 
 
CMV Modulation of the Immune System in AAV 265 
 
 
CMV Modulation of the Immune System in AAV 266 
 
 
CMV Modulation of the Immune System in AAV 267 
  
CMV Modulation of the Immune System in AAV 268 
 
 
CMV Modulation of the Immune System in AAV 269 
 
 
CMV Modulation of the Immune System in AAV 270 
 
 
CMV Modulation of the Immune System in AAV 271 
 
 
CMV Modulation of the Immune System in AAV 272 
 
 
CMV Modulation of the Immune System in AAV 273 
 
 
CMV Modulation of the Immune System in AAV 274 
  
CMV Modulation of the Immune System in AAV 275 
  
CMV Modulation of the Immune System in AAV 276 
 
 
CMV Modulation of the Immune System in AAV 277 
 
 
CMV Modulation of the Immune System in AAV 278 
 
 
CMV Modulation of the Immune System in AAV 279 
 
 
CMV Modulation of the Immune System in AAV 280 
 
 
CMV Modulation of the Immune System in AAV 281 
 
 
CMV Modulation of the Immune System in AAV 282 
 
 
CMV Modulation of the Immune System in AAV 283 
 
 
CMV Modulation of the Immune System in AAV 284 
  
CMV Modulation of the Immune System in AAV 285 
 
 
CMV Modulation of the Immune System in AAV 286 
 
 
CMV Modulation of the Immune System in AAV 287 
 
 
CMV Modulation of the Immune System in AAV 288 
 
 
CMV Modulation of the Immune System in AAV 289 
 
 
CMV Modulation of the Immune System in AAV 290 
  
CMV Modulation of the Immune System in AAV 291 
 
 
CMV Modulation of the Immune System in AAV 292 
 
 
CMV Modulation of the Immune System in AAV 293 
 
 
CMV Modulation of the Immune System in AAV 294 
 
 





CMV Modulation of the Immune System in AAV 296 
 
 
CMV Modulation of the Immune System in AAV 297 
 
 
CMV Modulation of the Immune System in AAV 298 
 
 
CMV Modulation of the Immune System in AAV 299 
 
 
CMV Modulation of the Immune System in AAV 300 
 
 
CMV Modulation of the Immune System in AAV 301 
 
 
CMV Modulation of the Immune System in AAV 302 
 
 





CMV Modulation of the Immune System in AAV 304 
 























































CMV Modulation of the Immune System in AAV 311 
 




















CMV Modulation of the Immune System in AAV 312 
 
CMV Modulation of the Immune System in AAV 313 
 
CMV Modulation of the Immune System in AAV 314 
 
CMV Modulation of the Immune System in AAV 315 
 
CMV Modulation of the Immune System in AAV 316 
 
CMV Modulation of the Immune System in AAV 317 
 
CMV Modulation of the Immune System in AAV 318 
 
CMV Modulation of the Immune System in AAV 319 
 




































CMV Modulation of the Immune System in AAV 324 
 




























































































CMV Modulation of the Immune System in AAV 343 
 
























CMV Modulation of the Immune System in AAV 345 
 
CMV Modulation of the Immune System in AAV 346 
 
CMV Modulation of the Immune System in AAV 347 
 
CMV Modulation of the Immune System in AAV 348 
 
CMV Modulation of the Immune System in AAV 349 
 
CMV Modulation of the Immune System in AAV 350 
 
CMV Modulation of the Immune System in AAV 351 
 
CMV Modulation of the Immune System in AAV 352 
 
CMV Modulation of the Immune System in AAV 353 
 
CMV Modulation of the Immune System in AAV 354 
 
CMV Modulation of the Immune System in AAV 355 
 
CMV Modulation of the Immune System in AAV 356 
 
CMV Modulation of the Immune System in AAV 357 
 
CMV Modulation of the Immune System in AAV 358 
 
CMV Modulation of the Immune System in AAV 359 
 
CMV Modulation of the Immune System in AAV 360 
 
CMV Modulation of the Immune System in AAV 361 
 




CMV Modulation of the Immune System in AAV 363 
 
CMV Modulation of the Immune System in AAV 364 
 
CMV Modulation of the Immune System in AAV 365 
 
CMV Modulation of the Immune System in AAV 366 
 
CMV Modulation of the Immune System in AAV 367 
 
CMV Modulation of the Immune System in AAV 368 
 
CMV Modulation of the Immune System in AAV 369 
 
CMV Modulation of the Immune System in AAV 370 
 




CMV Modulation of the Immune System in AAV 372 
 




















CMV Modulation of the Immune System in AAV 373 
 
 
CMV Modulation of the Immune System in AAV 374 
 
 
CMV Modulation of the Immune System in AAV 375 
 
 




















CMV Modulation of the Immune System in AAV 378 
 
 
CMV Modulation of the Immune System in AAV 379 
 




















CMV Modulation of the Immune System in AAV 380 
 
 
CMV Modulation of the Immune System in AAV 381 
 
 
CMV Modulation of the Immune System in AAV 382 
 
 
CMV Modulation of the Immune System in AAV 383 
 
 
CMV Modulation of the Immune System in AAV 384 
 
 
CMV Modulation of the Immune System in AAV 385 
 
 
CMV Modulation of the Immune System in AAV 386 
  
CMV Modulation of the Immune System in AAV 387 
 
 
CMV Modulation of the Immune System in AAV 388 
 
 
CMV Modulation of the Immune System in AAV 389 
 
 
















CMV Modulation of the Immune System in AAV 391 
 

























CMV Modulation of the Immune System in AAV 392 
 
 
CMV Modulation of the Immune System in AAV 393 
 
CMV Modulation of the Immune System in AAV 394 
 
 
CMV Modulation of the Immune System in AAV 395 
 
 
CMV Modulation of the Immune System in AAV 396 
 
